STUDYID,USUBJID,SUBJID,SITEID,PART,PARTN,SAFFL,SAFFN,PKPOPFL,PKPOPFN,TRTSEQP,TRTSEQPN,TRTSEQA,TRTSEQAN,TRTSDT,TRTSTM,TRTSDTM,TRTEDT,TRTETM,TRTEDTM,PPSEQ,EPOCH,TRTP,TRTPN,TRTA,TRTAN,AVISIT,AVISITN,APERIOD,APERIODC,PPCAT,CAT1N,CAT1,PARAMN,PARAM,PARAMCD,PARAML,AVAL,AVALC,AVALL,ATPTREF,TRT,TRTL
3110-103-002,3110-103-002.103001005,103001005,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,35280.0,1837417680.0,21280.0,35280.0,1838627280.0,1.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),873.92741433,873.927414333272,873.93,1837417680.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001005,103001005,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,35280.0,1837417680.0,21280.0,35280.0,1838627280.0,2.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),854.01820435,854.01820435713,854.02,1837417680.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001005,103001005,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,35280.0,1837417680.0,21280.0,35280.0,1838627280.0,3.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),2.2781308435,2.27813084354738,2.28,1837417680.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001005,103001005,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,35280.0,1837417680.0,21280.0,35280.0,1838627280.0,4.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),114.42597904,114.425979045744,114.43,1837417680.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001005,103001005,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,35280.0,1837417680.0,21280.0,35280.0,1838627280.0,5.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),255.88,255.88,255.88,1837417680.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001005,103001005,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,35280.0,1837417680.0,21280.0,35280.0,1838627280.0,6.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1160267033,0.116026703358301,0.12,1837417680.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001005,103001005,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,35280.0,1837417680.0,21280.0,35280.0,1838627280.0,7.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),5.9740314987,5.9740314987615,5.97,1837417680.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001005,103001005,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,35280.0,1837417680.0,21280.0,35280.0,1838627280.0,8.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1837417680.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001005,103001005,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,35280.0,1837417680.0,21280.0,35280.0,1838627280.0,9.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),986.20382837,986.203828375491,986.20,1837417680.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001005,103001005,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,35280.0,1837417680.0,21280.0,35280.0,1838627280.0,10.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1183.0087563,1183.00875639464,1183.01,1838022480.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001005,103001005,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,35280.0,1837417680.0,21280.0,35280.0,1838627280.0,11.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1166.7788541,1166.77885412446,1166.78,1838022480.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001005,103001005,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,35280.0,1837417680.0,21280.0,35280.0,1838627280.0,12.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.3719173406,1.37191734063276,1.37,1838022480.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001005,103001005,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,35280.0,1837417680.0,21280.0,35280.0,1838627280.0,13.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),84.530228081,84.530228081119,84.53,1838022480.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001005,103001005,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,35280.0,1837417680.0,21280.0,35280.0,1838627280.0,14.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),241.95,241.95,241.95,1838022480.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001005,103001005,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,35280.0,1837417680.0,21280.0,35280.0,1838627280.0,15.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1515720772,0.151572077209582,0.15,1838022480.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001005,103001005,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,35280.0,1837417680.0,21280.0,35280.0,1838627280.0,16.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.5730532517,4.57305325176426,4.57,1838022480.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001005,103001005,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,35280.0,1837417680.0,21280.0,35280.0,1838627280.0,17.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.5,1.5,1.50,1838022480.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001005,103001005,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,35280.0,1837417680.0,21280.0,35280.0,1838627280.0,18.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),557.68997586,557.689975866973,557.69,1838022480.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001005,103001005,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,35280.0,1837417680.0,21280.0,35280.0,1838627280.0,19.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),933.60536969,933.605369696691,933.61,1838627280.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001005,103001005,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,35280.0,1837417680.0,21280.0,35280.0,1838627280.0,20.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),911.20329521,911.203295211261,911.20,1838627280.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001005,103001005,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,35280.0,1837417680.0,21280.0,35280.0,1838627280.0,21.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),2.3995228832,2.3995228832829,2.40,1838627280.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001005,103001005,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,35280.0,1837417680.0,21280.0,35280.0,1838627280.0,22.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),107.11163757,107.111637578186,107.11,1838627280.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001005,103001005,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,35280.0,1837417680.0,21280.0,35280.0,1838627280.0,23.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),209.0,209,209.00,1838627280.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001005,103001005,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,35280.0,1837417680.0,21280.0,35280.0,1838627280.0,24.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1316842331,0.131684233168613,0.13,1838627280.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001005,103001005,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,35280.0,1837417680.0,21280.0,35280.0,1838627280.0,25.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),5.2637067011,5.26370670110838,5.26,1838627280.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001005,103001005,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,35280.0,1837417680.0,21280.0,35280.0,1838627280.0,26.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1838627280.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001005,103001005,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,35280.0,1837417680.0,21280.0,35280.0,1838627280.0,27.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),813.39758755,813.397587553526,813.40,1838627280.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001007,103001007,001,Part A,1.0,Y,1.0,N,0.0,6: CBA,6.0,6: CBA,6.0,21266.0,34860.0,1837417260.0,21266.0,34860.0,1837417260.0,1.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1562.249558,1562.24955803821,1562.25,1837417260.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001007,103001007,001,Part A,1.0,Y,1.0,N,0.0,6: CBA,6.0,6: CBA,6.0,21266.0,34860.0,1837417260.0,21266.0,34860.0,1837417260.0,2.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1549.2251879,1549.22518796306,1549.23,1837417260.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001007,103001007,001,Part A,1.0,Y,1.0,N,0.0,6: CBA,6.0,6: CBA,6.0,21266.0,34860.0,1837417260.0,21266.0,34860.0,1837417260.0,3.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),0.8336933115,0.833693311554127,0.83,1837417260.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001007,103001007,001,Part A,1.0,Y,1.0,N,0.0,6: CBA,6.0,6: CBA,6.0,21266.0,34860.0,1837417260.0,21266.0,34860.0,1837417260.0,4.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),64.010259747,64.0102597472166,64.01,1837417260.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001007,103001007,001,Part A,1.0,Y,1.0,N,0.0,6: CBA,6.0,6: CBA,6.0,21266.0,34860.0,1837417260.0,21266.0,34860.0,1837417260.0,5.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),406.84,406.84,406.84,1837417260.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001007,103001007,001,Part A,1.0,Y,1.0,N,0.0,6: CBA,6.0,6: CBA,6.0,21266.0,34860.0,1837417260.0,21266.0,34860.0,1837417260.0,6.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1696819106,0.169681910698841,0.17,1837417260.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001007,103001007,001,Part A,1.0,Y,1.0,N,0.0,6: CBA,6.0,6: CBA,6.0,21266.0,34860.0,1837417260.0,21266.0,34860.0,1837417260.0,7.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.0849798172,4.08497981726629,4.08,1837417260.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001007,103001007,001,Part A,1.0,Y,1.0,N,0.0,6: CBA,6.0,6: CBA,6.0,21266.0,34860.0,1837417260.0,21266.0,34860.0,1837417260.0,8.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),2.0,2,2.00,1837417260.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001007,103001007,001,Part A,1.0,Y,1.0,N,0.0,6: CBA,6.0,6: CBA,6.0,21266.0,34860.0,1837417260.0,21266.0,34860.0,1837417260.0,9.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),377.23679255,377.23679255843,377.24,1837417260.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001008,103001008,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35340.0,1837417740.0,21280.0,35340.0,1838627340.0,1.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1210.6755925,1210.67559256696,1210.68,1837417740.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001008,103001008,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35340.0,1837417740.0,21280.0,35340.0,1838627340.0,2.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1188.7945822,1188.79458229828,1188.79,1837417740.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001008,103001008,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35340.0,1837417740.0,21280.0,35340.0,1838627340.0,3.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.8073388447,1.80733884477578,1.81,1837417740.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001008,103001008,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35340.0,1837417740.0,21280.0,35340.0,1838627340.0,4.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),82.598509967,82.5985099674576,82.60,1837417740.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001008,103001008,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35340.0,1837417740.0,21280.0,35340.0,1838627340.0,5.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),525.64,525.64,525.64,1837417740.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001008,103001008,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35340.0,1837417740.0,21280.0,35340.0,1838627340.0,6.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1142543223,0.114254322323418,0.11,1837417740.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001008,103001008,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35340.0,1837417740.0,21280.0,35340.0,1838627340.0,7.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),6.0667042302,6.06670423021605,6.07,1837417740.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001008,103001008,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35340.0,1837417740.0,21280.0,35340.0,1838627340.0,8.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1837417740.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001008,103001008,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35340.0,1837417740.0,21280.0,35340.0,1838627340.0,9.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),722.93553791,722.935537910308,722.94,1837417740.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001008,103001008,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35340.0,1837417740.0,21280.0,35340.0,1838627340.0,10.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1204.8411481,1204.8411481601,1204.84,1838022540.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001008,103001008,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35340.0,1837417740.0,21280.0,35340.0,1838627340.0,11.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1192.0427967,1192.04279678514,1192.04,1838022540.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001008,103001008,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35340.0,1837417740.0,21280.0,35340.0,1838627340.0,12.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.0622438812,1.06224388123802,1.06,1838022540.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001008,103001008,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35340.0,1837417740.0,21280.0,35340.0,1838627340.0,13.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),82.99849333,82.9984933306009,83.00,1838022540.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001008,103001008,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35340.0,1837417740.0,21280.0,35340.0,1838627340.0,14.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),478.33,478.33,478.33,1838022540.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001008,103001008,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35340.0,1837417740.0,21280.0,35340.0,1838627340.0,15.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1453312184,0.145331218490987,0.15,1838022540.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001008,103001008,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35340.0,1837417740.0,21280.0,35340.0,1838627340.0,16.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.7694307372,4.76943073729842,4.77,1838022540.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001008,103001008,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35340.0,1837417740.0,21280.0,35340.0,1838627340.0,17.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1838022540.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001008,103001008,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35340.0,1837417740.0,21280.0,35340.0,1838627340.0,18.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),571.09886088,571.098860880659,571.10,1838022540.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001008,103001008,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35340.0,1837417740.0,21280.0,35340.0,1838627340.0,19.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1236.8621331,1236.86213317267,1236.86,1838627340.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001008,103001008,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35340.0,1837417740.0,21280.0,35340.0,1838627340.0,20.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1223.7564849,1223.75648498135,1223.76,1838627340.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001008,103001008,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35340.0,1837417740.0,21280.0,35340.0,1838627340.0,21.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.0595884407,1.05958844076681,1.06,1838627340.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001008,103001008,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35340.0,1837417740.0,21280.0,35340.0,1838627340.0,22.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),80.849754647,80.8497546476665,80.85,1838627340.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001008,103001008,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35340.0,1837417740.0,21280.0,35340.0,1838627340.0,23.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),565.24,565.24,565.24,1838627340.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001008,103001008,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35340.0,1837417740.0,21280.0,35340.0,1838627340.0,24.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1388714219,0.138871421957251,0.14,1838627340.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001008,103001008,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35340.0,1837417740.0,21280.0,35340.0,1838627340.0,25.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.9912874138,4.99128741385912,4.99,1838627340.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001008,103001008,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35340.0,1837417740.0,21280.0,35340.0,1838627340.0,26.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1838627340.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001008,103001008,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35340.0,1837417740.0,21280.0,35340.0,1838627340.0,27.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),582.19145097,582.191450970775,582.19,1838627340.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001009,103001009,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36360.0,1837418760.0,21280.0,36360.0,1838628360.0,1.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),767.27682865,767.276828653308,767.28,1837418760.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001009,103001009,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36360.0,1837418760.0,21280.0,36360.0,1838628360.0,2.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),759.73228563,759.732285636022,759.73,1837418760.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001009,103001009,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36360.0,1837418760.0,21280.0,36360.0,1838628360.0,3.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),0.9832882651,0.983288265139965,0.98,1837418760.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001009,103001009,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36360.0,1837418760.0,21280.0,36360.0,1838628360.0,4.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),130.33105688,130.33105688271,130.33,1837418760.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001009,103001009,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36360.0,1837418760.0,21280.0,36360.0,1838628360.0,5.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),259.24,259.24,259.24,1837418760.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001009,103001009,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36360.0,1837418760.0,21280.0,36360.0,1838628360.0,6.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1511025912,0.151102591288568,0.15,1837418760.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001009,103001009,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36360.0,1837418760.0,21280.0,36360.0,1838628360.0,7.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.587262036,4.58726203600444,4.59,1837418760.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001009,103001009,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36360.0,1837418760.0,21280.0,36360.0,1838628360.0,8.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1837418760.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001009,103001009,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36360.0,1837418760.0,21280.0,36360.0,1838628360.0,9.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),862.53356591,862.533565912252,862.53,1837418760.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001009,103001009,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36360.0,1837418760.0,21280.0,36360.0,1838628360.0,10.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),981.99519647,981.995196471419,982.00,1838023560.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001009,103001009,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36360.0,1837418760.0,21280.0,36360.0,1838628360.0,11.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),972.14207138,972.142071382164,972.14,1838023560.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001009,103001009,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36360.0,1837418760.0,21280.0,36360.0,1838628360.0,12.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.0033781351,1.00337813511314,1.00,1838023560.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001009,103001009,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36360.0,1837418760.0,21280.0,36360.0,1838628360.0,13.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),101.83349201,101.833492016384,101.83,1838023560.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001009,103001009,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36360.0,1837418760.0,21280.0,36360.0,1838628360.0,14.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),331.25,331.25,331.25,1838023560.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001009,103001009,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36360.0,1837418760.0,21280.0,36360.0,1838628360.0,15.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1359974615,0.135997461501958,0.14,1838023560.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001009,103001009,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36360.0,1837418760.0,21280.0,36360.0,1838628360.0,16.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),5.0967655785,5.09676557859844,5.10,1838023560.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001009,103001009,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36360.0,1837418760.0,21280.0,36360.0,1838628360.0,17.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),2.0,2,2.00,1838023560.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001009,103001009,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36360.0,1837418760.0,21280.0,36360.0,1838628360.0,18.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),748.78965306,748.789653069504,748.79,1838023560.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001009,103001009,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36360.0,1837418760.0,21280.0,36360.0,1838628360.0,19.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),921.65066385,921.650663852022,921.65,1838628360.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001009,103001009,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36360.0,1837418760.0,21280.0,36360.0,1838628360.0,20.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),902.7213198,902.721319802615,902.72,1838628360.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001009,103001009,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36360.0,1837418760.0,21280.0,36360.0,1838628360.0,21.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),2.053852375,2.05385237507366,2.05,1838628360.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001009,103001009,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36360.0,1837418760.0,21280.0,36360.0,1838628360.0,22.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),108.50097973,108.500979733527,108.50,1838628360.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001009,103001009,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36360.0,1837418760.0,21280.0,36360.0,1838628360.0,23.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),378.04,378.04,378.04,1838628360.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001009,103001009,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36360.0,1837418760.0,21280.0,36360.0,1838628360.0,24.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.0929773369,0.092977336954005,0.09,1838628360.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001009,103001009,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36360.0,1837418760.0,21280.0,36360.0,1838628360.0,25.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),7.4550121918,7.45501219187251,7.46,1838628360.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001009,103001009,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36360.0,1837418760.0,21280.0,36360.0,1838628360.0,26.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1838628360.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001009,103001009,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36360.0,1837418760.0,21280.0,36360.0,1838628360.0,27.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),1166.9615767,1166.9615767464,1166.96,1838628360.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001010,103001010,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34320.0,1837416720.0,21280.0,34320.0,1838626320.0,1.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1054.3893116,1054.38931167795,1054.39,1837416720.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001010,103001010,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34320.0,1837416720.0,21280.0,34320.0,1838626320.0,2.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1023.359133,1023.35913305317,1023.36,1837416720.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001010,103001010,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34320.0,1837416720.0,21280.0,34320.0,1838626320.0,3.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),2.9429526912,2.94295269129752,2.94,1837416720.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001010,103001010,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34320.0,1837416720.0,21280.0,34320.0,1838626320.0,4.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),94.841629076,94.8416290761333,94.84,1837416720.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001010,103001010,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34320.0,1837416720.0,21280.0,34320.0,1838626320.0,5.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),209.38,209.38,209.38,1837416720.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001010,103001010,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34320.0,1837416720.0,21280.0,34320.0,1838626320.0,6.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1179496916,0.117949691629465,0.12,1837416720.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001010,103001010,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34320.0,1837416720.0,21280.0,34320.0,1838626320.0,7.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),5.8766341054,5.87663410547475,5.88,1837416720.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001010,103001010,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34320.0,1837416720.0,21280.0,34320.0,1838626320.0,8.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1837416720.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001010,103001010,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34320.0,1837416720.0,21280.0,34320.0,1838626320.0,9.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),804.08543478,804.085434780744,804.09,1837416720.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001010,103001010,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34320.0,1837416720.0,21280.0,34320.0,1838626320.0,10.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1200.3122053,1200.31220534633,1200.31,1838021520.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001010,103001010,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34320.0,1837416720.0,21280.0,34320.0,1838626320.0,11.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1187.5494798,1187.54947984047,1187.55,1838021520.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001010,103001010,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34320.0,1837416720.0,21280.0,34320.0,1838626320.0,12.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.063283823,1.06328382307597,1.06,1838021520.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001010,103001010,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34320.0,1837416720.0,21280.0,34320.0,1838626320.0,13.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),83.311658045,83.311658045789,83.31,1838021520.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001010,103001010,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34320.0,1837416720.0,21280.0,34320.0,1838626320.0,14.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),432.34,432.34,432.34,1838021520.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001010,103001010,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34320.0,1837416720.0,21280.0,34320.0,1838626320.0,15.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1543557447,0.154355744711143,0.15,1838021520.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001010,103001010,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34320.0,1837416720.0,21280.0,34320.0,1838626320.0,16.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.4905823353,4.49058233535189,4.49,1838021520.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001010,103001010,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34320.0,1837416720.0,21280.0,34320.0,1838626320.0,17.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1838021520.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001010,103001010,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34320.0,1837416720.0,21280.0,34320.0,1838626320.0,18.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),539.73798125,539.737981256842,539.74,1838021520.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001010,103001010,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34320.0,1837416720.0,21280.0,34320.0,1838626320.0,19.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),892.2696973,892.269697300861,892.27,1838626320.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001010,103001010,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34320.0,1837416720.0,21280.0,34320.0,1838626320.0,20.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),859.06382979,859.063829794178,859.06,1838626320.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001010,103001010,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34320.0,1837416720.0,21280.0,34320.0,1838626320.0,21.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),3.7215056845,3.72150568456284,3.72,1838626320.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001010,103001010,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34320.0,1837416720.0,21280.0,34320.0,1838626320.0,22.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),112.07373768,112.073737685481,112.07,1838626320.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001010,103001010,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34320.0,1837416720.0,21280.0,34320.0,1838626320.0,23.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),138.31,138.31,138.31,1838626320.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001010,103001010,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34320.0,1837416720.0,21280.0,34320.0,1838626320.0,24.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1201594868,0.120159486849635,0.12,1838626320.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001010,103001010,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34320.0,1837416720.0,21280.0,34320.0,1838626320.0,25.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),5.7685597594,5.76855975947481,5.77,1838626320.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001010,103001010,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34320.0,1837416720.0,21280.0,34320.0,1838626320.0,26.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1838626320.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001010,103001010,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34320.0,1837416720.0,21280.0,34320.0,1838626320.0,27.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),932.70819161,932.708191619757,932.71,1838626320.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001015,103001015,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,34380.0,1837416780.0,21280.0,34380.0,1838626380.0,1.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1550.2934887,1550.29348873705,1550.29,1837416780.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001015,103001015,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,34380.0,1837416780.0,21280.0,34380.0,1838626380.0,2.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1536.5351338,1536.53513387247,1536.54,1837416780.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001015,103001015,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,34380.0,1837416780.0,21280.0,34380.0,1838626380.0,3.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),0.8874677578,0.887467757849186,0.89,1837416780.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001015,103001015,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,34380.0,1837416780.0,21280.0,34380.0,1838626380.0,4.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),64.503915372,64.503915372479,64.50,1837416780.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001015,103001015,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,34380.0,1837416780.0,21280.0,34380.0,1838626380.0,5.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),427.65,427.65,427.65,1837416780.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001015,103001015,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,34380.0,1837416780.0,21280.0,34380.0,1838626380.0,6.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1664443185,0.16644431856428,0.17,1837416780.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001015,103001015,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,34380.0,1837416780.0,21280.0,34380.0,1838626380.0,7.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.1644388137,4.16443881376614,4.16,1837416780.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001015,103001015,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,34380.0,1837416780.0,21280.0,34380.0,1838626380.0,8.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.5,1.5,1.50,1837416780.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001015,103001015,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,34380.0,1837416780.0,21280.0,34380.0,1838626380.0,9.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),387.54050561,387.540505610996,387.54,1837416780.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001015,103001015,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,34380.0,1837416780.0,21280.0,34380.0,1838626380.0,10.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1427.6066379,1427.60663796276,1427.61,1838021580.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001015,103001015,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,34380.0,1837416780.0,21280.0,34380.0,1838626380.0,11.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1411.4517588,1411.45175881308,1411.45,1838021580.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001015,103001015,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,34380.0,1837416780.0,21280.0,34380.0,1838626380.0,12.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.1316057743,1.13160577431421,1.13,1838021580.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001015,103001015,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,34380.0,1837416780.0,21280.0,34380.0,1838626380.0,13.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),70.047306688,70.047306688559,70.05,1838021580.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001015,103001015,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,34380.0,1837416780.0,21280.0,34380.0,1838626380.0,14.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),263.42,263.42,263.42,1838021580.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001015,103001015,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,34380.0,1837416780.0,21280.0,34380.0,1838626380.0,15.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1615610971,0.161561097165605,0.16,1838021580.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001015,103001015,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,34380.0,1837416780.0,21280.0,34380.0,1838626380.0,16.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.2903099367,4.29030993673834,4.29,1838021580.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001015,103001015,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,34380.0,1837416780.0,21280.0,34380.0,1838626380.0,17.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.5,1.5,1.50,1838021580.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001015,103001015,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,34380.0,1837416780.0,21280.0,34380.0,1838626380.0,18.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),433.56543077,433.565430771731,433.57,1838021580.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001015,103001015,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,34380.0,1837416780.0,21280.0,34380.0,1838626380.0,19.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),978.9377215,978.937721509577,978.94,1838626380.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001015,103001015,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,34380.0,1837416780.0,21280.0,34380.0,1838626380.0,20.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),964.13142008,964.131420081383,964.13,1838626380.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001015,103001015,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,34380.0,1837416780.0,21280.0,34380.0,1838626380.0,21.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.5124865558,1.51248655587219,1.51,1838626380.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001015,103001015,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,34380.0,1837416780.0,21280.0,34380.0,1838626380.0,22.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),102.15154427,102.15154427372,102.15,1838626380.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001015,103001015,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,34380.0,1837416780.0,21280.0,34380.0,1838626380.0,23.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),248.87,248.87,248.87,1838626380.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001015,103001015,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,34380.0,1837416780.0,21280.0,34380.0,1838626380.0,24.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1418315039,0.141831503983919,0.14,1838626380.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001015,103001015,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,34380.0,1837416780.0,21280.0,34380.0,1838626380.0,25.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.8871171854,4.8871171854635,4.89,1838626380.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001015,103001015,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,34380.0,1837416780.0,21280.0,34380.0,1838626380.0,26.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1838626380.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001015,103001015,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,34380.0,1837416780.0,21280.0,34380.0,1838626380.0,27.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),720.23169327,720.231693272475,720.23,1838626380.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001022,103001022,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,36420.0,1837418820.0,21280.0,36420.0,1838628420.0,1.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),998.33976163,998.339761633186,998.34,1837418820.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001022,103001022,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,36420.0,1837418820.0,21280.0,36420.0,1838628420.0,2.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),973.32335141,973.323351411592,973.32,1837418820.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001022,103001022,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,36420.0,1837418820.0,21280.0,36420.0,1838628420.0,3.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),2.5058012495,2.50580124953349,2.51,1837418820.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001022,103001022,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,36420.0,1837418820.0,21280.0,36420.0,1838628420.0,4.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),100.16629993,100.166299934213,100.17,1837418820.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001022,103001022,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,36420.0,1837418820.0,21280.0,36420.0,1838628420.0,5.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),357.43,357.43,357.43,1837418820.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001022,103001022,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,36420.0,1837418820.0,21280.0,36420.0,1838628420.0,6.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.0987351893,0.0987351893465479,0.10,1837418820.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001022,103001022,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,36420.0,1837418820.0,21280.0,36420.0,1838628420.0,7.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),7.0202648634,7.02026486349347,7.02,1837418820.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001022,103001022,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,36420.0,1837418820.0,21280.0,36420.0,1838628420.0,8.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1837418820.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001022,103001022,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,36420.0,1837418820.0,21280.0,36420.0,1838628420.0,9.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),1014.494433,1014.49443300951,1014.49,1837418820.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001022,103001022,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,36420.0,1837418820.0,21280.0,36420.0,1838628420.0,10.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1058.1689272,1058.16892726954,1058.17,1838023620.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001022,103001022,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,36420.0,1837418820.0,21280.0,36420.0,1838628420.0,11.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1031.0318858,1031.03188586846,1031.03,1838023620.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001022,103001022,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,36420.0,1837418820.0,21280.0,36420.0,1838628420.0,12.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),2.564528281,2.56452828104708,2.56,1838023620.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001022,103001022,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,36420.0,1837418820.0,21280.0,36420.0,1838628420.0,13.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),94.502869459,94.5028694596396,94.50,1838023620.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001022,103001022,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,36420.0,1837418820.0,21280.0,36420.0,1838628420.0,14.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),391.51,391.51,391.51,1838023620.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001022,103001022,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,36420.0,1837418820.0,21280.0,36420.0,1838628420.0,15.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.0976525023,0.0976525023798114,0.10,1838023620.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001022,103001022,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,36420.0,1837418820.0,21280.0,36420.0,1838628420.0,16.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),7.0980995229,7.09809952298003,7.10,1838023620.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001022,103001022,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,36420.0,1837418820.0,21280.0,36420.0,1838628420.0,17.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1838023620.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001022,103001022,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,36420.0,1837418820.0,21280.0,36420.0,1838628420.0,18.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),967.74652114,967.746521149847,967.75,1838023620.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001022,103001022,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,36420.0,1837418820.0,21280.0,36420.0,1838628420.0,19.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1070.5710358,1070.57103581484,1070.57,1838628420.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001022,103001022,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,36420.0,1837418820.0,21280.0,36420.0,1838628420.0,20.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1053.0407459,1053.04074597617,1053.04,1838628420.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001022,103001022,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,36420.0,1837418820.0,21280.0,36420.0,1838628420.0,21.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.6374709619,1.63747096196469,1.64,1838628420.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001022,103001022,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,36420.0,1837418820.0,21280.0,36420.0,1838628420.0,22.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),93.408094049,93.4080940494409,93.41,1838628420.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001022,103001022,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,36420.0,1837418820.0,21280.0,36420.0,1838628420.0,23.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),375.46,375.46,375.46,1838628420.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001022,103001022,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,36420.0,1837418820.0,21280.0,36420.0,1838628420.0,24.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1260675105,0.126067510596696,0.13,1838628420.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001022,103001022,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,36420.0,1837418820.0,21280.0,36420.0,1838628420.0,25.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),5.4982221611,5.49822216111968,5.50,1838628420.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001022,103001022,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,36420.0,1837418820.0,21280.0,36420.0,1838628420.0,26.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1838628420.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001022,103001022,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,36420.0,1837418820.0,21280.0,36420.0,1838628420.0,27.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),740.93708686,740.937086861846,740.94,1838628420.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001031,103001031,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,35400.0,1837417800.0,21280.0,35400.0,1838627400.0,1.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1196.2820794,1196.28207947299,1196.28,1837417800.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001031,103001031,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,35400.0,1837417800.0,21280.0,35400.0,1838627400.0,2.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1175.4974664,1175.49746641152,1175.50,1837417800.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001031,103001031,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,35400.0,1837417800.0,21280.0,35400.0,1838627400.0,3.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.7374341234,1.73743412344903,1.74,1837417800.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001031,103001031,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,35400.0,1837417800.0,21280.0,35400.0,1838627400.0,4.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),83.592324683,83.5923246832002,83.59,1837417800.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001031,103001031,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,35400.0,1837417800.0,21280.0,35400.0,1838627400.0,5.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),313.49,313.49,313.49,1837417800.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001031,103001031,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,35400.0,1837417800.0,21280.0,35400.0,1838627400.0,6.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1270170386,0.127017038623348,0.13,1837417800.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001031,103001031,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,35400.0,1837417800.0,21280.0,35400.0,1838627400.0,7.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),5.4571196752,5.45711967522231,5.46,1837417800.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001031,103001031,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,35400.0,1837417800.0,21280.0,35400.0,1838627400.0,8.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),3.0,3,3.00,1837417800.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001031,103001031,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,35400.0,1837417800.0,21280.0,35400.0,1838627400.0,9.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),658.11898615,658.118986154936,658.12,1837417800.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001031,103001031,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,35400.0,1837417800.0,21280.0,35400.0,1838627400.0,10.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1087.7903874,1087.7903874487,1087.79,1838022600.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001031,103001031,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,35400.0,1837417800.0,21280.0,35400.0,1838627400.0,11.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1066.7912269,1066.79122695567,1066.79,1838022600.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001031,103001031,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,35400.0,1837417800.0,21280.0,35400.0,1838627400.0,12.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.9304418144,1.93044181446346,1.93,1838022600.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001031,103001031,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,35400.0,1837417800.0,21280.0,35400.0,1838627400.0,13.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),91.929475709,91.9294757095067,91.93,1838022600.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001031,103001031,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,35400.0,1837417800.0,21280.0,35400.0,1838627400.0,14.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),216.91,216.91,216.91,1838022600.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001031,103001031,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,35400.0,1837417800.0,21280.0,35400.0,1838627400.0,15.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1300051971,0.130005197155713,0.13,1838022600.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001031,103001031,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,35400.0,1837417800.0,21280.0,35400.0,1838627400.0,16.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),5.331688238,5.33168823804585,5.33,1838022600.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001031,103001031,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,35400.0,1837417800.0,21280.0,35400.0,1838627400.0,17.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),3.0241666666,3.02416666666667,3.02,1838022600.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001031,103001031,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,35400.0,1837417800.0,21280.0,35400.0,1838627400.0,18.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),707.12154375,707.121543759508,707.12,1838022600.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001031,103001031,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,35400.0,1837417800.0,21280.0,35400.0,1838627400.0,19.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1382.8323848,1382.83238480326,1382.83,1838627400.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001031,103001031,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,35400.0,1837417800.0,21280.0,35400.0,1838627400.0,20.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1356.4859147,1356.48591477032,1356.49,1838627400.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001031,103001031,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,35400.0,1837417800.0,21280.0,35400.0,1838627400.0,21.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.9052540512,1.90525405121236,1.91,1838627400.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001031,103001031,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,35400.0,1837417800.0,21280.0,35400.0,1838627400.0,22.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),72.315344288,72.3153442882578,72.32,1838627400.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001031,103001031,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,35400.0,1837417800.0,21280.0,35400.0,1838627400.0,23.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),256.96,256.96,256.96,1838627400.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001031,103001031,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,35400.0,1837417800.0,21280.0,35400.0,1838627400.0,24.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.132086006,0.132086006043657,0.13,1838627400.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001031,103001031,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,35400.0,1837417800.0,21280.0,35400.0,1838627400.0,25.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),5.2476958106,5.24769581064362,5.25,1838627400.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001031,103001031,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,35400.0,1837417800.0,21280.0,35400.0,1838627400.0,26.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1838627400.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001031,103001031,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,35400.0,1837417800.0,21280.0,35400.0,1838627400.0,27.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),547.48679632,547.486796325391,547.49,1838627400.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001032,103001032,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,35460.0,1837417860.0,21280.0,35460.0,1838627460.0,1.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1079.5992265,1079.59922657045,1079.60,1837417860.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001032,103001032,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,35460.0,1837417860.0,21280.0,35460.0,1838627460.0,2.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1019.6437175,1019.64371757872,1019.64,1837417860.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001032,103001032,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,35460.0,1837417860.0,21280.0,35460.0,1838627460.0,3.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),5.5534968455,5.55349684550928,5.55,1837417860.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001032,103001032,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,35460.0,1837417860.0,21280.0,35460.0,1838627460.0,4.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),92.626965209,92.6269652097365,92.63,1837417860.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001032,103001032,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,35460.0,1837417860.0,21280.0,35460.0,1838627460.0,5.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),241.06,241.06,241.06,1837417860.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001032,103001032,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,35460.0,1837417860.0,21280.0,35460.0,1838627460.0,6.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1010749487,0.101074948773024,0.10,1837417860.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001032,103001032,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,35460.0,1837417860.0,21280.0,35460.0,1838627460.0,7.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),6.8577544581,6.85775445819407,6.86,1837417860.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001032,103001032,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,35460.0,1837417860.0,21280.0,35460.0,1838627460.0,8.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),0.5,0.5,0.50,1837417860.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001032,103001032,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,35460.0,1837417860.0,21280.0,35460.0,1838627460.0,9.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),916.41862137,916.418621371168,916.42,1837417860.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001032,103001032,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,35460.0,1837417860.0,21280.0,35460.0,1838627460.0,10.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1078.471847,1078.47184702266,1078.47,1838022660.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001032,103001032,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,35460.0,1837417860.0,21280.0,35460.0,1838627460.0,11.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1037.5447983,1037.54479838621,1037.54,1838022660.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001032,103001032,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,35460.0,1837417860.0,21280.0,35460.0,1838627460.0,12.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),3.7949111744,3.79491117449481,3.79,1838022660.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001032,103001032,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,35460.0,1837417860.0,21280.0,35460.0,1838627460.0,13.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),92.723792722,92.7237927221473,92.72,1838022660.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001032,103001032,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,35460.0,1837417860.0,21280.0,35460.0,1838627460.0,14.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),338.98,338.98,338.98,1838022660.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001032,103001032,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,35460.0,1837417860.0,21280.0,35460.0,1838627460.0,15.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1009112588,0.100911258876421,0.10,1838022660.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001032,103001032,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,35460.0,1837417860.0,21280.0,35460.0,1838627460.0,16.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),6.8688785401,6.8688785401914,6.87,1838022660.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001032,103001032,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,35460.0,1837417860.0,21280.0,35460.0,1838627460.0,17.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),0.5,0.5,0.50,1838022660.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001032,103001032,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,35460.0,1837417860.0,21280.0,35460.0,1838627460.0,18.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),918.86469116,918.864691160972,918.86,1838022660.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001032,103001032,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,35460.0,1837417860.0,21280.0,35460.0,1838627460.0,19.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1413.2254191,1413.2254191552,1413.23,1838627460.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001032,103001032,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,35460.0,1837417860.0,21280.0,35460.0,1838627460.0,20.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1378.8859572,1378.88595727867,1378.89,1838627460.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001032,103001032,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,35460.0,1837417860.0,21280.0,35460.0,1838627460.0,21.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),2.4298644371,2.42986443712981,2.43,1838627460.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001032,103001032,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,35460.0,1837417860.0,21280.0,35460.0,1838627460.0,22.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),70.760119825,70.7601198255961,70.76,1838627460.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001032,103001032,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,35460.0,1837417860.0,21280.0,35460.0,1838627460.0,23.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),495.75,495.75,495.75,1838627460.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001032,103001032,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,35460.0,1837417860.0,21280.0,35460.0,1838627460.0,24.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1144455907,0.114445590735537,0.11,1838627460.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001032,103001032,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,35460.0,1837417860.0,21280.0,35460.0,1838627460.0,25.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),6.0565651861,6.05656518617379,6.06,1838627460.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001032,103001032,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,35460.0,1837417860.0,21280.0,35460.0,1838627460.0,26.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1838627460.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001032,103001032,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,35460.0,1837417860.0,21280.0,35460.0,1838627460.0,27.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),618.28611631,618.286116318016,618.29,1838627460.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001034,103001034,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,34472.0,1837416872.0,21280.0,34440.0,1838626440.0,1.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),2447.2015995,2447.20159959804,2447.20,1837416872.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001034,103001034,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,34472.0,1837416872.0,21280.0,34440.0,1838626440.0,2.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),2335.7452021,2335.74520218883,2335.75,1837416872.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001034,103001034,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,34472.0,1837416872.0,21280.0,34440.0,1838626440.0,3.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),4.5544428144,4.55444281449921,4.55,1837416872.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001034,103001034,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,34472.0,1837416872.0,21280.0,34440.0,1838626440.0,4.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),40.863000423,40.8630004231877,40.86,1837416872.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001034,103001034,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,34472.0,1837416872.0,21280.0,34440.0,1838626440.0,5.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),557.99,557.99,557.99,1837416872.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001034,103001034,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,34472.0,1837416872.0,21280.0,34440.0,1838626440.0,6.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1121514806,0.112151480673714,0.11,1837416872.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001034,103001034,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,34472.0,1837416872.0,21280.0,34440.0,1838626440.0,7.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),6.1804550095,6.18045500956461,6.18,1837416872.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001034,103001034,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,34472.0,1837416872.0,21280.0,34440.0,1838626440.0,8.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),0.9911111111,0.991111111111111,0.99,1837416872.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001034,103001034,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,34472.0,1837416872.0,21280.0,34440.0,1838626440.0,9.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),364.35542515,364.355425159938,364.36,1837416872.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001034,103001034,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,34472.0,1837416872.0,21280.0,34440.0,1838626440.0,10.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1966.5304468,1966.53044686336,1966.53,1838021640.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001034,103001034,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,34472.0,1837416872.0,21280.0,34440.0,1838626440.0,11.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1914.3109572,1914.31095729237,1914.31,1838021640.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001034,103001034,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,34472.0,1837416872.0,21280.0,34440.0,1838626440.0,12.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),2.6554122085,2.65541220855626,2.66,1838021640.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001034,103001034,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,34472.0,1837416872.0,21280.0,34440.0,1838626440.0,13.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),50.850979784,50.8509797849819,50.85,1838021640.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001034,103001034,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,34472.0,1837416872.0,21280.0,34440.0,1838626440.0,14.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),543.34,543.34,543.34,1838021640.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001034,103001034,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,34472.0,1837416872.0,21280.0,34440.0,1838626440.0,15.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1210276096,0.121027609651542,0.12,1838021640.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001034,103001034,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,34472.0,1837416872.0,21280.0,34440.0,1838626440.0,16.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),5.7271822731,5.72718227316586,5.73,1838021640.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001034,103001034,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,34472.0,1837416872.0,21280.0,34440.0,1838626440.0,17.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1838021640.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001034,103001034,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,34472.0,1837416872.0,21280.0,34440.0,1838626440.0,18.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),420.16015958,420.160159581688,420.16,1838021640.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001034,103001034,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,34472.0,1837416872.0,21280.0,34440.0,1838626440.0,19.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1845.803553,1845.80355302698,1845.80,1838626440.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001034,103001034,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,34472.0,1837416872.0,21280.0,34440.0,1838626440.0,20.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1790.8921971,1790.8921971292,1790.89,1838626440.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001034,103001034,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,34472.0,1837416872.0,21280.0,34440.0,1838626440.0,21.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),2.9749295805,2.97492958054647,2.97,1838626440.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001034,103001034,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,34472.0,1837416872.0,21280.0,34440.0,1838626440.0,22.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),54.176946314,54.1769463147947,54.18,1838626440.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001034,103001034,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,34472.0,1837416872.0,21280.0,34440.0,1838626440.0,23.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),532.92,532.92,532.92,1838626440.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001034,103001034,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,34472.0,1837416872.0,21280.0,34440.0,1838626440.0,24.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.119283159,0.119283159064465,0.12,1838626440.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001034,103001034,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,34472.0,1837416872.0,21280.0,34440.0,1838626440.0,25.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),5.8109391635,5.81093916355238,5.81,1838626440.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001034,103001034,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,34472.0,1837416872.0,21280.0,34440.0,1838626440.0,26.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1838626440.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001034,103001034,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,34472.0,1837416872.0,21280.0,34440.0,1838626440.0,27.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),454.18772222,454.187722220834,454.19,1838626440.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001035,103001035,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,36480.0,1837418880.0,21280.0,36480.0,1838628480.0,1.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1237.2738398,1237.27383980469,1237.27,1837418880.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001035,103001035,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,36480.0,1837418880.0,21280.0,36480.0,1838628480.0,2.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1221.6982154,1221.698215455,1221.70,1837418880.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001035,103001035,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,36480.0,1837418880.0,21280.0,36480.0,1838628480.0,3.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.2588663761,1.25886637610852,1.26,1837418880.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001035,103001035,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,36480.0,1837418880.0,21280.0,36480.0,1838628480.0,4.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),80.822851645,80.8228516459911,80.82,1837418880.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001035,103001035,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,36480.0,1837418880.0,21280.0,36480.0,1838628480.0,5.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),355.97,355.97,355.97,1837418880.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001035,103001035,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,36480.0,1837418880.0,21280.0,36480.0,1838628480.0,6.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1136391042,0.113639104299241,0.11,1837418880.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001035,103001035,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,36480.0,1837418880.0,21280.0,36480.0,1838628480.0,7.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),6.099548081,6.09954808104359,6.10,1837418880.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001035,103001035,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,36480.0,1837418880.0,21280.0,36480.0,1838628480.0,8.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1837418880.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001035,103001035,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,36480.0,1837418880.0,21280.0,36480.0,1838628480.0,9.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),711.2239413,711.223941304255,711.22,1837418880.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001035,103001035,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,36480.0,1837418880.0,21280.0,36480.0,1838628480.0,10.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1489.6957511,1489.69575119907,1489.70,1838023680.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001035,103001035,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,36480.0,1837418880.0,21280.0,36480.0,1838628480.0,11.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1468.7850023,1468.78500238718,1468.79,1838023680.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001035,103001035,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,36480.0,1837418880.0,21280.0,36480.0,1838628480.0,12.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.4036925858,1.40369258588976,1.40,1838023680.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001035,103001035,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,36480.0,1837418880.0,21280.0,36480.0,1838628480.0,13.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),67.127801042,67.1278010422658,67.13,1838023680.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001035,103001035,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,36480.0,1837418880.0,21280.0,36480.0,1838628480.0,14.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),449.04,449.04,449.04,1838023680.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001035,103001035,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,36480.0,1837418880.0,21280.0,36480.0,1838628480.0,15.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1099912786,0.109991278681112,0.11,1838023680.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001035,103001035,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,36480.0,1837418880.0,21280.0,36480.0,1838628480.0,16.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),6.3018376445,6.30183764450568,6.30,1838023680.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001035,103001035,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,36480.0,1837418880.0,21280.0,36480.0,1838628480.0,17.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1838023680.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001035,103001035,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,36480.0,1837418880.0,21280.0,36480.0,1838628480.0,18.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),610.30112429,610.301124299896,610.30,1838023680.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001035,103001035,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,36480.0,1837418880.0,21280.0,36480.0,1838628480.0,19.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1390.793258,1390.79325807178,1390.79,1838628480.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001035,103001035,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,36480.0,1837418880.0,21280.0,36480.0,1838628480.0,20.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1370.7003792,1370.70037926821,1370.70,1838628480.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001035,103001035,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,36480.0,1837418880.0,21280.0,36480.0,1838628480.0,21.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.4447063707,1.44470637076761,1.44,1838628480.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001035,103001035,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,36480.0,1837418880.0,21280.0,36480.0,1838628480.0,22.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),71.901412679,71.9014126791512,71.90,1838628480.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001035,103001035,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,36480.0,1837418880.0,21280.0,36480.0,1838628480.0,23.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),453.57,453.57,453.57,1838628480.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001035,103001035,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,36480.0,1837418880.0,21280.0,36480.0,1838628480.0,24.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1020261964,0.102026196447063,0.10,1838628480.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001035,103001035,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,36480.0,1837418880.0,21280.0,36480.0,1838628480.0,25.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),6.7938157522,6.79381575220823,6.79,1838628480.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001035,103001035,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,36480.0,1837418880.0,21280.0,36480.0,1838628480.0,26.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.5,1.5,1.50,1838628480.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001035,103001035,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,36480.0,1837418880.0,21280.0,36480.0,1838628480.0,27.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),704.734815,704.734815008594,704.73,1838628480.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001037,103001037,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34920.0,1837417320.0,21280.0,34920.0,1838626920.0,1.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1532.4297402,1532.42974027838,1532.43,1837417320.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001037,103001037,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34920.0,1837417320.0,21280.0,34920.0,1838626920.0,2.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1512.3371525,1512.3371525188,1512.34,1837417320.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001037,103001037,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34920.0,1837417320.0,21280.0,34920.0,1838626920.0,3.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.3111588238,1.31115882389011,1.31,1837417320.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001037,103001037,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34920.0,1837417320.0,21280.0,34920.0,1838626920.0,4.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),65.255846562,65.2558465628802,65.26,1837417320.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001037,103001037,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34920.0,1837417320.0,21280.0,34920.0,1838626920.0,5.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),573.61,573.61,573.61,1837417320.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001037,103001037,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34920.0,1837417320.0,21280.0,34920.0,1838626920.0,6.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1378617843,0.137861784312964,0.14,1837417320.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001037,103001037,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34920.0,1837417320.0,21280.0,34920.0,1838626920.0,7.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),5.0278413558,5.02784135584965,5.03,1837417320.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001037,103001037,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34920.0,1837417320.0,21280.0,34920.0,1838626920.0,8.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1837417320.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001037,103001037,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34920.0,1837417320.0,21280.0,34920.0,1838626920.0,9.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),473.3425357,473.342535700402,473.34,1837417320.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001037,103001037,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34920.0,1837417320.0,21280.0,34920.0,1838626920.0,10.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1425.3865178,1425.38651785437,1425.39,1838022120.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001037,103001037,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34920.0,1837417320.0,21280.0,34920.0,1838626920.0,11.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1408.3991478,1408.3991478312,1408.40,1838022120.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001037,103001037,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34920.0,1837417320.0,21280.0,34920.0,1838626920.0,12.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.1917728847,1.19177288478487,1.19,1838022120.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001037,103001037,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34920.0,1837417320.0,21280.0,34920.0,1838626920.0,13.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),70.156409329,70.1564093299619,70.16,1838022120.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001037,103001037,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34920.0,1837417320.0,21280.0,34920.0,1838626920.0,14.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),453.39,453.39,453.39,1838022120.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001037,103001037,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34920.0,1837417320.0,21280.0,34920.0,1838626920.0,15.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1401040889,0.140104088905706,0.14,1838022120.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001037,103001037,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34920.0,1837417320.0,21280.0,34920.0,1838626920.0,16.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.9473729565,4.94737295659125,4.95,1838022120.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001037,103001037,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34920.0,1837417320.0,21280.0,34920.0,1838626920.0,17.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1838022120.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001037,103001037,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34920.0,1837417320.0,21280.0,34920.0,1838626920.0,18.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),500.74490957,500.744909573476,500.74,1838022120.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001037,103001037,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34920.0,1837417320.0,21280.0,34920.0,1838626920.0,19.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1387.0800245,1387.08002453029,1387.08,1838626920.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001037,103001037,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34920.0,1837417320.0,21280.0,34920.0,1838626920.0,20.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1355.2840594,1355.28405944403,1355.28,1838626920.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001037,103001037,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34920.0,1837417320.0,21280.0,34920.0,1838626920.0,21.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),2.2922949306,2.29229493064235,2.29,1838626920.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001037,103001037,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34920.0,1837417320.0,21280.0,34920.0,1838626920.0,22.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),72.093893813,72.093893813995,72.09,1838626920.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001037,103001037,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34920.0,1837417320.0,21280.0,34920.0,1838626920.0,23.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),406.24,406.24,406.24,1838626920.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001037,103001037,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34920.0,1837417320.0,21280.0,34920.0,1838626920.0,24.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1185685035,0.118568503574973,0.12,1838626920.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001037,103001037,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34920.0,1837417320.0,21280.0,34920.0,1838626920.0,25.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),5.845963807,5.84596380708856,5.85,1838626920.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001037,103001037,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34920.0,1837417320.0,21280.0,34920.0,1838626920.0,26.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1838626920.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001037,103001037,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34920.0,1837417320.0,21280.0,34920.0,1838626920.0,27.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),608.03579062,608.035790621313,608.04,1838626920.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001038,103001038,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35520.0,1837417920.0,21280.0,35520.0,1838627520.0,1.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),2039.1329156,2039.13291567762,2039.13,1837417920.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001038,103001038,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35520.0,1837417920.0,21280.0,35520.0,1838627520.0,2.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),2005.1499221,2005.14992210858,2005.15,1837417920.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001038,103001038,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35520.0,1837417920.0,21280.0,35520.0,1838627520.0,3.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.666541367,1.66654136705704,1.67,1837417920.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001038,103001038,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35520.0,1837417920.0,21280.0,35520.0,1838627520.0,4.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),49.040452062,49.0404520623262,49.04,1837417920.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001038,103001038,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35520.0,1837417920.0,21280.0,35520.0,1838627520.0,5.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),902.08,902.08,902.08,1837417920.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001038,103001038,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35520.0,1837417920.0,21280.0,35520.0,1838627520.0,6.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1168231395,0.11682313954873,0.12,1837417920.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001038,103001038,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35520.0,1837417920.0,21280.0,35520.0,1838627520.0,7.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),5.9333038235,5.93330382351878,5.93,1837417920.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001038,103001038,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35520.0,1837417920.0,21280.0,35520.0,1838627520.0,8.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1837417920.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001038,103001038,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35520.0,1837417920.0,21280.0,35520.0,1838627520.0,9.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),419.78371966,419.783719661722,419.78,1837417920.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001038,103001038,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35520.0,1837417920.0,21280.0,35520.0,1838627520.0,10.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1672.1805553,1672.18055531527,1672.18,1838022720.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001038,103001038,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35520.0,1837417920.0,21280.0,35520.0,1838627520.0,11.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1626.9672962,1626.96729620741,1626.97,1838022720.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001038,103001038,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35520.0,1837417920.0,21280.0,35520.0,1838627520.0,12.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),2.7038503087,2.70385030875625,2.70,1838022720.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001038,103001038,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35520.0,1837417920.0,21280.0,35520.0,1838627520.0,13.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),59.802154547,59.8021545473278,59.80,1838022720.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001038,103001038,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35520.0,1837417920.0,21280.0,35520.0,1838627520.0,14.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),426.74,426.74,426.74,1838022720.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001038,103001038,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35520.0,1837417920.0,21280.0,35520.0,1838627520.0,15.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1070482441,0.107048244154539,0.11,1838022720.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001038,103001038,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35520.0,1837417920.0,21280.0,35520.0,1838627520.0,16.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),6.4750915443,6.47509154432546,6.48,1838022720.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001038,103001038,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35520.0,1837417920.0,21280.0,35520.0,1838627520.0,17.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1838022720.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001038,103001038,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35520.0,1837417920.0,21280.0,35520.0,1838627520.0,18.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),558.646758,558.646758007491,558.65,1838022720.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001038,103001038,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35520.0,1837417920.0,21280.0,35520.0,1838627520.0,19.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1714.9213902,1714.92139027733,1714.92,1838627520.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001038,103001038,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35520.0,1837417920.0,21280.0,35520.0,1838627520.0,20.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1688.4829308,1688.48293089964,1688.48,1838627520.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001038,103001038,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35520.0,1837417920.0,21280.0,35520.0,1838627520.0,21.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.5416717948,1.54167179484663,1.54,1838627520.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001038,103001038,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35520.0,1837417920.0,21280.0,35520.0,1838627520.0,22.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),58.311710709,58.3117107098583,58.31,1838627520.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001038,103001038,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35520.0,1837417920.0,21280.0,35520.0,1838627520.0,23.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),475.21,475.21,475.21,1838627520.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001038,103001038,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35520.0,1837417920.0,21280.0,35520.0,1838627520.0,24.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1331393766,0.133139376607147,0.13,1838627520.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001038,103001038,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35520.0,1837417920.0,21280.0,35520.0,1838627520.0,25.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),5.2061771522,5.2061771522726,5.21,1838627520.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001038,103001038,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35520.0,1837417920.0,21280.0,35520.0,1838627520.0,26.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1838627520.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001038,103001038,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35520.0,1837417920.0,21280.0,35520.0,1838627520.0,27.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),437.97494171,437.974941717792,437.97,1838627520.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001044,103001044,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,36000.0,1837418400.0,21280.0,36000.0,1838628000.0,1.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1278.9325406,1278.93254060572,1278.93,1837418400.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001044,103001044,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,36000.0,1837418400.0,21280.0,36000.0,1838628000.0,2.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1169.0976633,1169.09766339824,1169.10,1837418400.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001044,103001044,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,36000.0,1837418400.0,21280.0,36000.0,1838628000.0,3.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),8.588011777,8.58801177702962,8.59,1837418400.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001044,103001044,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,36000.0,1837418400.0,21280.0,36000.0,1838628000.0,4.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),78.19020693,78.190206930413,78.19,1837418400.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001044,103001044,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,36000.0,1837418400.0,21280.0,36000.0,1838628000.0,5.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),393.44,393.44,393.44,1837418400.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001044,103001044,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,36000.0,1837418400.0,21280.0,36000.0,1838628000.0,6.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.0601812481,0.0601812481431867,0.06,1837418400.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001044,103001044,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,36000.0,1837418400.0,21280.0,36000.0,1838628000.0,7.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),11.517660433,11.5176604332095,11.52,1837418400.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001044,103001044,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,36000.0,1837418400.0,21280.0,36000.0,1838628000.0,8.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1837418400.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001044,103001044,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,36000.0,1837418400.0,21280.0,36000.0,1838628000.0,9.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),1299.245352,1299.24535204684,1299.25,1837418400.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001044,103001044,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,36000.0,1837418400.0,21280.0,36000.0,1838628000.0,10.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1569.8190273,1569.81902739586,1569.82,1838023200.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001044,103001044,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,36000.0,1837418400.0,21280.0,36000.0,1838628000.0,11.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1536.8526169,1536.85261693493,1536.85,1838023200.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001044,103001044,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,36000.0,1837418400.0,21280.0,36000.0,1838628000.0,12.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),2.1000134337,2.10001343375378,2.10,1838023200.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001044,103001044,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,36000.0,1837418400.0,21280.0,36000.0,1838628000.0,13.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),63.701610347,63.7016103479697,63.70,1838023200.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001044,103001044,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,36000.0,1837418400.0,21280.0,36000.0,1838628000.0,14.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),407.23,407.23,407.23,1838023200.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001044,103001044,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,36000.0,1837418400.0,21280.0,36000.0,1838628000.0,15.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1298291181,0.129829118189002,0.13,1838023200.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001044,103001044,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,36000.0,1837418400.0,21280.0,36000.0,1838628000.0,16.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),5.3389192673,5.33891926733169,5.34,1838023200.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001044,103001044,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,36000.0,1837418400.0,21280.0,36000.0,1838628000.0,17.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.5,1.5,1.50,1838023200.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001044,103001044,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,36000.0,1837418400.0,21280.0,36000.0,1838628000.0,18.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),490.65734433,490.657344334994,490.66,1838023200.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001044,103001044,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,36000.0,1837418400.0,21280.0,36000.0,1838628000.0,19.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1413.6254784,1413.62547847429,1413.63,1838628000.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001044,103001044,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,36000.0,1837418400.0,21280.0,36000.0,1838628000.0,20.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1369.0833997,1369.08339976194,1369.08,1838628000.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001044,103001044,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,36000.0,1837418400.0,21280.0,36000.0,1838628000.0,21.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),3.1509108593,3.15091085939021,3.15,1838628000.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001044,103001044,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,36000.0,1837418400.0,21280.0,36000.0,1838628000.0,22.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),70.740094546,70.7400945460667,70.74,1838628000.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001044,103001044,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,36000.0,1837418400.0,21280.0,36000.0,1838628000.0,23.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),378.95,378.95,378.95,1838628000.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001044,103001044,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,36000.0,1837418400.0,21280.0,36000.0,1838628000.0,24.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1093348164,0.109334816442892,0.11,1838628000.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001044,103001044,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,36000.0,1837418400.0,21280.0,36000.0,1838628000.0,25.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),6.3396747999,6.33967479994801,6.34,1838628000.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001044,103001044,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,36000.0,1837418400.0,21280.0,36000.0,1838628000.0,26.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1838628000.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001044,103001044,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,36000.0,1837418400.0,21280.0,36000.0,1838628000.0,27.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),647.00428324,647.004283242343,647.00,1838628000.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001048,103001048,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,34500.0,1837416900.0,21280.0,34500.0,1838626500.0,1.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),956.8901632,956.890163208042,956.89,1837416900.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001048,103001048,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,34500.0,1837416900.0,21280.0,34500.0,1838626500.0,2.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),949.49326343,949.493263434145,949.49,1837416900.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001048,103001048,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,34500.0,1837416900.0,21280.0,34500.0,1838626500.0,3.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),0.7730145066,0.773014506607355,0.77,1837416900.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001048,103001048,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,34500.0,1837416900.0,21280.0,34500.0,1838626500.0,4.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),104.50520221,104.505202211237,104.51,1837416900.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001048,103001048,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,34500.0,1837416900.0,21280.0,34500.0,1838626500.0,5.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),322.68,322.68,322.68,1837416900.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001048,103001048,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,34500.0,1837416900.0,21280.0,34500.0,1838626500.0,6.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.168989717,0.168989717071892,0.17,1837416900.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001048,103001048,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,34500.0,1837416900.0,21280.0,34500.0,1838626500.0,7.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.1017121785,4.10171217852896,4.10,1837416900.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001048,103001048,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,34500.0,1837416900.0,21280.0,34500.0,1838626500.0,8.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1837416900.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001048,103001048,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,34500.0,1837416900.0,21280.0,34500.0,1838626500.0,9.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),618.41160528,618.411605285888,618.41,1837416900.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001048,103001048,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,34500.0,1837416900.0,21280.0,34500.0,1838626500.0,10.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1124.5470584,1124.54705846927,1124.55,1838021700.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001048,103001048,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,34500.0,1837416900.0,21280.0,34500.0,1838626500.0,11.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1119.0899291,1119.08992915634,1119.09,1838021700.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001048,103001048,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,34500.0,1837416900.0,21280.0,34500.0,1838626500.0,12.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),0.4852735394,0.485273539406473,0.49,1838021700.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001048,103001048,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,34500.0,1837416900.0,21280.0,34500.0,1838626500.0,13.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),88.924691276,88.9246912762548,88.92,1838021700.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001048,103001048,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,34500.0,1837416900.0,21280.0,34500.0,1838626500.0,14.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),324.69,324.69,324.69,1838021700.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001048,103001048,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,34500.0,1837416900.0,21280.0,34500.0,1838626500.0,15.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1997387156,0.199738715631742,0.20,1838021700.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001048,103001048,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,34500.0,1837416900.0,21280.0,34500.0,1838626500.0,16.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),3.4702695387,3.47026953872028,3.47,1838021700.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001048,103001048,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,34500.0,1837416900.0,21280.0,34500.0,1838626500.0,17.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1838021700.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001048,103001048,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,34500.0,1837416900.0,21280.0,34500.0,1838626500.0,18.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),445.20508202,445.205082024284,445.21,1838021700.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001048,103001048,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,34500.0,1837416900.0,21280.0,34500.0,1838626500.0,19.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),938.09468979,938.0946897942,938.09,1838626500.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001048,103001048,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,34500.0,1837416900.0,21280.0,34500.0,1838626500.0,20.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),916.57565183,916.575651833734,916.58,1838626500.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001048,103001048,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,34500.0,1837416900.0,21280.0,34500.0,1838626500.0,21.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),2.2939089405,2.29390894059821,2.29,1838626500.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001048,103001048,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,34500.0,1837416900.0,21280.0,34500.0,1838626500.0,22.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),106.59904707,106.599047076941,106.60,1838626500.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001048,103001048,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,34500.0,1837416900.0,21280.0,34500.0,1838626500.0,23.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),314.69,314.69,314.69,1838626500.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001048,103001048,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,34500.0,1837416900.0,21280.0,34500.0,1838626500.0,24.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.2690640729,0.269064072968184,0.27,1838626500.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001048,103001048,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,34500.0,1837416900.0,21280.0,34500.0,1838626500.0,25.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),2.5761417082,2.57614170823136,2.58,1838626500.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001048,103001048,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,34500.0,1837416900.0,21280.0,34500.0,1838626500.0,26.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1838626500.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001048,103001048,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,34500.0,1837416900.0,21280.0,34500.0,1838626500.0,27.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),396.18461841,396.184618410744,396.18,1838626500.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001052,103001052,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,34560.0,1837416960.0,21280.0,34560.0,1838626560.0,1.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1013.7574956,1013.75749568253,1013.76,1837416960.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001052,103001052,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,34560.0,1837416960.0,21280.0,34560.0,1838626560.0,2.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),998.87700688,998.877006883088,998.88,1837416960.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001052,103001052,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,34560.0,1837416960.0,21280.0,34560.0,1838626560.0,3.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.4678548728,1.46785487286778,1.47,1837416960.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001052,103001052,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,34560.0,1837416960.0,21280.0,34560.0,1838626560.0,4.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),98.642920447,98.6429204478272,98.64,1837416960.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001052,103001052,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,34560.0,1837416960.0,21280.0,34560.0,1838626560.0,5.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),275.25,275.25,275.25,1837416960.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001052,103001052,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,34560.0,1837416960.0,21280.0,34560.0,1838626560.0,6.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1538927941,0.153892794172624,0.15,1837416960.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001052,103001052,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,34560.0,1837416960.0,21280.0,34560.0,1838626560.0,7.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.5040912037,4.50409120379236,4.50,1837416960.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001052,103001052,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,34560.0,1837416960.0,21280.0,34560.0,1838626560.0,8.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1837416960.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001052,103001052,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,34560.0,1837416960.0,21280.0,34560.0,1838626560.0,9.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),640.98466064,640.98466064095,640.98,1837416960.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001052,103001052,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,34560.0,1837416960.0,21280.0,34560.0,1838626560.0,10.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1398.6776635,1398.6776635528,1398.68,1838021760.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001052,103001052,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,34560.0,1837416960.0,21280.0,34560.0,1838626560.0,11.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1369.2523817,1369.25238174032,1369.25,1838021760.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001052,103001052,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,34560.0,1837416960.0,21280.0,34560.0,1838626560.0,12.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),2.1037929309,2.10379293094128,2.10,1838021760.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001052,103001052,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,34560.0,1837416960.0,21280.0,34560.0,1838626560.0,13.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),71.496101357,71.4961013576128,71.50,1838021760.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001052,103001052,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,34560.0,1837416960.0,21280.0,34560.0,1838626560.0,14.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),320.27,320.27,320.27,1838021760.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001052,103001052,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,34560.0,1837416960.0,21280.0,34560.0,1838626560.0,15.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1250625235,0.125062523562286,0.13,1838021760.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001052,103001052,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,34560.0,1837416960.0,21280.0,34560.0,1838626560.0,16.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),5.5424051971,5.54240519714709,5.54,1838021760.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001052,103001052,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,34560.0,1837416960.0,21280.0,34560.0,1838626560.0,17.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1838021760.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001052,103001052,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,34560.0,1837416960.0,21280.0,34560.0,1838626560.0,18.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),571.68286166,571.682861668826,571.68,1838021760.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001052,103001052,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,34560.0,1837416960.0,21280.0,34560.0,1838626560.0,19.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1536.2872726,1536.28727263971,1536.29,1838626560.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001052,103001052,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,34560.0,1837416960.0,21280.0,34560.0,1838626560.0,20.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1511.2444994,1511.24449946767,1511.24,1838626560.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001052,103001052,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,34560.0,1837416960.0,21280.0,34560.0,1838626560.0,21.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.6300840095,1.63008400954893,1.63,1838626560.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001052,103001052,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,34560.0,1837416960.0,21280.0,34560.0,1838626560.0,22.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),65.091992741,65.0919927418108,65.09,1838626560.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001052,103001052,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,34560.0,1837416960.0,21280.0,34560.0,1838626560.0,23.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),317.72,317.72,317.72,1838626560.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001052,103001052,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,34560.0,1837416960.0,21280.0,34560.0,1838626560.0,24.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1453513145,0.145351314528725,0.15,1838626560.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001052,103001052,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,34560.0,1837416960.0,21280.0,34560.0,1838626560.0,25.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.7687713235,4.76877132351604,4.77,1838626560.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001052,103001052,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,34560.0,1837416960.0,21280.0,34560.0,1838626560.0,26.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1838626560.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001052,103001052,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,34560.0,1837416960.0,21280.0,34560.0,1838626560.0,27.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),447.82527734,447.825277348606,447.83,1838626560.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001054,103001054,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,34620.0,1837417020.0,21280.0,34620.0,1838626620.0,1.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1107.6816065,1107.68160652215,1107.68,1837417020.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001054,103001054,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,34620.0,1837417020.0,21280.0,34620.0,1838626620.0,2.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1093.3192206,1093.31922063523,1093.32,1837417020.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001054,103001054,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,34620.0,1837417020.0,21280.0,34620.0,1838626620.0,3.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.2966168077,1.29661680778585,1.30,1837417020.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001054,103001054,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,34620.0,1837417020.0,21280.0,34620.0,1838626620.0,4.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),90.278649939,90.2786499398286,90.28,1837417020.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001054,103001054,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,34620.0,1837417020.0,21280.0,34620.0,1838626620.0,5.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),351.18,351.18,351.18,1837417020.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001054,103001054,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,34620.0,1837417020.0,21280.0,34620.0,1838626620.0,6.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1364675768,0.136467576865847,0.14,1837417020.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001054,103001054,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,34620.0,1837417020.0,21280.0,34620.0,1838626620.0,7.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),5.0792077977,5.07920779777116,5.08,1837417020.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001054,103001054,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,34620.0,1837417020.0,21280.0,34620.0,1838626620.0,8.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),2.0,2,2.00,1837417020.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001054,103001054,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,34620.0,1837417020.0,21280.0,34620.0,1838626620.0,9.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),661.53918764,661.53918764584,661.54,1837417020.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001054,103001054,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,34620.0,1837417020.0,21280.0,34620.0,1838626620.0,10.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1044.7860598,1044.78605987291,1044.79,1838021820.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001054,103001054,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,34620.0,1837417020.0,21280.0,34620.0,1838626620.0,11.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1018.8763554,1018.87635541222,1018.88,1838021820.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001054,103001054,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,34620.0,1837417020.0,21280.0,34620.0,1838626620.0,12.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),2.4799052605,2.47990526058851,2.48,1838021820.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001054,103001054,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,34620.0,1837417020.0,21280.0,34620.0,1838626620.0,13.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),95.713375054,95.7133750541853,95.71,1838021820.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001054,103001054,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,34620.0,1837417020.0,21280.0,34620.0,1838626620.0,14.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),299.49,299.49,299.49,1838021820.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001054,103001054,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,34620.0,1837417020.0,21280.0,34620.0,1838626620.0,15.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.108453572,0.108453572068489,0.11,1838021820.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001054,103001054,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,34620.0,1837417020.0,21280.0,34620.0,1838626620.0,16.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),6.3911881124,6.39118811247841,6.39,1838021820.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001054,103001054,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,34620.0,1837417020.0,21280.0,34620.0,1838626620.0,17.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1838021820.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001054,103001054,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,34620.0,1837417020.0,21280.0,34620.0,1838626620.0,18.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),882.52856248,882.528562487015,882.53,1838021820.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001054,103001054,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,34620.0,1837417020.0,21280.0,34620.0,1838626620.0,19.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),945.18170158,945.181701582248,945.18,1838626620.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001054,103001054,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,34620.0,1837417020.0,21280.0,34620.0,1838626620.0,20.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),931.41595079,931.415950799274,931.42,1838626620.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001054,103001054,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,34620.0,1837417020.0,21280.0,34620.0,1838626620.0,21.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.45641317,1.45641317007411,1.46,1838626620.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001054,103001054,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,34620.0,1837417020.0,21280.0,34620.0,1838626620.0,22.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),105.79976297,105.79976297954,105.80,1838626620.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001054,103001054,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,34620.0,1837417020.0,21280.0,34620.0,1838626620.0,23.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),212.49,212.49,212.49,1838626620.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001054,103001054,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,34620.0,1837417020.0,21280.0,34620.0,1838626620.0,24.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1431087945,0.143108794504438,0.14,1838626620.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001054,103001054,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,34620.0,1837417020.0,21280.0,34620.0,1838626620.0,25.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.8434981439,4.84349814391352,4.84,1838626620.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001054,103001054,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,34620.0,1837417020.0,21280.0,34620.0,1838626620.0,26.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.5,1.5,1.50,1838626620.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001054,103001054,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,34620.0,1837417020.0,21280.0,34620.0,1838626620.0,27.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),739.29602541,739.296025418333,739.30,1838626620.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001057,103001057,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35220.0,1837417620.0,21280.0,35220.0,1838627220.0,1.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),642.32901467,642.329014675107,642.33,1837417620.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001057,103001057,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35220.0,1837417620.0,21280.0,35220.0,1838627220.0,2.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),624.70747127,624.707471273648,624.71,1837417620.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001057,103001057,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35220.0,1837417620.0,21280.0,35220.0,1838627220.0,3.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),2.7433827522,2.74338275227563,2.74,1837417620.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001057,103001057,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35220.0,1837417620.0,21280.0,35220.0,1838627220.0,4.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),155.6834546,155.683454608664,155.68,1837417620.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001057,103001057,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35220.0,1837417620.0,21280.0,35220.0,1838627220.0,5.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),141.01,141.01,141.01,1837417620.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001057,103001057,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35220.0,1837417620.0,21280.0,35220.0,1838627220.0,6.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1078225645,0.107822564500377,0.11,1837417620.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001057,103001057,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35220.0,1837417620.0,21280.0,35220.0,1838627220.0,7.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),6.4285911188,6.42859111886103,6.43,1837417620.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001057,103001057,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35220.0,1837417620.0,21280.0,35220.0,1838627220.0,8.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.5,1.5,1.50,1837417620.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001057,103001057,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35220.0,1837417620.0,21280.0,35220.0,1838627220.0,9.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),1443.885659,1443.88565909244,1443.89,1837417620.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001057,103001057,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35220.0,1837417620.0,21280.0,35220.0,1838627220.0,10.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),586.51099532,586.510995328274,586.51,1838022420.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001057,103001057,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35220.0,1837417620.0,21280.0,35220.0,1838627220.0,11.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),574.48969568,574.489695687681,574.49,1838022420.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001057,103001057,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35220.0,1837417620.0,21280.0,35220.0,1838627220.0,12.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),2.0496290327,2.04962903276263,2.05,1838022420.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001057,103001057,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35220.0,1837417620.0,21280.0,35220.0,1838627220.0,13.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),170.49978738,170.499787380847,170.50,1838022420.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001057,103001057,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35220.0,1837417620.0,21280.0,35220.0,1838627220.0,14.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),143.43,143.43,143.43,1838022420.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001057,103001057,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35220.0,1837417620.0,21280.0,35220.0,1838627220.0,15.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1231148082,0.123114808236071,0.12,1838022420.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001057,103001057,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35220.0,1837417620.0,21280.0,35220.0,1838627220.0,16.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),5.6300878057,5.63008780577268,5.63,1838022420.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001057,103001057,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35220.0,1837417620.0,21280.0,35220.0,1838627220.0,17.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0122222222,1.01222222222222,1.01,1838022420.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001057,103001057,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35220.0,1837417620.0,21280.0,35220.0,1838627220.0,18.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),1384.8844815,1384.88448159637,1384.88,1838022420.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001057,103001057,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35220.0,1837417620.0,21280.0,35220.0,1838627220.0,19.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),611.03163433,611.031634337863,611.03,1838627220.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001057,103001057,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35220.0,1837417620.0,21280.0,35220.0,1838627220.0,20.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),600.46751626,600.467516267901,600.47,1838627220.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001057,103001057,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35220.0,1837417620.0,21280.0,35220.0,1838627220.0,21.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.7288987142,1.7288987142883,1.73,1838627220.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001057,103001057,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35220.0,1837417620.0,21280.0,35220.0,1838627220.0,22.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),163.65764778,163.65764778834,163.66,1838627220.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001057,103001057,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35220.0,1837417620.0,21280.0,35220.0,1838627220.0,23.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),112.44,112.44,112.44,1838627220.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001057,103001057,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35220.0,1837417620.0,21280.0,35220.0,1838627220.0,24.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.13725708,0.137257080089147,0.14,1838627220.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001057,103001057,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35220.0,1837417620.0,21280.0,35220.0,1838627220.0,25.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),5.049992176,5.04999217606663,5.05,1838627220.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001057,103001057,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35220.0,1837417620.0,21280.0,35220.0,1838627220.0,26.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1838627220.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001057,103001057,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35220.0,1837417620.0,21280.0,35220.0,1838627220.0,27.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),1192.3439408,1192.34394088848,1192.34,1838627220.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001058,103001058,001,Part A,1.0,Y,1.0,N,0.0,5: CAB,5.0,5: CAB,5.0,21266.0,34980.0,1837417380.0,21266.0,34980.0,1837417380.0,1.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1061.3019741,1061.30197418448,1061.30,1837417380.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001058,103001058,001,Part A,1.0,Y,1.0,N,0.0,5: CAB,5.0,5: CAB,5.0,21266.0,34980.0,1837417380.0,21266.0,34980.0,1837417380.0,2.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1042.1415181,1042.14151816371,1042.14,1837417380.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001058,103001058,001,Part A,1.0,Y,1.0,N,0.0,5: CAB,5.0,5: CAB,5.0,21266.0,34980.0,1837417380.0,21266.0,34980.0,1837417380.0,3.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.8053726919,1.80537269192396,1.81,1837417380.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001058,103001058,001,Part A,1.0,Y,1.0,N,0.0,5: CAB,5.0,5: CAB,5.0,21266.0,34980.0,1837417380.0,21266.0,34980.0,1837417380.0,4.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),94.223889554,94.2238895549414,94.22,1837417380.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001058,103001058,001,Part A,1.0,Y,1.0,N,0.0,5: CAB,5.0,5: CAB,5.0,21266.0,34980.0,1837417380.0,21266.0,34980.0,1837417380.0,5.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),262.3,262.3,262.30,1837417380.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001058,103001058,001,Part A,1.0,Y,1.0,N,0.0,5: CAB,5.0,5: CAB,5.0,21266.0,34980.0,1837417380.0,21266.0,34980.0,1837417380.0,6.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1341304192,0.134130419297601,0.13,1837417380.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001058,103001058,001,Part A,1.0,Y,1.0,N,0.0,5: CAB,5.0,5: CAB,5.0,21266.0,34980.0,1837417380.0,21266.0,34980.0,1837417380.0,7.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),5.1677105327,5.16771053270199,5.17,1837417380.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001058,103001058,001,Part A,1.0,Y,1.0,N,0.0,5: CAB,5.0,5: CAB,5.0,21266.0,34980.0,1837417380.0,21266.0,34980.0,1837417380.0,8.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),2.0202777777,2.02027777777778,2.02,1837417380.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001058,103001058,001,Part A,1.0,Y,1.0,N,0.0,5: CAB,5.0,5: CAB,5.0,21266.0,34980.0,1837417380.0,21266.0,34980.0,1837417380.0,9.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),702.47964666,702.47964666302,702.48,1837417380.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001059,103001059,001,Part A,1.0,Y,1.0,N,0.0,1: ABC,1.0,1: ABC,1.0,21266.0,36540.0,1837418940.0,21266.0,36540.0,1837418940.0,1.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1009.3942173,1009.39421737375,1009.39,1837418940.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001059,103001059,001,Part A,1.0,Y,1.0,N,0.0,1: ABC,1.0,1: ABC,1.0,21266.0,36540.0,1837418940.0,21266.0,36540.0,1837418940.0,2.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),407.55,407.55,407.55,1837418940.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001059,103001059,001,Part A,1.0,Y,1.0,N,0.0,1: ABC,1.0,1: ABC,1.0,21266.0,36540.0,1837418940.0,21266.0,36540.0,1837418940.0,3.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.5,1.5,1.50,1837418940.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001066,103001066,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,35580.0,1837417980.0,21280.0,35580.0,1838627580.0,1.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1756.422466,1756.4224660973,1756.42,1837417980.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001066,103001066,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,35580.0,1837417980.0,21280.0,35580.0,1838627580.0,2.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1714.4493235,1714.44932357838,1714.45,1837417980.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001066,103001066,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,35580.0,1837417980.0,21280.0,35580.0,1838627580.0,3.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),2.3896951518,2.38969515188341,2.39,1837417980.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001066,103001066,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,35580.0,1837417980.0,21280.0,35580.0,1838627580.0,4.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),56.933910793,56.9339107932251,56.93,1837417980.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001066,103001066,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,35580.0,1837417980.0,21280.0,35580.0,1838627580.0,5.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),472.93,472.93,472.93,1837417980.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001066,103001066,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,35580.0,1837417980.0,21280.0,35580.0,1838627580.0,6.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1212680227,0.121268022705372,0.12,1837417980.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001066,103001066,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,35580.0,1837417980.0,21280.0,35580.0,1838627580.0,7.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),5.7158281721,5.71582817214713,5.72,1837417980.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001066,103001066,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,35580.0,1837417980.0,21280.0,35580.0,1838627580.0,8.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),3.0,3,3.00,1837417980.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001066,103001066,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,35580.0,1837417980.0,21280.0,35580.0,1838627580.0,9.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),469.48824202,469.488242020316,469.49,1837417980.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001066,103001066,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,35580.0,1837417980.0,21280.0,35580.0,1838627580.0,10.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1598.7641179,1598.76411795283,1598.76,1838022780.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001066,103001066,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,35580.0,1837417980.0,21280.0,35580.0,1838627580.0,11.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1530.8894579,1530.88945796804,1530.89,1838022780.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001066,103001066,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,35580.0,1837417980.0,21280.0,35580.0,1838627580.0,12.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),4.2454455427,4.24544554275464,4.25,1838022780.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001066,103001066,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,35580.0,1837417980.0,21280.0,35580.0,1838627580.0,13.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),62.548313961,62.5483139614411,62.55,1838022780.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001066,103001066,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,35580.0,1837417980.0,21280.0,35580.0,1838627580.0,14.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),411.96,411.96,411.96,1838022780.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001066,103001066,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,35580.0,1837417980.0,21280.0,35580.0,1838627580.0,15.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.0913448406,0.0913448406428769,0.09,1838022780.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001066,103001066,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,35580.0,1837417980.0,21280.0,35580.0,1838627580.0,16.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),7.5882466451,7.58824664514861,7.59,1838022780.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001066,103001066,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,35580.0,1837417980.0,21280.0,35580.0,1838627580.0,17.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.5,1.5,1.50,1838022780.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001066,103001066,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,35580.0,1837417980.0,21280.0,35580.0,1838627580.0,18.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),684.74928108,684.749281089458,684.75,1838022780.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001066,103001066,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,35580.0,1837417980.0,21280.0,35580.0,1838627580.0,19.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1184.2869589,1184.28695898324,1184.29,1838627580.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001066,103001066,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,35580.0,1837417980.0,21280.0,35580.0,1838627580.0,20.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1147.6617439,1147.66174399094,1147.66,1838627580.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001066,103001066,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,35580.0,1837417980.0,21280.0,35580.0,1838627580.0,21.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),3.0925963268,3.09259632680077,3.09,1838627580.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001066,103001066,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,35580.0,1837417980.0,21280.0,35580.0,1838627580.0,22.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),84.438994486,84.4389944864836,84.44,1838627580.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001066,103001066,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,35580.0,1837417980.0,21280.0,35580.0,1838627580.0,23.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),241.08,241.08,241.08,1838627580.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001066,103001066,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,35580.0,1837417980.0,21280.0,35580.0,1838627580.0,24.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1144020588,0.114402058824265,0.11,1838627580.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001066,103001066,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,35580.0,1837417980.0,21280.0,35580.0,1838627580.0,25.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),6.0588698112,6.05886981129162,6.06,1838627580.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001066,103001066,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,35580.0,1837417980.0,21280.0,35580.0,1838627580.0,26.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),2.0,2,2.00,1838627580.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001066,103001066,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,35580.0,1837417980.0,21280.0,35580.0,1838627580.0,27.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),738.08981546,738.089815465577,738.09,1838627580.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001067,103001067,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,35640.0,1837418040.0,21280.0,35640.0,1838627640.0,1.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),2125.2569227,2125.25692278646,2125.26,1837418040.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001067,103001067,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,35640.0,1837418040.0,21280.0,35640.0,1838627640.0,2.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),2103.9786179,2103.9786179007,2103.98,1837418040.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001067,103001067,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,35640.0,1837418040.0,21280.0,35640.0,1838627640.0,3.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.0012109433,1.0012109433744,1.00,1837418040.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001067,103001067,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,35640.0,1837418040.0,21280.0,35640.0,1838627640.0,4.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),47.053134577,47.0531345776719,47.05,1837418040.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001067,103001067,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,35640.0,1837418040.0,21280.0,35640.0,1838627640.0,5.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),610.07,610.07,610.07,1837418040.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001067,103001067,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,35640.0,1837418040.0,21280.0,35640.0,1838627640.0,6.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1626069378,0.162606937844732,0.16,1837418040.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001067,103001067,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,35640.0,1837418040.0,21280.0,35640.0,1838627640.0,7.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.2627159071,4.26271590712698,4.26,1837418040.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001067,103001067,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,35640.0,1837418040.0,21280.0,35640.0,1838627640.0,8.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1837418040.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001067,103001067,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,35640.0,1837418040.0,21280.0,35640.0,1838627640.0,9.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),289.36732467,289.367324674679,289.37,1837418040.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001067,103001067,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,35640.0,1837418040.0,21280.0,35640.0,1838627640.0,10.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1782.3856652,1782.38566526291,1782.39,1838022840.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001067,103001067,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,35640.0,1837418040.0,21280.0,35640.0,1838627640.0,11.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1766.6472927,1766.64729274548,1766.65,1838022840.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001067,103001067,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,35640.0,1837418040.0,21280.0,35640.0,1838627640.0,12.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),0.8829947875,0.88299478750048,0.88,1838022840.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001067,103001067,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,35640.0,1837418040.0,21280.0,35640.0,1838627640.0,13.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),56.104580478,56.1045804782376,56.10,1838022840.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001067,103001067,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,35640.0,1837418040.0,21280.0,35640.0,1838627640.0,14.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),450.25,450.25,450.25,1838022840.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001067,103001067,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,35640.0,1837418040.0,21280.0,35640.0,1838627640.0,15.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1632951562,0.163295156291047,0.16,1838022840.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001067,103001067,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,35640.0,1837418040.0,21280.0,35640.0,1838627640.0,16.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.2447504035,4.24475040352404,4.24,1838022840.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001067,103001067,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,35640.0,1837418040.0,21280.0,35640.0,1838627640.0,17.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1838022840.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001067,103001067,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,35640.0,1837418040.0,21280.0,35640.0,1838627640.0,18.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),343.57773832,343.577738327034,343.58,1838022840.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001067,103001067,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,35640.0,1837418040.0,21280.0,35640.0,1838627640.0,19.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1419.6205697,1419.62056978721,1419.62,1838627640.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001067,103001067,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,35640.0,1837418040.0,21280.0,35640.0,1838627640.0,20.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1402.6114094,1402.61140943245,1402.61,1838627640.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001067,103001067,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,35640.0,1837418040.0,21280.0,35640.0,1838627640.0,21.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.1981483444,1.19814834447691,1.20,1838627640.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001067,103001067,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,35640.0,1837418040.0,21280.0,35640.0,1838627640.0,22.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),70.44135745,70.4413574501736,70.44,1838627640.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001067,103001067,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,35640.0,1837418040.0,21280.0,35640.0,1838627640.0,23.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),371.6,371.6,371.60,1838627640.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001067,103001067,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,35640.0,1837418040.0,21280.0,35640.0,1838627640.0,24.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1557984018,0.155798401845187,0.16,1838627640.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001067,103001067,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,35640.0,1837418040.0,21280.0,35640.0,1838627640.0,25.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.4490005824,4.44900058248805,4.45,1838627640.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001067,103001067,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,35640.0,1837418040.0,21280.0,35640.0,1838627640.0,26.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1838627640.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001067,103001067,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,35640.0,1837418040.0,21280.0,35640.0,1838627640.0,27.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),452.13145074,452.131450746006,452.13,1838627640.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001074,103001074,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36720.0,1837419120.0,21280.0,36720.0,1838628720.0,1.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1168.3269356,1168.32693565687,1168.33,1837419120.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001074,103001074,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36720.0,1837419120.0,21280.0,36720.0,1838628720.0,2.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1158.8448626,1158.84486262234,1158.84,1837419120.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001074,103001074,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36720.0,1837419120.0,21280.0,36720.0,1838628720.0,3.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),0.8115941475,0.811594147591976,0.81,1837419120.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001074,103001074,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36720.0,1837419120.0,21280.0,36720.0,1838628720.0,4.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),85.592480108,85.5924801081273,85.59,1837419120.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001074,103001074,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36720.0,1837419120.0,21280.0,36720.0,1838628720.0,5.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),342.36,342.36,342.36,1837419120.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001074,103001074,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36720.0,1837419120.0,21280.0,36720.0,1838628720.0,6.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1708487156,0.170848715686992,0.17,1837419120.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001074,103001074,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36720.0,1837419120.0,21280.0,36720.0,1838628720.0,7.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.0570815986,4.05708159861059,4.06,1837419120.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001074,103001074,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36720.0,1837419120.0,21280.0,36720.0,1838628720.0,8.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1837419120.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001074,103001074,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36720.0,1837419120.0,21280.0,36720.0,1838628720.0,9.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),500.98404172,500.984041723437,500.98,1837419120.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001074,103001074,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36720.0,1837419120.0,21280.0,36720.0,1838628720.0,10.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1590.713575,1590.71357506777,1590.71,1838023920.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001074,103001074,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36720.0,1837419120.0,21280.0,36720.0,1838628720.0,11.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1573.8318773,1573.83187737916,1573.83,1838023920.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001074,103001074,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36720.0,1837419120.0,21280.0,36720.0,1838628720.0,12.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.0612657082,1.06126570824597,1.06,1838023920.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001074,103001074,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36720.0,1837419120.0,21280.0,36720.0,1838628720.0,13.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),62.864868677,62.8648686774044,62.86,1838023920.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001074,103001074,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36720.0,1837419120.0,21280.0,36720.0,1838628720.0,14.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),265.61,265.61,265.61,1838023920.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001074,103001074,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36720.0,1837419120.0,21280.0,36720.0,1838628720.0,15.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1842231781,0.184223178104813,0.18,1838023920.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001074,103001074,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36720.0,1837419120.0,21280.0,36720.0,1838628720.0,16.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),3.7625405646,3.76254056460573,3.76,1838023920.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001074,103001074,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36720.0,1837419120.0,21280.0,36720.0,1838628720.0,17.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1838023920.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001074,103001074,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36720.0,1837419120.0,21280.0,36720.0,1838628720.0,18.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),341.242993,341.242993005135,341.24,1838023920.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001074,103001074,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36720.0,1837419120.0,21280.0,36720.0,1838628720.0,19.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1521.7001845,1521.70018453667,1521.70,1838628720.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001074,103001074,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36720.0,1837419120.0,21280.0,36720.0,1838628720.0,20.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1503.6472146,1503.64721466416,1503.65,1838628720.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001074,103001074,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36720.0,1837419120.0,21280.0,36720.0,1838628720.0,21.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.1863683829,1.1863683829414,1.19,1838628720.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001074,103001074,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36720.0,1837419120.0,21280.0,36720.0,1838628720.0,22.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),65.715967584,65.715967584277,65.72,1838628720.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001074,103001074,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36720.0,1837419120.0,21280.0,36720.0,1838628720.0,23.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),349.21,349.21,349.21,1838628720.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001074,103001074,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36720.0,1837419120.0,21280.0,36720.0,1838628720.0,24.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1589766127,0.158976612727372,0.16,1838628720.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001074,103001074,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36720.0,1837419120.0,21280.0,36720.0,1838628720.0,25.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.3600575497,4.36005754977695,4.36,1838628720.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001074,103001074,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36720.0,1837419120.0,21280.0,36720.0,1838628720.0,26.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1838628720.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001074,103001074,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36720.0,1837419120.0,21280.0,36720.0,1838628720.0,27.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),413.36877454,413.368774544045,413.37,1838628720.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001079,103001079,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,35700.0,1837418100.0,21280.0,35700.0,1838627700.0,1.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1483.5283578,1483.52835789774,1483.53,1837418100.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001079,103001079,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,35700.0,1837418100.0,21280.0,35700.0,1838627700.0,2.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1448.7484029,1448.74840294959,1448.75,1837418100.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001079,103001079,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,35700.0,1837418100.0,21280.0,35700.0,1838627700.0,3.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),2.3444078276,2.34440782766257,2.34,1837418100.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001079,103001079,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,35700.0,1837418100.0,21280.0,35700.0,1838627700.0,4.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),67.406867868,67.4068678685098,67.41,1837418100.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001079,103001079,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,35700.0,1837418100.0,21280.0,35700.0,1838627700.0,5.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),321.19,321.19,321.19,1837418100.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001079,103001079,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,35700.0,1837418100.0,21280.0,35700.0,1838627700.0,6.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1256470862,0.125647086274695,0.13,1837418100.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001079,103001079,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,35700.0,1837418100.0,21280.0,35700.0,1838627700.0,7.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),5.5166196138,5.51661961380115,5.52,1837418100.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001079,103001079,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,35700.0,1837418100.0,21280.0,35700.0,1838627700.0,8.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),2.0,2,2.00,1837418100.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001079,103001079,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,35700.0,1837418100.0,21280.0,35700.0,1838627700.0,9.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),536.47776376,536.477763767178,536.48,1837418100.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001079,103001079,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,35700.0,1837418100.0,21280.0,35700.0,1838627700.0,10.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1557.3073298,1557.30732989346,1557.31,1838022958.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001079,103001079,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,35700.0,1837418100.0,21280.0,35700.0,1838627700.0,11.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1519.2795626,1519.27956265777,1519.28,1838022958.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001079,103001079,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,35700.0,1837418100.0,21280.0,35700.0,1838627700.0,12.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),2.4418922653,2.44189226530428,2.44,1838022958.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001079,103001079,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,35700.0,1837418100.0,21280.0,35700.0,1838627700.0,13.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),64.213400964,64.2134009648831,64.21,1838022958.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001079,103001079,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,35700.0,1837418100.0,21280.0,35700.0,1838627700.0,14.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),354.4,354.4,354.40,1838022958.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001079,103001079,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,35700.0,1837418100.0,21280.0,35700.0,1838627700.0,15.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1230679669,0.123067966914669,0.12,1838022958.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001079,103001079,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,35700.0,1837418100.0,21280.0,35700.0,1838627700.0,16.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),5.6322306928,5.63223069282155,5.63,1838022958.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001079,103001079,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,35700.0,1837418100.0,21280.0,35700.0,1838627700.0,17.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.9838888888,1.98388888888889,1.98,1838022958.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001079,103001079,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,35700.0,1837418100.0,21280.0,35700.0,1838627700.0,18.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),521.77185156,521.771851560743,521.77,1838022958.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001079,103001079,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,35700.0,1837418100.0,21280.0,35700.0,1838627700.0,19.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1982.2719462,1982.27194620834,1982.27,1838627700.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001079,103001079,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,35700.0,1837418100.0,21280.0,35700.0,1838627700.0,20.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1954.9505794,1954.95057943314,1954.95,1838627700.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001079,103001079,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,35700.0,1837418100.0,21280.0,35700.0,1838627700.0,21.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.3782854984,1.3782854984887,1.38,1838627700.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001079,103001079,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,35700.0,1837418100.0,21280.0,35700.0,1838627700.0,22.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),50.447165027,50.4471650276233,50.45,1838627700.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001079,103001079,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,35700.0,1837418100.0,21280.0,35700.0,1838627700.0,23.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),450.54,450.54,450.54,1838627700.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001079,103001079,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,35700.0,1837418100.0,21280.0,35700.0,1838627700.0,24.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1504317127,0.150431712798893,0.15,1838627700.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001079,103001079,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,35700.0,1837418100.0,21280.0,35700.0,1838627700.0,25.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.607719793,4.60771979301059,4.61,1838627700.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001079,103001079,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,35700.0,1837418100.0,21280.0,35700.0,1838627700.0,26.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1838627700.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001079,103001079,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,35700.0,1837418100.0,21280.0,35700.0,1838627700.0,27.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),335.3492697,335.34926970528,335.35,1838627700.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001089,103001089,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36780.0,1837419180.0,21280.0,36780.0,1838628780.0,1.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1715.1501288,1715.15012882253,1715.15,1837419180.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001089,103001089,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36780.0,1837419180.0,21280.0,36780.0,1838628780.0,2.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1696.7845867,1696.78458679601,1696.78,1837419180.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001089,103001089,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36780.0,1837419180.0,21280.0,36780.0,1838628780.0,3.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.0707833511,1.07078335114188,1.07,1837419180.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001089,103001089,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36780.0,1837419180.0,21280.0,36780.0,1838628780.0,4.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),58.303934051,58.3039340519137,58.30,1837419180.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001089,103001089,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36780.0,1837419180.0,21280.0,36780.0,1838628780.0,5.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),408.09,408.09,408.09,1837419180.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001089,103001089,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36780.0,1837419180.0,21280.0,36780.0,1838628780.0,6.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1698833606,0.16988336067047,0.17,1837419180.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001089,103001089,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36780.0,1837419180.0,21280.0,36780.0,1838628780.0,7.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.0801357933,4.08013579331334,4.08,1837419180.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001089,103001089,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36780.0,1837419180.0,21280.0,36780.0,1838628780.0,8.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),2.0,2,2.00,1837419180.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001089,103001089,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36780.0,1837419180.0,21280.0,36780.0,1838628780.0,9.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),343.19979203,343.199792032654,343.20,1837419180.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001089,103001089,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36780.0,1837419180.0,21280.0,36780.0,1838628780.0,10.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1359.7794631,1359.77946314168,1359.78,1838023980.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001089,103001089,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36780.0,1837419180.0,21280.0,36780.0,1838628780.0,11.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1341.7854467,1341.78544676498,1341.79,1838023980.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001089,103001089,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36780.0,1837419180.0,21280.0,36780.0,1838628780.0,12.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.3233040257,1.32330402572247,1.32,1838023980.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001089,103001089,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36780.0,1837419180.0,21280.0,36780.0,1838628780.0,13.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),73.541337187,73.5413371878381,73.54,1838023980.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001089,103001089,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36780.0,1837419180.0,21280.0,36780.0,1838628780.0,14.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),308.57,308.57,308.57,1838023980.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001089,103001089,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36780.0,1837419180.0,21280.0,36780.0,1838628780.0,15.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1500498801,0.15004988010881,0.15,1838023980.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001089,103001089,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36780.0,1837419180.0,21280.0,36780.0,1838628780.0,16.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.6194450809,4.61944508091111,4.62,1838023980.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001089,103001089,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36780.0,1837419180.0,21280.0,36780.0,1838628780.0,17.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.5,1.5,1.50,1838023980.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001089,103001089,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36780.0,1837419180.0,21280.0,36780.0,1838628780.0,18.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),490.11260211,490.112602119434,490.11,1838023980.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001089,103001089,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36780.0,1837419180.0,21280.0,36780.0,1838628780.0,19.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1796.6647576,1796.66475763933,1796.66,1838628780.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001089,103001089,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36780.0,1837419180.0,21280.0,36780.0,1838628780.0,20.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1779.1420841,1779.14208419903,1779.14,1838628780.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001089,103001089,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36780.0,1837419180.0,21280.0,36780.0,1838628780.0,21.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),0.9752889828,0.975288982866317,0.98,1838628780.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001089,103001089,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36780.0,1837419180.0,21280.0,36780.0,1838628780.0,22.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),55.658686226,55.6586862266904,55.66,1838628780.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001089,103001089,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36780.0,1837419180.0,21280.0,36780.0,1838628780.0,23.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),376.28,376.28,376.28,1838628780.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001089,103001089,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36780.0,1837419180.0,21280.0,36780.0,1838628780.0,24.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1734895083,0.173489508342299,0.17,1838628780.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001089,103001089,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36780.0,1837419180.0,21280.0,36780.0,1838628780.0,25.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),3.9953262141,3.99532621414978,4.00,1838628780.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001089,103001089,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36780.0,1837419180.0,21280.0,36780.0,1838628780.0,26.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),2.0,2,2.00,1838628780.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001089,103001089,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36780.0,1837419180.0,21280.0,36780.0,1838628780.0,27.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),320.81874436,320.818744363921,320.82,1838628780.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001092,103001092,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35100.0,1837417500.0,21280.0,35100.0,1838627100.0,1.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),822.63907596,822.639075960013,822.64,1837417500.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001092,103001092,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35100.0,1837417500.0,21280.0,35100.0,1838627100.0,2.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),805.31724377,805.31724377541,805.32,1837417500.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001092,103001092,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35100.0,1837417500.0,21280.0,35100.0,1838627100.0,3.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),2.1056417924,2.10564179246992,2.11,1837417500.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001092,103001092,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35100.0,1837417500.0,21280.0,35100.0,1838627100.0,4.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),121.55999261,121.559992616812,121.56,1837417500.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001092,103001092,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35100.0,1837417500.0,21280.0,35100.0,1838627100.0,5.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),182.21,182.21,182.21,1837417500.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001092,103001092,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35100.0,1837417500.0,21280.0,35100.0,1838627100.0,6.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1391307786,0.139130778679537,0.14,1837417500.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001092,103001092,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35100.0,1837417500.0,21280.0,35100.0,1838627100.0,7.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.981983046,4.9819830460123,4.98,1837417500.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001092,103001092,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35100.0,1837417500.0,21280.0,35100.0,1838627100.0,8.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0172222222,1.01722222222222,1.02,1837417500.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001092,103001092,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35100.0,1837417500.0,21280.0,35100.0,1838627100.0,9.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),873.71028733,873.710287331915,873.71,1837417500.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001092,103001092,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35100.0,1837417500.0,21280.0,35100.0,1838627100.0,10.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),840.29550081,840.295500812014,840.30,1838022300.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001092,103001092,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35100.0,1837417500.0,21280.0,35100.0,1838627100.0,11.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),819.89494364,819.894943647944,819.89,1838022300.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001092,103001092,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35100.0,1837417500.0,21280.0,35100.0,1838627100.0,12.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),2.4277836956,2.42778369565906,2.43,1838022300.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001092,103001092,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35100.0,1837417500.0,21280.0,35100.0,1838627100.0,13.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),119.0057544,119.00575440826,119.01,1838022300.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001092,103001092,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35100.0,1837417500.0,21280.0,35100.0,1838627100.0,14.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),149.89,149.89,149.89,1838022300.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001092,103001092,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35100.0,1837417500.0,21280.0,35100.0,1838627100.0,15.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1264671341,0.126467134169446,0.13,1838022300.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001092,103001092,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35100.0,1837417500.0,21280.0,35100.0,1838627100.0,16.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),5.4808483256,5.48084832563088,5.48,1838022300.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001092,103001092,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35100.0,1837417500.0,21280.0,35100.0,1838627100.0,17.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.5,1.5,1.50,1838022300.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001092,103001092,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35100.0,1837417500.0,21280.0,35100.0,1838627100.0,18.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),941.00143242,941.001432425995,941.00,1838022300.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001092,103001092,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35100.0,1837417500.0,21280.0,35100.0,1838627100.0,19.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),883.18903859,883.189038591078,883.19,1838627100.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001092,103001092,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35100.0,1837417500.0,21280.0,35100.0,1838627100.0,20.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),868.03483031,868.034830318114,868.03,1838627100.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001092,103001092,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35100.0,1837417500.0,21280.0,35100.0,1838627100.0,21.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.7158510365,1.71585103650506,1.72,1838627100.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001092,103001092,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35100.0,1837417500.0,21280.0,35100.0,1838627100.0,22.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),113.22604293,113.226042931337,113.23,1838627100.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001092,103001092,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35100.0,1837417500.0,21280.0,35100.0,1838627100.0,23.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),216.47,216.47,216.47,1838627100.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001092,103001092,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35100.0,1837417500.0,21280.0,35100.0,1838627100.0,24.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1629910289,0.162991028994013,0.16,1838627100.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001092,103001092,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35100.0,1837417500.0,21280.0,35100.0,1838627100.0,25.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.2526707441,4.25267074413897,4.25,1838627100.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001092,103001092,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35100.0,1837417500.0,21280.0,35100.0,1838627100.0,26.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),3.0,3,3.00,1838627100.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001092,103001092,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35100.0,1837417500.0,21280.0,35100.0,1838627100.0,27.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),694.67653299,694.676532997999,694.68,1838627100.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001096,103001096,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35940.0,1837418340.0,21280.0,35940.0,1838627940.0,1.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1954.6179826,1954.61798264155,1954.62,1837418340.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001096,103001096,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35940.0,1837418340.0,21280.0,35940.0,1838627940.0,2.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1928.4536654,1928.45366545294,1928.45,1837418340.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001096,103001096,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35940.0,1837418340.0,21280.0,35940.0,1838627940.0,3.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.3385898124,1.33858981248356,1.34,1837418340.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001096,103001096,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35940.0,1837418340.0,21280.0,35940.0,1838627940.0,4.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),51.16089225,51.1608922500835,51.16,1837418340.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001096,103001096,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35940.0,1837418340.0,21280.0,35940.0,1838627940.0,5.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),613.87,613.87,613.87,1837418340.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001096,103001096,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35940.0,1837418340.0,21280.0,35940.0,1838627940.0,6.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1490579697,0.149057969748875,0.15,1837418340.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001096,103001096,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35940.0,1837418340.0,21280.0,35940.0,1838627940.0,7.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.6501853052,4.65018530527234,4.65,1837418340.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001096,103001096,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35940.0,1837418340.0,21280.0,35940.0,1838627940.0,8.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1837418340.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001096,103001096,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35940.0,1837418340.0,21280.0,35940.0,1838627940.0,9.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),343.22815704,343.228157047066,343.23,1837418340.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001096,103001096,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35940.0,1837418340.0,21280.0,35940.0,1838627940.0,10.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1606.7680147,1606.76801476993,1606.77,1838023140.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001096,103001096,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35940.0,1837418340.0,21280.0,35940.0,1838627940.0,11.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1592.9176146,1592.91761464852,1592.92,1838023140.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001096,103001096,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35940.0,1837418340.0,21280.0,35940.0,1838627940.0,12.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),0.8620037238,0.862003723878857,0.86,1838023140.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001096,103001096,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35940.0,1837418340.0,21280.0,35940.0,1838627940.0,13.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),62.236738023,62.2367380236397,62.24,1838023140.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001096,103001096,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35940.0,1837418340.0,21280.0,35940.0,1838627940.0,14.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),580.63,580.63,580.63,1838023140.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001096,103001096,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35940.0,1837418340.0,21280.0,35940.0,1838627940.0,15.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1732801925,0.173280192554862,0.17,1838023140.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001096,103001096,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35940.0,1837418340.0,21280.0,35940.0,1838627940.0,16.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.000152414,4.00015241407635,4.00,1838023140.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001096,103001096,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35940.0,1837418340.0,21280.0,35940.0,1838627940.0,17.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1838023140.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001096,103001096,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35940.0,1837418340.0,21280.0,35940.0,1838627940.0,18.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),359.16821828,359.168218282854,359.17,1838023140.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001096,103001096,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35940.0,1837418340.0,21280.0,35940.0,1838627940.0,19.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1639.3787793,1639.37877934105,1639.38,1838627940.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001096,103001096,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35940.0,1837418340.0,21280.0,35940.0,1838627940.0,20.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1619.2490796,1619.24907963565,1619.25,1838627940.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001096,103001096,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35940.0,1837418340.0,21280.0,35940.0,1838627940.0,21.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.2278858284,1.22788582840476,1.23,1838627940.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001096,103001096,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35940.0,1837418340.0,21280.0,35940.0,1838627940.0,22.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),60.998715647,60.9987156477619,61.00,1838627940.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001096,103001096,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35940.0,1837418340.0,21280.0,35940.0,1838627940.0,23.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),555.95,555.95,555.95,1838627940.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001096,103001096,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35940.0,1837418340.0,21280.0,35940.0,1838627940.0,24.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1584723094,0.158472309407758,0.16,1838627940.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001096,103001096,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35940.0,1837418340.0,21280.0,35940.0,1838627940.0,25.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.3739324753,4.37393247533511,4.37,1838627940.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001096,103001096,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35940.0,1837418340.0,21280.0,35940.0,1838627940.0,26.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1838627940.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001096,103001096,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,35940.0,1837418340.0,21280.0,35940.0,1838627940.0,27.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),384.91718758,384.9171875877,384.92,1838627940.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001098,103001098,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,36120.0,1837418520.0,21280.0,36120.0,1838628120.0,1.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),2005.0367201,2005.03672014673,2005.04,1837418520.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001098,103001098,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,36120.0,1837418520.0,21280.0,36120.0,1838628120.0,2.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1976.1701413,1976.17014138841,1976.17,1837418520.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001098,103001098,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,36120.0,1837418520.0,21280.0,36120.0,1838628120.0,3.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.4397032467,1.43970324674207,1.44,1837418520.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001098,103001098,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,36120.0,1837418520.0,21280.0,36120.0,1838628120.0,4.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),49.874398306,49.8743983066214,49.87,1837418520.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001098,103001098,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,36120.0,1837418520.0,21280.0,36120.0,1838628120.0,5.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),536.45,536.45,536.45,1837418520.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001098,103001098,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,36120.0,1837418520.0,21280.0,36120.0,1838628120.0,6.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1340650733,0.134065073398563,0.13,1837418520.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001098,103001098,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,36120.0,1837418520.0,21280.0,36120.0,1838628120.0,7.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),5.1702293743,5.17022937435227,5.17,1837418520.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001098,103001098,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,36120.0,1837418520.0,21280.0,36120.0,1838628120.0,8.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.5,1.5,1.50,1837418520.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001098,103001098,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,36120.0,1837418520.0,21280.0,36120.0,1838628120.0,9.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),372.01634282,372.016342827407,372.02,1837418520.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001098,103001098,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,36120.0,1837418520.0,21280.0,36120.0,1838628120.0,10.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1897.0299049,1897.02990491706,1897.03,1838023320.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001098,103001098,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,36120.0,1837418520.0,21280.0,36120.0,1838628120.0,11.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1851.3897761,1851.38977615395,1851.39,1838023320.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001098,103001098,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,36120.0,1837418520.0,21280.0,36120.0,1838628120.0,12.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),2.4058729198,2.40587291981065,2.41,1838023320.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001098,103001098,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,36120.0,1837418520.0,21280.0,36120.0,1838628120.0,13.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),52.713981862,52.7139818622796,52.71,1838023320.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001098,103001098,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,36120.0,1837418520.0,21280.0,36120.0,1838628120.0,14.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),279.44,279.44,279.44,1838023320.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001098,103001098,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,36120.0,1837418520.0,21280.0,36120.0,1838628120.0,15.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1347498389,0.134749838939346,0.13,1838023320.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001098,103001098,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,36120.0,1837418520.0,21280.0,36120.0,1838628120.0,16.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),5.1439555402,5.14395554025074,5.14,1838023320.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001098,103001098,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,36120.0,1837418520.0,21280.0,36120.0,1838628120.0,17.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),5.0,5,5.00,1838023320.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001098,103001098,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,36120.0,1837418520.0,21280.0,36120.0,1838628120.0,18.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),391.19884874,391.198848749699,391.20,1838023320.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001098,103001098,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,36120.0,1837418520.0,21280.0,36120.0,1838628120.0,19.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1817.4707539,1817.47075396835,1817.47,1838628120.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001098,103001098,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,36120.0,1837418520.0,21280.0,36120.0,1838628120.0,20.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1781.0885969,1781.08859693408,1781.09,1838628120.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001098,103001098,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,36120.0,1837418520.0,21280.0,36120.0,1838628120.0,21.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),2.001801512,2.00180151206443,2.00,1838628120.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001098,103001098,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,36120.0,1837418520.0,21280.0,36120.0,1838628120.0,22.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),55.021518107,55.0215181078736,55.02,1838628120.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001098,103001098,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,36120.0,1837418520.0,21280.0,36120.0,1838628120.0,23.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),313.69,313.69,313.69,1838628120.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001098,103001098,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,36120.0,1837418520.0,21280.0,36120.0,1838628120.0,24.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1396288844,0.139628884434074,0.14,1838628120.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001098,103001098,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,36120.0,1837418520.0,21280.0,36120.0,1838628120.0,25.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.9642105454,4.96421054547074,4.96,1838628120.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001098,103001098,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,36120.0,1837418520.0,21280.0,36120.0,1838628120.0,26.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),3.0,3,3.00,1838628120.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001098,103001098,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,36120.0,1837418520.0,21280.0,36120.0,1838628120.0,27.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),394.05541576,394.055415760713,394.06,1838628120.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001105,103001105,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35820.0,1837418220.0,21273.0,35820.0,1838023020.0,1.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),2757.2901893,2757.29018934751,2757.29,1837418220.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001105,103001105,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35820.0,1837418220.0,21273.0,35820.0,1838023020.0,2.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),2726.2438403,2726.243840372,2726.24,1837418220.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001105,103001105,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35820.0,1837418220.0,21273.0,35820.0,1838023020.0,3.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.1259732144,1.12597321440668,1.13,1837418220.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001105,103001105,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35820.0,1837418220.0,21273.0,35820.0,1838023020.0,4.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),36.267492042,36.2674920421285,36.27,1837418220.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001105,103001105,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35820.0,1837418220.0,21273.0,35820.0,1838023020.0,5.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),606.16,606.16,606.16,1837418220.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001105,103001105,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35820.0,1837418220.0,21273.0,35820.0,1838023020.0,6.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1613716319,0.16137163194136,0.16,1837418220.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001105,103001105,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35820.0,1837418220.0,21273.0,35820.0,1838023020.0,7.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.2953471574,4.29534715749684,4.30,1837418220.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001105,103001105,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35820.0,1837418220.0,21273.0,35820.0,1838023020.0,8.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1837418220.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001105,103001105,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35820.0,1837418220.0,21273.0,35820.0,1838023020.0,9.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),224.74515257,224.745152576183,224.75,1837418220.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001105,103001105,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35820.0,1837418220.0,21273.0,35820.0,1838023020.0,10.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),2308.1304608,2308.13046083072,2308.13,1838023020.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001105,103001105,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35820.0,1837418220.0,21273.0,35820.0,1838023020.0,11.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),2272.442121,2272.44212108792,2272.44,1838023020.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001105,103001105,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35820.0,1837418220.0,21273.0,35820.0,1838023020.0,12.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.5462011506,1.54620115060402,1.55,1838023020.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001105,103001105,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35820.0,1837418220.0,21273.0,35820.0,1838023020.0,13.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),43.325107352,43.3251073529045,43.33,1838023020.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001105,103001105,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35820.0,1837418220.0,21273.0,35820.0,1838023020.0,14.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),437.07,437.07,437.07,1838023020.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001105,103001105,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35820.0,1837418220.0,21273.0,35820.0,1838023020.0,15.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1538317568,0.153831756802489,0.15,1838023020.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001105,103001105,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35820.0,1837418220.0,21273.0,35820.0,1838023020.0,16.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.5058783372,4.50587833726626,4.51,1838023020.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001105,103001105,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35820.0,1837418220.0,21273.0,35820.0,1838023020.0,17.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),2.0438888888,2.04388888888889,2.04,1838023020.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001105,103001105,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,35820.0,1837418220.0,21273.0,35820.0,1838023020.0,18.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),281.63955384,281.639553844083,281.64,1838023020.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001107,103001107,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,34680.0,1837417080.0,21280.0,34680.0,1838626680.0,1.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1217.9580923,1217.95809230665,1217.96,1837417080.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001107,103001107,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,34680.0,1837417080.0,21280.0,34680.0,1838626680.0,2.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1192.8796862,1192.87968629006,1192.88,1837417080.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001107,103001107,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,34680.0,1837417080.0,21280.0,34680.0,1838626680.0,3.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),2.0590532773,2.05905327736672,2.06,1837417080.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001107,103001107,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,34680.0,1837417080.0,21280.0,34680.0,1838626680.0,4.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),82.104631211,82.1046312115822,82.10,1837417080.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001107,103001107,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,34680.0,1837417080.0,21280.0,34680.0,1838626680.0,5.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),248.16,248.16,248.16,1837417080.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001107,103001107,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,34680.0,1837417080.0,21280.0,34680.0,1838626680.0,6.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1351760553,0.135176055358422,0.14,1837417080.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001107,103001107,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,34680.0,1837417080.0,21280.0,34680.0,1838626680.0,7.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),5.127736408,5.12773640806466,5.13,1837417080.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001107,103001107,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,34680.0,1837417080.0,21280.0,34680.0,1838626680.0,8.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),2.0,2,2.00,1837417080.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001107,103001107,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,34680.0,1837417080.0,21280.0,34680.0,1838626680.0,9.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),607.3903473,607.390347305816,607.39,1837417080.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001107,103001107,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,34680.0,1837417080.0,21280.0,34680.0,1838626680.0,10.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1158.6736176,1158.67361766122,1158.67,1838021880.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001107,103001107,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,34680.0,1837417080.0,21280.0,34680.0,1838626680.0,11.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1144.2220999,1144.22209994628,1144.22,1838021880.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001107,103001107,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,34680.0,1837417080.0,21280.0,34680.0,1838626680.0,12.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.2472466356,1.24724663569278,1.25,1838021880.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001107,103001107,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,34680.0,1837417080.0,21280.0,34680.0,1838626680.0,13.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),86.305581205,86.3055812057324,86.31,1838021880.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001107,103001107,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,34680.0,1837417080.0,21280.0,34680.0,1838626680.0,14.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),275.81,275.81,275.81,1838021880.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001107,103001107,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,34680.0,1837417080.0,21280.0,34680.0,1838626680.0,15.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1570769274,0.157076927474086,0.16,1838021880.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001107,103001107,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,34680.0,1837417080.0,21280.0,34680.0,1838626680.0,16.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.4127879995,4.41278799952526,4.41,1838021880.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001107,103001107,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,34680.0,1837417080.0,21280.0,34680.0,1838626680.0,17.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1838021880.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001107,103001107,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,34680.0,1837417080.0,21280.0,34680.0,1838626680.0,18.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),549.44785713,549.447857133384,549.45,1838021880.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001107,103001107,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,34680.0,1837417080.0,21280.0,34680.0,1838626680.0,19.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1359.944926,1359.94492608657,1359.94,1838626680.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001107,103001107,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,34680.0,1837417080.0,21280.0,34680.0,1838626680.0,20.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1346.5331978,1346.53319784504,1346.53,1838626680.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001107,103001107,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,34680.0,1837417080.0,21280.0,34680.0,1838626680.0,21.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),0.9861964248,0.98619642488919,0.99,1838626680.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001107,103001107,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,34680.0,1837417080.0,21280.0,34680.0,1838626680.0,22.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),73.532389497,73.5323894973921,73.53,1838626680.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001107,103001107,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,34680.0,1837417080.0,21280.0,34680.0,1838626680.0,23.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),218.7,218.7,218.70,1838626680.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001107,103001107,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,34680.0,1837417080.0,21280.0,34680.0,1838626680.0,24.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1960970243,0.196097024383221,0.20,1838626680.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001107,103001107,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,34680.0,1837417080.0,21280.0,34680.0,1838626680.0,25.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),3.5347154437,3.53471544374568,3.53,1838626680.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001107,103001107,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,34680.0,1837417080.0,21280.0,34680.0,1838626680.0,26.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),4.0,4,4.00,1838626680.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001107,103001107,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,34680.0,1837417080.0,21280.0,34680.0,1838626680.0,27.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),374.97962923,374.979629235434,374.98,1838626680.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001111,103001111,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36600.0,1837419000.0,21287.0,36600.0,1839233400.0,1.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1256.0829037,1256.08290379534,1256.08,1837419000.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001111,103001111,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36600.0,1837419000.0,21287.0,36600.0,1839233400.0,2.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1239.6761489,1239.67614893949,1239.68,1837419000.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001111,103001111,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36600.0,1837419000.0,21287.0,36600.0,1839233400.0,3.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.3061840748,1.30618407481447,1.31,1837419000.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001111,103001111,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36600.0,1837419000.0,21287.0,36600.0,1839233400.0,4.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),79.61257947,79.6125794705457,79.61,1837419000.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001111,103001111,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36600.0,1837419000.0,21287.0,36600.0,1839233400.0,5.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),497.23,497.23,497.23,1837419000.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001111,103001111,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36600.0,1837419000.0,21287.0,36600.0,1839233400.0,6.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1401861623,0.140186162358673,0.14,1837419000.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001111,103001111,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36600.0,1837419000.0,21287.0,36600.0,1839233400.0,7.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.9444764654,4.94447646541957,4.94,1837419000.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001111,103001111,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36600.0,1837419000.0,21287.0,36600.0,1839233400.0,8.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1837419000.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001111,103001111,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36600.0,1837419000.0,21287.0,36600.0,1839233400.0,9.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),567.90611948,567.906119484555,567.91,1837419000.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001111,103001111,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36600.0,1837419000.0,21287.0,36600.0,1839233400.0,10.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1314.1681432,1314.16814322977,1314.17,1838023800.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001111,103001111,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36600.0,1837419000.0,21287.0,36600.0,1839233400.0,11.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1283.7298451,1283.72984516356,1283.73,1838023800.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001111,103001111,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36600.0,1837419000.0,21287.0,36600.0,1839233400.0,12.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),2.3161646569,2.31616465693662,2.32,1838023800.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001111,103001111,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36600.0,1837419000.0,21287.0,36600.0,1839233400.0,13.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),76.093763583,76.0937635835815,76.09,1838023800.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001111,103001111,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36600.0,1837419000.0,21287.0,36600.0,1839233400.0,14.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),394.81,394.81,394.81,1838023800.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001111,103001111,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36600.0,1837419000.0,21287.0,36600.0,1839233400.0,15.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.133384593,0.133384593027142,0.13,1838023800.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001111,103001111,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36600.0,1837419000.0,21287.0,36600.0,1839233400.0,16.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),5.1966060309,5.19660603094465,5.20,1838023800.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001111,103001111,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36600.0,1837419000.0,21287.0,36600.0,1839233400.0,17.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1838023800.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001111,103001111,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36600.0,1837419000.0,21287.0,36600.0,1839233400.0,18.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),570.48390564,570.483905649412,570.48,1838023800.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001111,103001111,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36600.0,1837419000.0,21287.0,36600.0,1839233400.0,19.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1339.68486,1339.68486006536,1339.68,1839233400.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001111,103001111,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36600.0,1837419000.0,21287.0,36600.0,1839233400.0,20.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1322.8815106,1322.8815106365,1322.88,1839233400.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001111,103001111,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36600.0,1837419000.0,21287.0,36600.0,1839233400.0,21.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.2542762801,1.2542762801723,1.25,1839233400.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001111,103001111,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36600.0,1837419000.0,21287.0,36600.0,1839233400.0,22.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),74.644420475,74.6444204759627,74.64,1839233400.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001111,103001111,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36600.0,1837419000.0,21287.0,36600.0,1839233400.0,23.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),354.26,354.26,354.26,1839233400.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001111,103001111,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36600.0,1837419000.0,21287.0,36600.0,1839233400.0,24.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1458042642,0.145804264225571,0.15,1839233400.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001111,103001111,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36600.0,1837419000.0,21287.0,36600.0,1839233400.0,25.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.7539568492,4.75395684921528,4.75,1839233400.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001111,103001111,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36600.0,1837419000.0,21287.0,36600.0,1839233400.0,26.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1839233400.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001111,103001111,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36600.0,1837419000.0,21287.0,36600.0,1839233400.0,27.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),511.94950211,511.949502111145,511.95,1839233400.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001114,103001114,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34740.0,1837417140.0,21280.0,34740.0,1838626740.0,1.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),873.55496402,873.554964021885,873.55,1837417140.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001114,103001114,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34740.0,1837417140.0,21280.0,34740.0,1838626740.0,2.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),865.27749437,865.277494370896,865.28,1837417140.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001114,103001114,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34740.0,1837417140.0,21280.0,34740.0,1838626740.0,3.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),0.9475614004,0.947561400473223,0.95,1837417140.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001114,103001114,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34740.0,1837417140.0,21280.0,34740.0,1838626740.0,4.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),114.47476589,114.474765891771,114.47,1837417140.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001114,103001114,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34740.0,1837417140.0,21280.0,34740.0,1838626740.0,5.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),257.23,257.23,257.23,1837417140.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001114,103001114,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34740.0,1837417140.0,21280.0,34740.0,1838626740.0,6.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1643014178,0.164301417865965,0.16,1837417140.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001114,103001114,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34740.0,1837417140.0,21280.0,34740.0,1838626740.0,7.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.2187534932,4.21875349320117,4.22,1837417140.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001114,103001114,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34740.0,1837417140.0,21280.0,34740.0,1838626740.0,8.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1837417140.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001114,103001114,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34740.0,1837417140.0,21280.0,34740.0,1838626740.0,9.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),696.73632387,696.736323877365,696.74,1837417140.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001114,103001114,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34740.0,1837417140.0,21280.0,34740.0,1838626740.0,10.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1055.9193471,1055.9193471813,1055.92,1838021940.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001114,103001114,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34740.0,1837417140.0,21280.0,34740.0,1838626740.0,11.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1050.7515268,1050.75152681784,1050.75,1838021940.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001114,103001114,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34740.0,1837417140.0,21280.0,34740.0,1838626740.0,12.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),0.4894143077,0.489414307754404,0.49,1838021940.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001114,103001114,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34740.0,1837417140.0,21280.0,34740.0,1838626740.0,13.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),94.704202803,94.7042028038818,94.70,1838021940.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001114,103001114,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34740.0,1837417140.0,21280.0,34740.0,1838626740.0,14.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),282.42,282.42,282.42,1838021940.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001114,103001114,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34740.0,1837417140.0,21280.0,34740.0,1838626740.0,15.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1973752816,0.197375281697801,0.20,1838021940.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001114,103001114,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34740.0,1837417140.0,21280.0,34740.0,1838626740.0,16.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),3.5118236417,3.51182364173247,3.51,1838021940.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001114,103001114,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34740.0,1837417140.0,21280.0,34740.0,1838626740.0,17.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1838021940.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001114,103001114,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34740.0,1837417140.0,21280.0,34740.0,1838626740.0,18.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),479.81794877,479.817948778825,479.82,1838021940.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001114,103001114,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34740.0,1837417140.0,21280.0,34740.0,1838626740.0,19.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),949.90989383,949.909893831748,949.91,1838626740.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001114,103001114,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34740.0,1837417140.0,21280.0,34740.0,1838626740.0,20.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),938.45730407,938.457304070129,938.46,1838626740.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001114,103001114,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34740.0,1837417140.0,21280.0,34740.0,1838626740.0,21.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.2056501186,1.20565011860454,1.21,1838626740.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001114,103001114,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34740.0,1837417140.0,21280.0,34740.0,1838626740.0,22.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),105.2731429,105.273142904765,105.27,1838626740.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001114,103001114,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34740.0,1837417140.0,21280.0,34740.0,1838626740.0,23.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),210.45,210.45,210.45,1838626740.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001114,103001114,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34740.0,1837417140.0,21280.0,34740.0,1838626740.0,24.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1493112069,0.149311206949082,0.15,1838626740.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001114,103001114,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34740.0,1837417140.0,21280.0,34740.0,1838626740.0,25.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.642298423,4.64229842302674,4.64,1838626740.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001114,103001114,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34740.0,1837417140.0,21280.0,34740.0,1838626740.0,26.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),3.0,3,3.00,1838626740.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001114,103001114,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21266.0,34740.0,1837417140.0,21280.0,34740.0,1838626740.0,27.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),705.05854889,705.058548891545,705.06,1838626740.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001129,103001129,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36300.0,1837418700.0,21280.0,36300.0,1838628300.0,1.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1025.6457456,1025.64574560506,1025.65,1837418700.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001129,103001129,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36300.0,1837418700.0,21280.0,36300.0,1838628300.0,2.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1014.2320461,1014.23204613486,1014.23,1837418700.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001129,103001129,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36300.0,1837418700.0,21280.0,36300.0,1838628300.0,3.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.1128305771,1.1128305771372,1.11,1837418700.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001129,103001129,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36300.0,1837418700.0,21280.0,36300.0,1838628300.0,4.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),97.49955131,97.4995513104836,97.50,1837418700.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001129,103001129,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36300.0,1837418700.0,21280.0,36300.0,1838628300.0,5.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),266.99,266.99,266.99,1837418700.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001129,103001129,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36300.0,1837418700.0,21280.0,36300.0,1838628300.0,6.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1261641769,0.126164176983957,0.13,1837418700.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001129,103001129,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36300.0,1837418700.0,21280.0,36300.0,1838628300.0,7.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),5.4940094496,5.49400944967196,5.49,1837418700.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001129,103001129,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36300.0,1837418700.0,21280.0,36300.0,1838628300.0,8.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.5,1.5,1.50,1837418700.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001129,103001129,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36300.0,1837418700.0,21280.0,36300.0,1838628300.0,9.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),772.7990119,772.799011900832,772.80,1837418700.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001129,103001129,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36300.0,1837418700.0,21280.0,36300.0,1838628300.0,10.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1314.5058336,1314.50583360435,1314.51,1838023500.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001129,103001129,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36300.0,1837418700.0,21280.0,36300.0,1838628300.0,11.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1301.6616819,1301.66168196161,1301.66,1838023500.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001129,103001129,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36300.0,1837418700.0,21280.0,36300.0,1838628300.0,12.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),0.9771087593,0.977108759382888,0.98,1838023500.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001129,103001129,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36300.0,1837418700.0,21280.0,36300.0,1838628300.0,13.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),76.074215453,76.0742154531194,76.07,1838023500.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001129,103001129,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36300.0,1837418700.0,21280.0,36300.0,1838628300.0,14.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),387.62,387.62,387.62,1838023500.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001129,103001129,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36300.0,1837418700.0,21280.0,36300.0,1838628300.0,15.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1362487806,0.136248780664948,0.14,1838023500.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001129,103001129,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36300.0,1837418700.0,21280.0,36300.0,1838628300.0,16.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),5.0873642844,5.08736428448835,5.09,1838023500.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001129,103001129,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36300.0,1837418700.0,21280.0,36300.0,1838628300.0,17.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1838023500.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001129,103001129,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36300.0,1837418700.0,21280.0,36300.0,1838628300.0,18.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),558.3478625,558.347862504508,558.35,1838023500.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001129,103001129,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36300.0,1837418700.0,21280.0,36300.0,1838628300.0,19.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1147.0042845,1147.00428457927,1147.00,1838628300.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001129,103001129,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36300.0,1837418700.0,21280.0,36300.0,1838628300.0,20.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1134.7944883,1134.79448831362,1134.79,1838628300.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001129,103001129,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36300.0,1837418700.0,21280.0,36300.0,1838628300.0,21.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.0644943902,1.06449439028287,1.06,1838628300.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001129,103001129,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36300.0,1837418700.0,21280.0,36300.0,1838628300.0,22.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),87.18363248,87.1836324802227,87.18,1838628300.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001129,103001129,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36300.0,1837418700.0,21280.0,36300.0,1838628300.0,23.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),326.46,326.46,326.46,1838628300.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001129,103001129,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36300.0,1837418700.0,21280.0,36300.0,1838628300.0,24.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.13513739,0.135137390018694,0.14,1838628300.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001129,103001129,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36300.0,1837418700.0,21280.0,36300.0,1838628300.0,25.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),5.1292035495,5.12920354954363,5.13,1838628300.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001129,103001129,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36300.0,1837418700.0,21280.0,36300.0,1838628300.0,26.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1838628300.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001129,103001129,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21266.0,36300.0,1837418700.0,21280.0,36300.0,1838628300.0,27.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),645.14811532,645.14811532295,645.15,1838628300.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001136,103001136,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,35160.0,1837417560.0,21280.0,35160.0,1838627160.0,1.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1806.1003227,1806.10032278602,1806.10,1837417560.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001136,103001136,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,35160.0,1837417560.0,21280.0,35160.0,1838627160.0,2.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1789.4807577,1789.48075779606,1789.48,1837417560.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001136,103001136,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,35160.0,1837417560.0,21280.0,35160.0,1838627160.0,3.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),0.9201905774,0.920190577471515,0.92,1837417560.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001136,103001136,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,35160.0,1837417560.0,21280.0,35160.0,1838627160.0,4.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),55.367909931,55.3679099319044,55.37,1837417560.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001136,103001136,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,35160.0,1837417560.0,21280.0,35160.0,1838627160.0,5.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),468.96,468.96,468.96,1837417560.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001136,103001136,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,35160.0,1837417560.0,21280.0,35160.0,1838627160.0,6.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1534336188,0.153433618842642,0.15,1837417560.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001136,103001136,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,35160.0,1837417560.0,21280.0,35160.0,1838627160.0,7.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.5175704372,4.51757043722484,4.52,1837417560.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001136,103001136,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,35160.0,1837417560.0,21280.0,35160.0,1838627160.0,8.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1837417560.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001136,103001136,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,35160.0,1837417560.0,21280.0,35160.0,1838627160.0,9.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),360.85904998,360.859049988832,360.86,1837417560.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001136,103001136,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,35160.0,1837417560.0,21280.0,35160.0,1838627160.0,10.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1487.5921789,1487.59217891888,1487.59,1838022360.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001136,103001136,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,35160.0,1837417560.0,21280.0,35160.0,1838627160.0,11.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1475.185607,1475.1856070521,1475.19,1838022360.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001136,103001136,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,35160.0,1837417560.0,21280.0,35160.0,1838627160.0,12.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),0.8340035691,0.834003569163606,0.83,1838022360.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001136,103001136,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,35160.0,1837417560.0,21280.0,35160.0,1838627160.0,13.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),67.222725029,67.2227250298371,67.22,1838022360.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001136,103001136,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,35160.0,1837417560.0,21280.0,35160.0,1838627160.0,14.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),341.91,341.91,341.91,1838022360.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001136,103001136,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,35160.0,1837417560.0,21280.0,35160.0,1838627160.0,15.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.16926513,0.169265130009253,0.17,1838022360.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001136,103001136,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,35160.0,1837417560.0,21280.0,35160.0,1838627160.0,16.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.0950382427,4.09503824279728,4.10,1838022360.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001136,103001136,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,35160.0,1837417560.0,21280.0,35160.0,1838627160.0,17.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1838022360.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001136,103001136,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,35160.0,1837417560.0,21280.0,35160.0,1838627160.0,18.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),397.14455674,397.144556744571,397.14,1838022360.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001136,103001136,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,35160.0,1837417560.0,21280.0,35160.0,1838627160.0,19.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),2068.179931,2068.1799310997,2068.18,1838627160.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001136,103001136,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,35160.0,1837417560.0,21280.0,35160.0,1838627160.0,20.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),2051.7474236,2051.74742360529,2051.75,1838627160.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001136,103001136,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,35160.0,1837417560.0,21280.0,35160.0,1838627160.0,21.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),0.7945395488,0.794539548871015,0.79,1838627160.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001136,103001136,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,35160.0,1837417560.0,21280.0,35160.0,1838627160.0,22.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),48.351692469,48.3516924694399,48.35,1838627160.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001136,103001136,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,35160.0,1837417560.0,21280.0,35160.0,1838627160.0,23.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),673.91,673.91,673.91,1838627160.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001136,103001136,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,35160.0,1837417560.0,21280.0,35160.0,1838627160.0,24.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1636999101,0.163699910127328,0.16,1838627160.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001136,103001136,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,35160.0,1837417560.0,21280.0,35160.0,1838627160.0,25.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.2342551075,4.23425510753676,4.23,1838627160.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001136,103001136,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,35160.0,1837417560.0,21280.0,35160.0,1838627160.0,26.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1838627160.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001136,103001136,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,35160.0,1837417560.0,21280.0,35160.0,1838627160.0,27.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),295.36786203,295.367862033836,295.37,1838627160.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001141,103001141,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,34800.0,1837417200.0,21280.0,34800.0,1838626800.0,1.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1188.2620928,1188.26209284803,1188.26,1837417200.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001141,103001141,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,34800.0,1837417200.0,21280.0,34800.0,1838626800.0,2.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1156.0692684,1156.06926847003,1156.07,1837417200.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001141,103001141,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,34800.0,1837417200.0,21280.0,34800.0,1838626800.0,3.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),2.7092359986,2.70923599867072,2.71,1837417200.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001141,103001141,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,34800.0,1837417200.0,21280.0,34800.0,1838626800.0,4.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),84.156517827,84.1565178270727,84.16,1837417200.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001141,103001141,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,34800.0,1837417200.0,21280.0,34800.0,1838626800.0,5.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),232.5,232.5,232.50,1837417200.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001141,103001141,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,34800.0,1837417200.0,21280.0,34800.0,1838626800.0,6.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.121145009,0.121145009030819,0.12,1837417200.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001141,103001141,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,34800.0,1837417200.0,21280.0,34800.0,1838626800.0,7.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),5.7216321671,5.72163216714615,5.72,1837417200.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001141,103001141,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,34800.0,1837417200.0,21280.0,34800.0,1838626800.0,8.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1837417200.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001141,103001141,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,34800.0,1837417200.0,21280.0,34800.0,1838626800.0,9.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),694.67589709,694.675897095054,694.68,1837417200.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001141,103001141,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,34800.0,1837417200.0,21280.0,34800.0,1838626800.0,10.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),821.54120453,821.54120453417,821.54,1838022000.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001141,103001141,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,34800.0,1837417200.0,21280.0,34800.0,1838626800.0,11.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),778.99755842,778.997558423646,779.00,1838022000.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001141,103001141,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,34800.0,1837417200.0,21280.0,34800.0,1838626800.0,12.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),5.1785164122,5.17851641228959,5.18,1838022000.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001141,103001141,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,34800.0,1837417200.0,21280.0,34800.0,1838626800.0,13.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),121.72244002,121.72244002868,121.72,1838022000.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001141,103001141,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,34800.0,1837417200.0,21280.0,34800.0,1838626800.0,14.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),138.8,138.8,138.80,1838022000.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001141,103001141,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,34800.0,1837417200.0,21280.0,34800.0,1838626800.0,15.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.0914355104,0.0914355104847905,0.09,1838022000.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001141,103001141,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,34800.0,1837417200.0,21280.0,34800.0,1838626800.0,16.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),7.5807219414,7.58072194145232,7.58,1838022000.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001141,103001141,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,34800.0,1837417200.0,21280.0,34800.0,1838626800.0,17.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.5,1.5,1.50,1838022000.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001141,103001141,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,34800.0,1837417200.0,21280.0,34800.0,1838626800.0,18.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),1331.2381522,1331.23815225954,1331.24,1838022000.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001141,103001141,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,34800.0,1837417200.0,21280.0,34800.0,1838626800.0,19.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1036.8341092,1036.8341092643,1036.83,1838626800.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001141,103001141,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,34800.0,1837417200.0,21280.0,34800.0,1838626800.0,20.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1009.0859826,1009.0859826238,1009.09,1838626800.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001141,103001141,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,34800.0,1837417200.0,21280.0,34800.0,1838626800.0,21.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),2.6762358985,2.67623589854583,2.68,1838626800.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001141,103001141,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,34800.0,1837417200.0,21280.0,34800.0,1838626800.0,22.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),96.447444298,96.4474442984488,96.45,1838626800.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001141,103001141,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,34800.0,1837417200.0,21280.0,34800.0,1838626800.0,23.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),195.97,195.97,195.97,1838626800.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001141,103001141,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,34800.0,1837417200.0,21280.0,34800.0,1838626800.0,24.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1156834852,0.115683485288514,0.12,1838626800.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001141,103001141,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,34800.0,1837417200.0,21280.0,34800.0,1838626800.0,25.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),5.9917556843,5.99175568432467,5.99,1838626800.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001141,103001141,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,34800.0,1837417200.0,21280.0,34800.0,1838626800.0,26.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),2.0,2,2.00,1838626800.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001141,103001141,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,34800.0,1837417200.0,21280.0,34800.0,1838626800.0,27.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),833.71834845,833.718348456645,833.72,1838626800.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001149,103001149,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,36060.0,1837418460.0,21280.0,36060.0,1838628060.0,1.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1888.8404424,1888.84044248709,1888.84,1837418460.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001149,103001149,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,36060.0,1837418460.0,21280.0,36060.0,1838628060.0,2.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1879.3092848,1879.30928481222,1879.31,1837418460.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001149,103001149,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,36060.0,1837418460.0,21280.0,36060.0,1838628060.0,3.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),0.5046036425,0.504603642556478,0.50,1837418460.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001149,103001149,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,36060.0,1837418460.0,21280.0,36060.0,1838628060.0,4.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),52.942534345,52.9425343457424,52.94,1837418460.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001149,103001149,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,36060.0,1837418460.0,21280.0,36060.0,1838628060.0,5.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),657.94,657.94,657.94,1837418460.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001149,103001149,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,36060.0,1837418460.0,21280.0,36060.0,1838628060.0,6.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1888542883,0.188854288366876,0.19,1837418460.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001149,103001149,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,36060.0,1837418460.0,21280.0,36060.0,1838628060.0,7.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),3.6702750387,3.67027503878232,3.67,1837418460.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001149,103001149,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,36060.0,1837418460.0,21280.0,36060.0,1838628060.0,8.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1837418460.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001149,103001149,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,36060.0,1837418460.0,21280.0,36060.0,1838628060.0,9.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),280.33535697,280.335356975818,280.34,1837418460.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001149,103001149,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,36060.0,1837418460.0,21280.0,36060.0,1838628060.0,10.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1910.2462489,1910.24624894651,1910.25,1838023260.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001149,103001149,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,36060.0,1837418460.0,21280.0,36060.0,1838628060.0,11.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1894.5414168,1894.54141681307,1894.54,1838023260.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001149,103001149,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,36060.0,1837418460.0,21280.0,36060.0,1838628060.0,12.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),0.8221365251,0.822136525178427,0.82,1838023260.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001149,103001149,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,36060.0,1837418460.0,21280.0,36060.0,1838628060.0,13.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),52.349271752,52.3492717523459,52.35,1838023260.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001149,103001149,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,36060.0,1837418460.0,21280.0,36060.0,1838628060.0,14.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),553.93,553.93,553.93,1838023260.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001149,103001149,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,36060.0,1837418460.0,21280.0,36060.0,1838628060.0,15.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1700113683,0.170011368304589,0.17,1838023260.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001149,103001149,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,36060.0,1837418460.0,21280.0,36060.0,1838628060.0,16.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.0770637132,4.07706371328132,4.08,1838023260.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001149,103001149,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,36060.0,1837418460.0,21280.0,36060.0,1838628060.0,17.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.5,1.5,1.50,1838023260.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001149,103001149,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,36060.0,1837418460.0,21280.0,36060.0,1838628060.0,18.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),307.91630156,307.916301564952,307.92,1838023260.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001149,103001149,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,36060.0,1837418460.0,21280.0,36060.0,1838628060.0,19.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1780.1963429,1780.19634299288,1780.20,1838628060.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001149,103001149,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,36060.0,1837418460.0,21280.0,36060.0,1838628060.0,20.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1766.2543614,1766.25436141046,1766.25,1838628060.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001149,103001149,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,36060.0,1837418460.0,21280.0,36060.0,1838628060.0,21.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),0.7831710045,0.783171004552269,0.78,1838628060.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001149,103001149,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,36060.0,1837418460.0,21280.0,36060.0,1838628060.0,22.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),56.173579051,56.1735790513304,56.17,1838628060.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001149,103001149,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,36060.0,1837418460.0,21280.0,36060.0,1838628060.0,23.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),436.62,436.62,436.62,1838628060.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001149,103001149,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,36060.0,1837418460.0,21280.0,36060.0,1838628060.0,24.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1606658269,0.160665826931265,0.16,1838628060.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001149,103001149,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,36060.0,1837418460.0,21280.0,36060.0,1838628060.0,25.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.3142166184,4.31421661842555,4.31,1838628060.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001149,103001149,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,36060.0,1837418460.0,21280.0,36060.0,1838628060.0,26.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1838628060.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001149,103001149,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,36060.0,1837418460.0,21280.0,36060.0,1838628060.0,27.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),349.62991274,349.62991274655,349.63,1838628060.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001150,103001150,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,36660.0,1837419060.0,21280.0,36660.0,1838628660.0,1.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1499.9125863,1499.91258637792,1499.91,1837419060.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001150,103001150,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,36660.0,1837419060.0,21280.0,36660.0,1838628660.0,2.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1476.6167553,1476.61675536493,1476.62,1837419060.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001150,103001150,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,36660.0,1837419060.0,21280.0,36660.0,1838628660.0,3.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.5531459116,1.55314591160624,1.55,1837419060.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001150,103001150,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,36660.0,1837419060.0,21280.0,36660.0,1838628660.0,4.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),66.670551942,66.6705519429541,66.67,1837419060.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001150,103001150,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,36660.0,1837419060.0,21280.0,36660.0,1838628660.0,5.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),497.51,497.51,497.51,1837419060.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001150,103001150,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,36660.0,1837419060.0,21280.0,36660.0,1838628660.0,6.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1223394863,0.122339486340284,0.12,1837419060.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001150,103001150,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,36660.0,1837419060.0,21280.0,36660.0,1838628660.0,7.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),5.6657682755,5.6657682755997,5.67,1837419060.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001150,103001150,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,36660.0,1837419060.0,21280.0,36660.0,1838628660.0,8.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1837419060.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001150,103001150,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,36660.0,1837419060.0,21280.0,36660.0,1838628660.0,9.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),544.96347775,544.963477756574,544.96,1837419060.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001150,103001150,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,36660.0,1837419060.0,21280.0,36660.0,1838628660.0,10.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1633.2577997,1633.25779976285,1633.26,1838023860.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001150,103001150,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,36660.0,1837419060.0,21280.0,36660.0,1838628660.0,11.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1579.4879024,1579.4879024607,1579.49,1838023860.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001150,103001150,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,36660.0,1837419060.0,21280.0,36660.0,1838628660.0,12.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),3.292186776,3.29218677602294,3.29,1838023860.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001150,103001150,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,36660.0,1837419060.0,21280.0,36660.0,1838628660.0,13.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),61.227321256,61.2273212560319,61.23,1838023860.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001150,103001150,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,36660.0,1837419060.0,21280.0,36660.0,1838628660.0,14.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),454.93,454.93,454.93,1838023860.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001150,103001150,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,36660.0,1837419060.0,21280.0,36660.0,1838628660.0,15.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.0816441953,0.0816441953632667,0.08,1838023860.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001150,103001150,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,36660.0,1837419060.0,21280.0,36660.0,1838628660.0,16.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),8.4898525544,8.48985255443899,8.49,1838023860.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001150,103001150,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,36660.0,1837419060.0,21280.0,36660.0,1838628660.0,17.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1838023860.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001150,103001150,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,36660.0,1837419060.0,21280.0,36660.0,1838628660.0,18.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),749.92865057,749.928650574701,749.93,1838023860.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001150,103001150,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,36660.0,1837419060.0,21280.0,36660.0,1838628660.0,19.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1388.9810351,1388.98103513926,1388.98,1838628660.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001150,103001150,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,36660.0,1837419060.0,21280.0,36660.0,1838628660.0,20.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1364.97798,1364.9779800262,1364.98,1838628660.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001150,103001150,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,36660.0,1837419060.0,21280.0,36660.0,1838628660.0,21.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.7281053164,1.72810531647408,1.73,1838628660.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001150,103001150,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,36660.0,1837419060.0,21280.0,36660.0,1838628660.0,22.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),71.995223455,71.9952234552819,72.00,1838628660.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001150,103001150,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,36660.0,1837419060.0,21280.0,36660.0,1838628660.0,23.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),309.33,309.33,309.33,1838628660.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001150,103001150,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,36660.0,1837419060.0,21280.0,36660.0,1838628660.0,24.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1095693855,0.109569385547476,0.11,1838628660.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001150,103001150,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,36660.0,1837419060.0,21280.0,36660.0,1838628660.0,25.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),6.3261026526,6.32610265263929,6.33,1838628660.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001150,103001150,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,36660.0,1837419060.0,21280.0,36660.0,1838628660.0,26.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),2.0,2,2.00,1838628660.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001150,103001150,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21266.0,36660.0,1837419060.0,21280.0,36660.0,1838628660.0,27.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),657.07426481,657.074264819042,657.07,1838628660.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001155,103001155,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36240.0,1837418640.0,21280.0,36240.0,1838628240.0,1.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1464.8780351,1464.8780351561,1464.88,1837418640.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001155,103001155,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36240.0,1837418640.0,21280.0,36240.0,1838628240.0,2.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1445.0195493,1445.01954934196,1445.02,1837418640.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001155,103001155,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36240.0,1837418640.0,21280.0,36240.0,1838628240.0,3.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.3556409023,1.35564090235158,1.36,1837418640.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001155,103001155,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36240.0,1837418640.0,21280.0,36240.0,1838628240.0,4.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),68.265068899,68.2650688999809,68.27,1837418640.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001155,103001155,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36240.0,1837418640.0,21280.0,36240.0,1838628240.0,5.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),425.93,425.93,425.93,1837418640.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001155,103001155,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36240.0,1837418640.0,21280.0,36240.0,1838628240.0,6.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.2955915196,0.295591519662605,0.30,1837418640.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001155,103001155,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36240.0,1837418640.0,21280.0,36240.0,1838628240.0,7.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),2.3449494807,2.34494948079404,2.34,1837418640.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001155,103001155,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36240.0,1837418640.0,21280.0,36240.0,1838628240.0,8.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),2.0,2,2.00,1837418640.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001155,103001155,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36240.0,1837418640.0,21280.0,36240.0,1838628240.0,9.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),230.94393566,230.943935664664,230.94,1837418640.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001155,103001155,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36240.0,1837418640.0,21280.0,36240.0,1838628240.0,10.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1345.8641889,1345.86418896553,1345.86,1838023440.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001155,103001155,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36240.0,1837418640.0,21280.0,36240.0,1838628240.0,11.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1335.5269264,1335.52692645802,1335.53,1838023440.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001155,103001155,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36240.0,1837418640.0,21280.0,36240.0,1838628240.0,12.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),0.768076199,0.768076199088987,0.77,1838023440.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001155,103001155,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36240.0,1837418640.0,21280.0,36240.0,1838628240.0,13.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),74.301702073,74.3017020735674,74.30,1838023440.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001155,103001155,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36240.0,1837418640.0,21280.0,36240.0,1838628240.0,14.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),250.32,250.32,250.32,1838023440.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001155,103001155,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36240.0,1837418640.0,21280.0,36240.0,1838628240.0,15.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1634862226,0.163486222660288,0.16,1838023440.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001155,103001155,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36240.0,1837418640.0,21280.0,36240.0,1838628240.0,16.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.2397895631,4.23978956318694,4.24,1838023440.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001155,103001155,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36240.0,1837418640.0,21280.0,36240.0,1838628240.0,17.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),2.0,2,2.00,1838023440.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001155,103001155,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36240.0,1837418640.0,21280.0,36240.0,1838628240.0,18.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),454.48295804,454.482958040817,454.48,1838023440.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001155,103001155,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36240.0,1837418640.0,21280.0,36240.0,1838628240.0,19.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1538.6272587,1538.62725878326,1538.63,1838628240.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001155,103001155,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36240.0,1837418640.0,21280.0,36240.0,1838628240.0,20.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1532.8743955,1532.87439550019,1532.87,1838628240.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001155,103001155,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36240.0,1837418640.0,21280.0,36240.0,1838628240.0,21.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),0.373895838,0.37389583800945,0.37,1838628240.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001155,103001155,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36240.0,1837418640.0,21280.0,36240.0,1838628240.0,22.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),64.99299907,64.992999070535,64.99,1838628240.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001155,103001155,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36240.0,1837418640.0,21280.0,36240.0,1838628240.0,23.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),480.19,480.19,480.19,1838628240.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001155,103001155,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36240.0,1837418640.0,21280.0,36240.0,1838628240.0,24.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1825178086,0.182517808669312,0.18,1838628240.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001155,103001155,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36240.0,1837418640.0,21280.0,36240.0,1838628240.0,25.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),3.7976961569,3.79769615695857,3.80,1838628240.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001155,103001155,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36240.0,1837418640.0,21280.0,36240.0,1838628240.0,26.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),2.0,2,2.00,1838628240.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001155,103001155,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,36240.0,1837418640.0,21280.0,36240.0,1838628240.0,27.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),356.09127429,356.091274294719,356.09,1838628240.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001156,103001156,001,Part A,1.0,Y,1.0,N,0.0,3: BAC,3.0,3: BAC,3.0,21266.0,35880.0,1837418280.0,21266.0,35880.0,1837418280.0,1.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1217.0104813,1217.01048137432,1217.01,1837418280.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001156,103001156,001,Part A,1.0,Y,1.0,N,0.0,3: BAC,3.0,3: BAC,3.0,21266.0,35880.0,1837418280.0,21266.0,35880.0,1837418280.0,2.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1165.1793168,1165.17931686753,1165.18,1837418280.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001156,103001156,001,Part A,1.0,Y,1.0,N,0.0,3: BAC,3.0,3: BAC,3.0,21266.0,35880.0,1837418280.0,21266.0,35880.0,1837418280.0,3.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),4.2588922034,4.25889220348086,4.26,1837418280.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001156,103001156,001,Part A,1.0,Y,1.0,N,0.0,3: BAC,3.0,3: BAC,3.0,21266.0,35880.0,1837418280.0,21266.0,35880.0,1837418280.0,4.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),82.168561019,82.1685610193545,82.17,1837418280.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001156,103001156,001,Part A,1.0,Y,1.0,N,0.0,3: BAC,3.0,3: BAC,3.0,21266.0,35880.0,1837418280.0,21266.0,35880.0,1837418280.0,5.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),240.2,240.2,240.20,1837418280.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001156,103001156,001,Part A,1.0,Y,1.0,N,0.0,3: BAC,3.0,3: BAC,3.0,21266.0,35880.0,1837418280.0,21266.0,35880.0,1837418280.0,6.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1012904118,0.101290411858519,0.10,1837418280.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001156,103001156,001,Part A,1.0,Y,1.0,N,0.0,3: BAC,3.0,3: BAC,3.0,21266.0,35880.0,1837418280.0,21266.0,35880.0,1837418280.0,7.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),6.84316677,6.84316677009986,6.84,1837418280.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001156,103001156,001,Part A,1.0,Y,1.0,N,0.0,3: BAC,3.0,3: BAC,3.0,21266.0,35880.0,1837418280.0,21266.0,35880.0,1837418280.0,8.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),2.0,2,2.00,1837418280.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001156,103001156,001,Part A,1.0,Y,1.0,N,0.0,3: BAC,3.0,3: BAC,3.0,21266.0,35880.0,1837418280.0,21266.0,35880.0,1837418280.0,9.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),811.21756256,811.217562567782,811.22,1837418280.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001193,103001193,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,36180.0,1837418580.0,21280.0,36180.0,1838628180.0,1.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),2145.2378515,2145.23785157032,2145.24,1837418580.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001193,103001193,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,36180.0,1837418580.0,21280.0,36180.0,1838628180.0,2.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),2122.2632534,2122.26325343911,2122.26,1837418580.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001193,103001193,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,36180.0,1837418580.0,21280.0,36180.0,1838628180.0,3.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.0709580811,1.07095808114666,1.07,1837418580.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001193,103001193,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,36180.0,1837418580.0,21280.0,36180.0,1838628180.0,4.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),46.614877658,46.6148776588105,46.61,1837418580.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001193,103001193,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,36180.0,1837418580.0,21280.0,36180.0,1838628180.0,5.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),490.38,490.38,490.38,1837418580.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001193,103001193,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,36180.0,1837418580.0,21280.0,36180.0,1838628180.0,6.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1379784743,0.137978474395762,0.14,1837418580.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001193,103001193,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,36180.0,1837418580.0,21280.0,36180.0,1838628180.0,7.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),5.0235892489,5.02358924894185,5.02,1837418580.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001193,103001193,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,36180.0,1837418580.0,21280.0,36180.0,1838628180.0,8.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.5,1.5,1.50,1837418580.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001193,103001193,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,36180.0,1837418580.0,21280.0,36180.0,1838628180.0,9.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),337.84166597,337.841665976867,337.84,1837418580.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001193,103001193,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,36180.0,1837418580.0,21280.0,36180.0,1838628180.0,10.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),2838.7242837,2838.72428379662,2838.72,1838023380.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001193,103001193,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,36180.0,1837418580.0,21280.0,36180.0,1838628180.0,11.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),2799.090043,2799.09004301848,2799.09,1838023380.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001193,103001193,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,36180.0,1837418580.0,21280.0,36180.0,1838628180.0,12.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.3961990251,1.39619902518797,1.40,1838023380.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001193,103001193,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,36180.0,1837418580.0,21280.0,36180.0,1838628180.0,13.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),35.227091468,35.2270914687974,35.23,1838023380.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001193,103001193,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,36180.0,1837418580.0,21280.0,36180.0,1838628180.0,14.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),599.78,599.78,599.78,1838023380.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001193,103001193,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,36180.0,1837418580.0,21280.0,36180.0,1838628180.0,15.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1463381128,0.146338112857169,0.15,1838023380.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001193,103001193,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,36180.0,1837418580.0,21280.0,36180.0,1838628180.0,16.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.7366141808,4.73661418086266,4.74,1838023380.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001193,103001193,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,36180.0,1837418580.0,21280.0,36180.0,1838628180.0,17.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),2.0,2,2.00,1838023380.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001193,103001193,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,36180.0,1837418580.0,21280.0,36180.0,1838628180.0,18.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),240.72396985,240.723969859993,240.72,1838023380.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001193,103001193,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,36180.0,1837418580.0,21280.0,36180.0,1838628180.0,19.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),2395.4505241,2395.45052418906,2395.45,1838628180.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001193,103001193,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,36180.0,1837418580.0,21280.0,36180.0,1838628180.0,20.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),2371.5376328,2371.53763288932,2371.54,1838628180.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001193,103001193,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,36180.0,1837418580.0,21280.0,36180.0,1838628180.0,21.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),0.9982627926,0.998262792667351,1.00,1838628180.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001193,103001193,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,36180.0,1837418580.0,21280.0,36180.0,1838628180.0,22.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),41.745800629,41.745800629238,41.75,1838628180.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001193,103001193,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,36180.0,1837418580.0,21280.0,36180.0,1838628180.0,23.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),559.32,559.32,559.32,1838628180.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001193,103001193,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,36180.0,1837418580.0,21280.0,36180.0,1838628180.0,24.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1601646556,0.160164655624164,0.16,1838628180.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001193,103001193,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,36180.0,1837418580.0,21280.0,36180.0,1838628180.0,25.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.3277162358,4.327716235887,4.33,1838628180.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001193,103001193,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,36180.0,1837418580.0,21280.0,36180.0,1838628180.0,26.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),2.0,2,2.00,1838628180.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001193,103001193,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21266.0,36180.0,1837418580.0,21280.0,36180.0,1838628180.0,27.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),260.6430268,260.643026806095,260.64,1838628180.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001201,103001201,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,34200.0,1837416600.0,21280.0,34200.0,1838626200.0,1.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1170.1940889,1170.19408891301,1170.19,1837416600.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001201,103001201,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,34200.0,1837416600.0,21280.0,34200.0,1838626200.0,2.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1071.0623303,1071.06233036033,1071.06,1837416600.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001201,103001201,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,34200.0,1837416600.0,21280.0,34200.0,1838626200.0,3.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),8.4713945739,8.47139457393416,8.47,1837416600.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001201,103001201,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,34200.0,1837416600.0,21280.0,34200.0,1838626200.0,4.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),85.455909363,85.4559093636253,85.46,1837416600.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001201,103001201,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,34200.0,1837416600.0,21280.0,34200.0,1838626200.0,5.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),269.48,269.48,269.48,1837416600.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001201,103001201,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,34200.0,1837416600.0,21280.0,34200.0,1838626200.0,6.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.0570957287,0.0570957287819372,0.06,1837416600.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001201,103001201,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,34200.0,1837416600.0,21280.0,34200.0,1838626200.0,7.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),12.140088152,12.1400881527802,12.14,1837416600.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001201,103001201,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,34200.0,1837416600.0,21280.0,34200.0,1838626200.0,8.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),2.0,2,2.00,1837416600.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001201,103001201,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,34200.0,1837416600.0,21280.0,34200.0,1838626200.0,9.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),1496.7128222,1496.71282224985,1496.71,1837416600.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001201,103001201,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,34200.0,1837416600.0,21280.0,34200.0,1838626200.0,10.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1080.5858478,1080.5858478724,1080.59,1838021400.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001201,103001201,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,34200.0,1837416600.0,21280.0,34200.0,1838626200.0,11.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1038.4926686,1038.49266865173,1038.49,1838021400.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001201,103001201,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,34200.0,1837416600.0,21280.0,34200.0,1838626200.0,12.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),3.8954035261,3.89540352611027,3.90,1838021400.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001201,103001201,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,34200.0,1837416600.0,21280.0,34200.0,1838626200.0,13.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),92.542392811,92.5423928111711,92.54,1838021400.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001201,103001201,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,34200.0,1837416600.0,21280.0,34200.0,1838626200.0,14.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),196.32,196.32,196.32,1838021400.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001201,103001201,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,34200.0,1837416600.0,21280.0,34200.0,1838626200.0,15.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.0938394313,0.0938394313076819,0.09,1838021400.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001201,103001201,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,34200.0,1837416600.0,21280.0,34200.0,1838626200.0,16.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),7.3865236702,7.38652367028148,7.39,1838021400.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001201,103001201,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,34200.0,1837416600.0,21280.0,34200.0,1838626200.0,17.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),3.0,3,3.00,1838021400.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001201,103001201,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,34200.0,1837416600.0,21280.0,34200.0,1838626200.0,18.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),986.17810787,986.178107876016,986.18,1838021400.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001201,103001201,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,34200.0,1837416600.0,21280.0,34200.0,1838626200.0,19.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),382.79361564,382.793615641156,382.79,1838626200.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001201,103001201,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,34200.0,1837416600.0,21280.0,34200.0,1838626200.0,20.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),49.62,49.62,49.62,1838626200.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001201,103001201,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21266.0,34200.0,1837416600.0,21280.0,34200.0,1838626200.0,21.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),2.0,2,2.00,1838626200.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001211,103001211,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,34260.0,1837416660.0,21280.0,34260.0,1838626260.0,1.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1380.6333785,1380.63337856491,1380.63,1837416660.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001211,103001211,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,34260.0,1837416660.0,21280.0,34260.0,1838626260.0,2.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1360.0613431,1360.06134318691,1360.06,1837416660.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001211,103001211,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,34260.0,1837416660.0,21280.0,34260.0,1838626260.0,3.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.4900433161,1.49004331616106,1.49,1837416660.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001211,103001211,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,34260.0,1837416660.0,21280.0,34260.0,1838626260.0,4.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),72.430524679,72.4305246798715,72.43,1837416660.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001211,103001211,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,34260.0,1837416660.0,21280.0,34260.0,1838626260.0,5.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),332.67,332.67,332.67,1837416660.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001211,103001211,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,34260.0,1837416660.0,21280.0,34260.0,1838626260.0,6.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.147287322,0.147287322052783,0.15,1837416660.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001211,103001211,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,34260.0,1837416660.0,21280.0,34260.0,1838626260.0,7.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.7060885546,4.70608855466559,4.71,1837416660.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001211,103001211,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,34260.0,1837416660.0,21280.0,34260.0,1838626260.0,8.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1837416660.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001211,103001211,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,34260.0,1837416660.0,21280.0,34260.0,1838626260.0,9.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),491.76347068,491.763470680219,491.76,1837416660.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001211,103001211,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,34260.0,1837416660.0,21280.0,34260.0,1838626260.0,10.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1259.3330975,1259.33309757984,1259.33,1838021460.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001211,103001211,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,34260.0,1837416660.0,21280.0,34260.0,1838626260.0,11.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1238.9682245,1238.96822452104,1238.97,1838021460.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001211,103001211,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,34260.0,1837416660.0,21280.0,34260.0,1838626260.0,12.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.6171156859,1.61711568590815,1.62,1838021460.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001211,103001211,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,34260.0,1837416660.0,21280.0,34260.0,1838626260.0,13.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),79.407108565,79.4071085657784,79.41,1838021460.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001211,103001211,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,34260.0,1837416660.0,21280.0,34260.0,1838626260.0,14.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),281.57,281.57,281.57,1838021460.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001211,103001211,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,34260.0,1837416660.0,21280.0,34260.0,1838626260.0,15.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1497676902,0.149767690237704,0.15,1838021460.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001211,103001211,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,34260.0,1837416660.0,21280.0,34260.0,1838626260.0,16.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.6281489649,4.62814896497247,4.63,1838021460.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001211,103001211,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,34260.0,1837416660.0,21280.0,34260.0,1838626260.0,17.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),2.0,2,2.00,1838021460.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001211,103001211,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,34260.0,1837416660.0,21280.0,34260.0,1838626260.0,18.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),530.20186423,530.201864232181,530.20,1838021460.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001211,103001211,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,34260.0,1837416660.0,21280.0,34260.0,1838626260.0,19.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1398.0796805,1398.07968051266,1398.08,1838626260.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001211,103001211,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,34260.0,1837416660.0,21280.0,34260.0,1838626260.0,20.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1384.6273306,1384.62733060765,1384.63,1838626260.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001211,103001211,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,34260.0,1837416660.0,21280.0,34260.0,1838626260.0,21.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),0.9622019468,0.962201946893701,0.96,1838626260.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001211,103001211,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,34260.0,1837416660.0,21280.0,34260.0,1838626260.0,22.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),71.526681485,71.5266814859443,71.53,1838626260.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001211,103001211,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,34260.0,1837416660.0,21280.0,34260.0,1838626260.0,23.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),366.95,366.95,366.95,1838626260.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001211,103001211,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,34260.0,1837416660.0,21280.0,34260.0,1838626260.0,24.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.165770294,0.165770294093238,0.17,1838626260.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001211,103001211,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,34260.0,1837416660.0,21280.0,34260.0,1838626260.0,25.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.1813714836,4.18137148366332,4.18,1838626260.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001211,103001211,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,34260.0,1837416660.0,21280.0,34260.0,1838626260.0,26.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1838626260.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001211,103001211,001,Part A,1.0,Y,1.0,Y,1.0,4: BCA,4.0,4: BCA,4.0,21266.0,34260.0,1837416660.0,21280.0,34260.0,1838626260.0,27.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),431.48069367,431.480693674308,431.48,1838626260.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001218,103001218,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21292.0,29880.0,1839658680.0,21306.0,29880.0,1840868280.0,1.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1205.4118074,1205.41180746003,1205.41,1839658680.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001218,103001218,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21292.0,29880.0,1839658680.0,21306.0,29880.0,1840868280.0,2.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1137.5815926,1137.58159261846,1137.58,1839658680.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001218,103001218,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21292.0,29880.0,1839658680.0,21306.0,29880.0,1840868280.0,3.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),5.6271404031,5.62714040312032,5.63,1839658680.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001218,103001218,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21292.0,29880.0,1839658680.0,21306.0,29880.0,1840868280.0,4.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),82.959200649,82.9592006492074,82.96,1839658680.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001218,103001218,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21292.0,29880.0,1839658680.0,21306.0,29880.0,1840868280.0,5.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),315.13,315.13,315.13,1839658680.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001218,103001218,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21292.0,29880.0,1839658680.0,21306.0,29880.0,1840868280.0,6.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.0656049816,0.0656049816500518,0.07,1839658680.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001218,103001218,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21292.0,29880.0,1839658680.0,21306.0,29880.0,1840868280.0,7.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),10.565465657,10.5654656571251,10.57,1839658680.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001218,103001218,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21292.0,29880.0,1839658680.0,21306.0,29880.0,1840868280.0,8.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1839658680.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001218,103001218,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21292.0,29880.0,1839658680.0,21306.0,29880.0,1840868280.0,9.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),1264.5259332,1264.52593328546,1264.53,1839658680.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001218,103001218,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21292.0,29880.0,1839658680.0,21306.0,29880.0,1840868280.0,10.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1004.6865987,1004.68659872613,1004.69,1840263480.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001218,103001218,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21292.0,29880.0,1839658680.0,21306.0,29880.0,1840868280.0,11.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),980.75292381,980.752923811234,980.75,1840263480.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001218,103001218,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21292.0,29880.0,1839658680.0,21306.0,29880.0,1840868280.0,12.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),2.3822030616,2.38220306165584,2.38,1840263480.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001218,103001218,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21292.0,29880.0,1839658680.0,21306.0,29880.0,1840868280.0,13.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),99.533526302,99.5335263024234,99.53,1840263480.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001218,103001218,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21292.0,29880.0,1839658680.0,21306.0,29880.0,1840868280.0,14.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),313.52,313.52,313.52,1840263480.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001218,103001218,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21292.0,29880.0,1839658680.0,21306.0,29880.0,1840868280.0,15.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.0965167283,0.0965167283425373,0.10,1840263480.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001218,103001218,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21292.0,29880.0,1839658680.0,21306.0,29880.0,1840868280.0,16.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),7.1816273972,7.18162739727325,7.18,1840263480.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001218,103001218,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21292.0,29880.0,1839658680.0,21306.0,29880.0,1840868280.0,17.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1840263480.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001218,103001218,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21292.0,29880.0,1839658680.0,21306.0,29880.0,1840868280.0,18.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),1031.2567366,1031.25673664755,1031.26,1840263480.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001218,103001218,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21292.0,29880.0,1839658680.0,21306.0,29880.0,1840868280.0,19.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),984.31360087,984.313600874303,984.31,1840868280.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001218,103001218,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21292.0,29880.0,1839658680.0,21306.0,29880.0,1840868280.0,20.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),973.68761193,973.687611934228,973.69,1840868280.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001218,103001218,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21292.0,29880.0,1839658680.0,21306.0,29880.0,1840868280.0,21.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.0795328775,1.07953287759473,1.08,1840868280.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001218,103001218,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21292.0,29880.0,1839658680.0,21306.0,29880.0,1840868280.0,22.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),101.59363835,101.593638359946,101.59,1840868280.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001218,103001218,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21292.0,29880.0,1839658680.0,21306.0,29880.0,1840868280.0,23.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),378.47,378.47,378.47,1840868280.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001218,103001218,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21292.0,29880.0,1839658680.0,21306.0,29880.0,1840868280.0,24.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1317524427,0.13175244279806,0.13,1840868280.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001218,103001218,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21292.0,29880.0,1839658680.0,21306.0,29880.0,1840868280.0,25.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),5.2609816246,5.26098162462421,5.26,1840868280.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001218,103001218,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21292.0,29880.0,1839658680.0,21306.0,29880.0,1840868280.0,26.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1840868280.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001218,103001218,001,Part A,1.0,Y,1.0,Y,1.0,5: CAB,5.0,5: CAB,5.0,21292.0,29880.0,1839658680.0,21306.0,29880.0,1840868280.0,27.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),771.09491256,771.094912567662,771.09,1840868280.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001220,103001220,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21292.0,30000.0,1839658800.0,21306.0,30000.0,1840868400.0,1.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1584.2942706,1584.2942706152,1584.29,1839658800.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001220,103001220,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21292.0,30000.0,1839658800.0,21306.0,30000.0,1840868400.0,2.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1564.1346088,1564.13460887445,1564.13,1839658800.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001220,103001220,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21292.0,30000.0,1839658800.0,21306.0,30000.0,1840868400.0,3.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.2724695225,1.27246952252849,1.27,1839658800.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001220,103001220,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21292.0,30000.0,1839658800.0,21306.0,30000.0,1840868400.0,4.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),63.119586969,63.1195869698936,63.12,1839658800.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001220,103001220,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21292.0,30000.0,1839658800.0,21306.0,30000.0,1840868400.0,5.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),505.13,505.13,505.13,1839658800.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001220,103001220,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21292.0,30000.0,1839658800.0,21306.0,30000.0,1840868400.0,6.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1448437001,0.144843700135037,0.14,1839658800.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001220,103001220,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21292.0,30000.0,1839658800.0,21306.0,30000.0,1840868400.0,7.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.7854838002,4.78548380021863,4.79,1839658800.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001220,103001220,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21292.0,30000.0,1839658800.0,21306.0,30000.0,1840868400.0,8.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1839658800.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001220,103001220,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21292.0,30000.0,1839658800.0,21306.0,30000.0,1840868400.0,9.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),435.77723374,435.777233742631,435.78,1839658800.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001220,103001220,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21292.0,30000.0,1839658800.0,21306.0,30000.0,1840868400.0,10.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1494.7523117,1494.75231172222,1494.75,1840263600.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001220,103001220,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21292.0,30000.0,1839658800.0,21306.0,30000.0,1840868400.0,11.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1473.1265363,1473.1265363729,1473.13,1840263600.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001220,103001220,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21292.0,30000.0,1839658800.0,21306.0,30000.0,1840868400.0,12.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.4467798564,1.44677985641643,1.45,1840263600.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001220,103001220,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21292.0,30000.0,1839658800.0,21306.0,30000.0,1840868400.0,13.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),66.900716068,66.9007160689936,66.90,1840263600.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001220,103001220,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21292.0,30000.0,1839658800.0,21306.0,30000.0,1840868400.0,14.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),317.38,317.38,317.38,1840263600.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001220,103001220,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21292.0,30000.0,1839658800.0,21306.0,30000.0,1840868400.0,15.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1461219285,0.146121928530066,0.15,1840263600.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001220,103001220,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21292.0,30000.0,1839658800.0,21306.0,30000.0,1840868400.0,16.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.7436219021,4.74362190215225,4.74,1840263600.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001220,103001220,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21292.0,30000.0,1839658800.0,21306.0,30000.0,1840868400.0,17.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),2.0,2,2.00,1840263600.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001220,103001220,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21292.0,30000.0,1839658800.0,21306.0,30000.0,1840868400.0,18.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),457.84172671,457.841726714059,457.84,1840263600.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001220,103001220,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21292.0,30000.0,1839658800.0,21306.0,30000.0,1840868400.0,19.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1399.5449489,1399.54494897538,1399.54,1840868400.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001220,103001220,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21292.0,30000.0,1839658800.0,21306.0,30000.0,1840868400.0,20.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1381.3091375,1381.30913751599,1381.31,1840868400.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001220,103001220,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21292.0,30000.0,1839658800.0,21306.0,30000.0,1840868400.0,21.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.3029814778,1.30298147785404,1.30,1840868400.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001220,103001220,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21292.0,30000.0,1839658800.0,21306.0,30000.0,1840868400.0,22.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),71.451795866,71.4517958663713,71.45,1840868400.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001220,103001220,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21292.0,30000.0,1839658800.0,21306.0,30000.0,1840868400.0,23.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),371.46,371.46,371.46,1840868400.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001220,103001220,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21292.0,30000.0,1839658800.0,21306.0,30000.0,1840868400.0,24.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1436733432,0.143673343291272,0.14,1840868400.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001220,103001220,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21292.0,30000.0,1839658800.0,21306.0,30000.0,1840868400.0,25.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.8244661443,4.82446614438917,4.82,1840868400.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001220,103001220,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21292.0,30000.0,1839658800.0,21306.0,30000.0,1840868400.0,26.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),2.0,2,2.00,1840868400.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001220,103001220,001,Part A,1.0,Y,1.0,Y,1.0,2: ACB,2.0,2: ACB,2.0,21292.0,30000.0,1839658800.0,21306.0,30000.0,1840868400.0,27.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),497.32117475,497.321174753451,497.32,1840868400.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001222,103001222,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21292.0,30240.0,1839659040.0,21306.0,30240.0,1840868640.0,1.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1110.882169,1110.88216907198,1110.88,1839659040.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001222,103001222,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21292.0,30240.0,1839659040.0,21306.0,30240.0,1840868640.0,2.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1096.4060745,1096.40607453062,1096.41,1839659040.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001222,103001222,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21292.0,30240.0,1839659040.0,21306.0,30240.0,1840868640.0,3.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.3031170131,1.303117013162,1.30,1839659040.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001222,103001222,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21292.0,30240.0,1839659040.0,21306.0,30240.0,1840868640.0,4.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),90.018548126,90.0185481269714,90.02,1839659040.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001222,103001222,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21292.0,30240.0,1839659040.0,21306.0,30240.0,1840868640.0,5.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),279.76,279.76,279.76,1839659040.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001222,103001222,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21292.0,30240.0,1839659040.0,21306.0,30240.0,1840868640.0,6.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1588826318,0.15888263187482,0.16,1839659040.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001222,103001222,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21292.0,30240.0,1839659040.0,21306.0,30240.0,1840868640.0,7.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.3626365725,4.36263657254911,4.36,1839659040.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001222,103001222,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21292.0,30240.0,1839659040.0,21306.0,30240.0,1840868640.0,8.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.5,1.5,1.50,1839659040.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001222,103001222,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21292.0,30240.0,1839659040.0,21306.0,30240.0,1840868640.0,9.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),566.57261441,566.572614418265,566.57,1839659040.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001222,103001222,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21292.0,30240.0,1839659040.0,21306.0,30240.0,1840868640.0,10.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),869.95567976,869.955679768356,869.96,1840263840.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001222,103001222,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21292.0,30240.0,1839659040.0,21306.0,30240.0,1840868640.0,11.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),850.2975187,850.297518702503,850.30,1840263840.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001222,103001222,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21292.0,30240.0,1839659040.0,21306.0,30240.0,1840868640.0,12.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),2.2596738573,2.2596738573036,2.26,1840263840.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001222,103001222,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21292.0,30240.0,1839659040.0,21306.0,30240.0,1840868640.0,13.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),114.94838452,114.94838452762,114.95,1840263840.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001222,103001222,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21292.0,30240.0,1839659040.0,21306.0,30240.0,1840868640.0,14.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),216.5,216.5,216.50,1840263840.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001222,103001222,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21292.0,30240.0,1839659040.0,21306.0,30240.0,1840868640.0,15.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1266649505,0.126664950585087,0.13,1840263840.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001222,103001222,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21292.0,30240.0,1839659040.0,21306.0,30240.0,1840868640.0,16.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),5.472288722,5.47228872200385,5.47,1840263840.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001222,103001222,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21292.0,30240.0,1839659040.0,21306.0,30240.0,1840868640.0,17.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1840263840.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001222,103001222,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21292.0,30240.0,1839659040.0,21306.0,30240.0,1840868640.0,18.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),907.49954108,907.499541085785,907.50,1840263840.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001222,103001222,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21292.0,30240.0,1839659040.0,21306.0,30240.0,1840868640.0,19.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1102.2681927,1102.2681927663,1102.27,1840868640.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001222,103001222,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21292.0,30240.0,1839659040.0,21306.0,30240.0,1840868640.0,20.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1089.7543694,1089.75436948488,1089.75,1840868640.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001222,103001222,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21292.0,30240.0,1839659040.0,21306.0,30240.0,1840868640.0,21.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.1352793597,1.13527935973656,1.14,1840868640.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001222,103001222,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21292.0,30240.0,1839659040.0,21306.0,30240.0,1840868640.0,22.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),90.722022694,90.7220226948902,90.72,1840868640.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001222,103001222,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21292.0,30240.0,1839659040.0,21306.0,30240.0,1840868640.0,23.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),327.39,327.39,327.39,1840868640.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001222,103001222,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21292.0,30240.0,1839659040.0,21306.0,30240.0,1840868640.0,24.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1566267923,0.156626792301805,0.16,1840868640.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001222,103001222,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21292.0,30240.0,1839659040.0,21306.0,30240.0,1840868640.0,25.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.425470064,4.42547006405085,4.43,1840868640.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001222,103001222,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21292.0,30240.0,1839659040.0,21306.0,30240.0,1840868640.0,26.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),2.0,2,2.00,1840868640.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001222,103001222,001,Part A,1.0,Y,1.0,Y,1.0,1: ABC,1.0,1: ABC,1.0,21292.0,30240.0,1839659040.0,21306.0,30240.0,1840868640.0,27.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),579.22416313,579.224163130902,579.22,1840868640.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001225,103001225,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,28920.0,1839657720.0,21299.0,28920.0,1840262520.0,1.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1236.0060823,1236.00608235801,1236.01,1839657720.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001225,103001225,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,28920.0,1839657720.0,21299.0,28920.0,1840262520.0,2.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1219.9413013,1219.94130136001,1219.94,1839657720.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001225,103001225,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,28920.0,1839657720.0,21299.0,28920.0,1840262520.0,3.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.2997331669,1.29973316695563,1.30,1839657720.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001225,103001225,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,28920.0,1839657720.0,21299.0,28920.0,1840262520.0,4.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),80.905750729,80.9057507299834,80.91,1839657720.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001225,103001225,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,28920.0,1839657720.0,21299.0,28920.0,1840262520.0,5.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),310.92,310.92,310.92,1839657720.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001225,103001225,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,28920.0,1839657720.0,21299.0,28920.0,1840262520.0,6.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1587323226,0.158732322607952,0.16,1839657720.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001225,103001225,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,28920.0,1839657720.0,21299.0,28920.0,1840262520.0,7.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.3667677078,4.36676770787212,4.37,1839657720.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001225,103001225,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,28920.0,1839657720.0,21299.0,28920.0,1840262520.0,8.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),3.0,3,3.00,1839657720.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001225,103001225,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,28920.0,1839657720.0,21299.0,28920.0,1840262520.0,9.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),509.69928115,509.699281159073,509.70,1839657720.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001225,103001225,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,28920.0,1839657720.0,21299.0,28920.0,1840262520.0,10.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1075.3324376,1075.3324376213,1075.33,1840262520.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001225,103001225,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,28920.0,1839657720.0,21299.0,28920.0,1840262520.0,11.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1062.0515587,1062.05155874933,1062.05,1840262520.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001225,103001225,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,28920.0,1839657720.0,21299.0,28920.0,1840262520.0,12.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.2350486609,1.2350486609838,1.24,1840262520.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001225,103001225,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,28920.0,1839657720.0,21299.0,28920.0,1840262520.0,13.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),92.994497795,92.9944977956831,92.99,1840262520.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001225,103001225,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,28920.0,1839657720.0,21299.0,28920.0,1840262520.0,14.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),342.37,342.37,342.37,1840262520.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001225,103001225,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,28920.0,1839657720.0,21299.0,28920.0,1840262520.0,15.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1543572544,0.154357254498211,0.15,1840262520.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001225,103001225,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,28920.0,1839657720.0,21299.0,28920.0,1840262520.0,16.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.4905384124,4.49053841242026,4.49,1840262520.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001225,103001225,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,28920.0,1839657720.0,21299.0,28920.0,1840262520.0,17.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1840262520.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001225,103001225,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,28920.0,1839657720.0,21299.0,28920.0,1840262520.0,18.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),602.46276145,602.46276145551,602.46,1840262520.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001233,103001233,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21292.0,29040.0,1839657840.0,21299.0,29040.0,1840262640.0,1.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1785.2581165,1785.25811651206,1785.26,1839657840.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001233,103001233,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21292.0,29040.0,1839657840.0,21299.0,29040.0,1840262640.0,2.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1741.0582883,1741.05828834297,1741.06,1839657840.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001233,103001233,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21292.0,29040.0,1839657840.0,21299.0,29040.0,1840262640.0,3.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),2.4758228381,2.47582283818128,2.48,1839657840.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001233,103001233,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21292.0,29040.0,1839657840.0,21299.0,29040.0,1840262640.0,4.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),56.014309121,56.0143091215148,56.01,1839657840.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001233,103001233,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21292.0,29040.0,1839657840.0,21299.0,29040.0,1840262640.0,5.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),409.04,409.04,409.04,1839657840.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001233,103001233,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21292.0,29040.0,1839657840.0,21299.0,29040.0,1840262640.0,6.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1015841053,0.101584105323285,0.10,1839657840.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001233,103001233,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21292.0,29040.0,1839657840.0,21299.0,29040.0,1840262640.0,7.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),6.8233822442,6.82338224424036,6.82,1839657840.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001233,103001233,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21292.0,29040.0,1839657840.0,21299.0,29040.0,1840262640.0,8.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),2.0,2,2.00,1839657840.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001233,103001233,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21292.0,29040.0,1839657840.0,21299.0,29040.0,1840262640.0,9.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),551.40820449,551.408204494717,551.41,1839657840.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001233,103001233,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21292.0,29040.0,1839657840.0,21299.0,29040.0,1840262640.0,10.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1757.4549151,1757.45491514477,1757.45,1840262640.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001233,103001233,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21292.0,29040.0,1839657840.0,21299.0,29040.0,1840262640.0,11.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1742.1586476,1742.15864760292,1742.16,1840262640.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001233,103001233,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21292.0,29040.0,1839657840.0,21299.0,29040.0,1840262640.0,12.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),0.8703647194,0.870364719460672,0.87,1840262640.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001233,103001233,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21292.0,29040.0,1839657840.0,21299.0,29040.0,1840262640.0,13.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),56.900463925,56.900463925564,56.90,1840262640.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001233,103001233,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21292.0,29040.0,1839657840.0,21299.0,29040.0,1840262640.0,14.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),726.53,726.53,726.53,1840262640.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001233,103001233,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21292.0,29040.0,1839657840.0,21299.0,29040.0,1840262640.0,15.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1470947075,0.147094707505897,0.15,1840262640.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001233,103001233,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21292.0,29040.0,1839657840.0,21299.0,29040.0,1840262640.0,16.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.7122509865,4.71225098654321,4.71,1840262640.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001233,103001233,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21292.0,29040.0,1839657840.0,21299.0,29040.0,1840262640.0,17.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),0.5,0.5,0.50,1840262640.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001233,103001233,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21292.0,29040.0,1839657840.0,21299.0,29040.0,1840262640.0,18.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),386.8287642,386.828764204742,386.83,1840262640.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001234,103001234,001,Part B,2.0,Y,1.0,N,0.0,2: ED,8.0,2: ED,8.0,21292.0,29280.0,1839658080.0,21292.0,29280.0,1839658080.0,1.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1164.6101436,1164.61014367275,1164.61,1839658080.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001234,103001234,001,Part B,2.0,Y,1.0,N,0.0,2: ED,8.0,2: ED,8.0,21292.0,29280.0,1839658080.0,21292.0,29280.0,1839658080.0,2.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1122.5914821,1122.59148210281,1122.59,1839658080.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001234,103001234,001,Part B,2.0,Y,1.0,N,0.0,2: ED,8.0,2: ED,8.0,21292.0,29280.0,1839658080.0,21292.0,29280.0,1839658080.0,3.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),3.6079594358,3.60795943588712,3.61,1839658080.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001234,103001234,001,Part B,2.0,Y,1.0,N,0.0,2: ED,8.0,2: ED,8.0,21292.0,29280.0,1839658080.0,21292.0,29280.0,1839658080.0,4.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),85.865644003,85.8656440039554,85.87,1839658080.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001234,103001234,001,Part B,2.0,Y,1.0,N,0.0,2: ED,8.0,2: ED,8.0,21292.0,29280.0,1839658080.0,21292.0,29280.0,1839658080.0,5.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),270.99,270.99,270.99,1839658080.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001234,103001234,001,Part B,2.0,Y,1.0,N,0.0,2: ED,8.0,2: ED,8.0,21292.0,29280.0,1839658080.0,21292.0,29280.0,1839658080.0,6.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.0925779131,0.0925779131142748,0.09,1839658080.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001234,103001234,001,Part B,2.0,Y,1.0,N,0.0,2: ED,8.0,2: ED,8.0,21292.0,29280.0,1839658080.0,21292.0,29280.0,1839658080.0,7.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),7.4871765547,7.4871765547831,7.49,1839658080.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001234,103001234,001,Part B,2.0,Y,1.0,N,0.0,2: ED,8.0,2: ED,8.0,21292.0,29280.0,1839658080.0,21292.0,29280.0,1839658080.0,8.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1839658080.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001234,103001234,001,Part B,2.0,Y,1.0,N,0.0,2: ED,8.0,2: ED,8.0,21292.0,29280.0,1839658080.0,21292.0,29280.0,1839658080.0,9.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),927.49599894,927.495998942707,927.50,1839658080.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001241,103001241,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21292.0,29640.0,1839658440.0,21299.0,29640.0,1840263240.0,1.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1048.6438168,1048.64381686264,1048.64,1839658440.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001241,103001241,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21292.0,29640.0,1839658440.0,21299.0,29640.0,1840263240.0,2.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1041.0068425,1041.00684259645,1041.01,1839658440.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001241,103001241,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21292.0,29640.0,1839658440.0,21299.0,29640.0,1840263240.0,3.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),0.7282715201,0.728271520165911,0.73,1839658440.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001241,103001241,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21292.0,29640.0,1839658440.0,21299.0,29640.0,1840263240.0,4.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),95.361264131,95.3612641317837,95.36,1839658440.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001241,103001241,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21292.0,29640.0,1839658440.0,21299.0,29640.0,1840263240.0,5.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),317.62,317.62,317.62,1839658440.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001241,103001241,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21292.0,29640.0,1839658440.0,21299.0,29640.0,1840263240.0,6.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1951034464,0.195103446478294,0.20,1839658440.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001241,103001241,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21292.0,29640.0,1839658440.0,21299.0,29640.0,1840263240.0,7.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),3.5527162286,3.55271622860368,3.55,1839658440.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001241,103001241,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21292.0,29640.0,1839658440.0,21299.0,29640.0,1840263240.0,8.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1839658440.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001241,103001241,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21292.0,29640.0,1839658440.0,21299.0,29640.0,1840263240.0,9.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),488.77283232,488.772832326121,488.77,1839658440.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001241,103001241,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21292.0,29640.0,1839658440.0,21299.0,29640.0,1840263240.0,10.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1155.8649265,1155.86492656856,1155.86,1840263240.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001241,103001241,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21292.0,29640.0,1839658440.0,21299.0,29640.0,1840263240.0,11.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1134.0883284,1134.08832840704,1134.09,1840263240.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001241,103001241,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21292.0,29640.0,1839658440.0,21299.0,29640.0,1840263240.0,12.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.8840089063,1.88400890631496,1.88,1840263240.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001241,103001241,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21292.0,29640.0,1839658440.0,21299.0,29640.0,1840263240.0,13.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),86.515299237,86.5152992373181,86.52,1840263240.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001241,103001241,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21292.0,29640.0,1839658440.0,21299.0,29640.0,1840263240.0,14.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),227.78,227.78,227.78,1840263240.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001241,103001241,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21292.0,29640.0,1839658440.0,21299.0,29640.0,1840263240.0,15.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1593453658,0.159345365803334,0.16,1840263240.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001241,103001241,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21292.0,29640.0,1839658440.0,21299.0,29640.0,1840263240.0,16.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.3499676132,4.34996761321216,4.35,1840263240.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001241,103001241,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21292.0,29640.0,1839658440.0,21299.0,29640.0,1840263240.0,17.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),4.0,4,4.00,1840263240.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001241,103001241,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21292.0,29640.0,1839658440.0,21299.0,29640.0,1840263240.0,18.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),542.94204792,542.94204792938,542.94,1840263240.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001248,103001248,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,29160.0,1839657960.0,21299.0,29160.0,1840262760.0,1.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1205.1110672,1205.11106723694,1205.11,1839657960.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001248,103001248,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,29160.0,1839657960.0,21299.0,29160.0,1840262760.0,2.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1185.8859085,1185.88590859832,1185.89,1839657960.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001248,103001248,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,29160.0,1839657960.0,21299.0,29160.0,1840262760.0,3.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.5953018075,1.59530180755028,1.60,1839657960.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001248,103001248,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,29160.0,1839657960.0,21299.0,29160.0,1840262760.0,4.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),82.979903445,82.9799034451476,82.98,1839657960.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001248,103001248,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,29160.0,1839657960.0,21299.0,29160.0,1840262760.0,5.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),272.51,272.51,272.51,1839657960.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001248,103001248,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,29160.0,1839657960.0,21299.0,29160.0,1840262760.0,6.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1544850711,0.154485071141825,0.15,1839657960.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001248,103001248,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,29160.0,1839657960.0,21299.0,29160.0,1840262760.0,7.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.486823066,4.48682306605277,4.49,1839657960.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001248,103001248,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,29160.0,1839657960.0,21299.0,29160.0,1840262760.0,8.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),4.0,4,4.00,1839657960.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001248,103001248,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,29160.0,1839657960.0,21299.0,29160.0,1840262760.0,9.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),537.13865574,537.138655740837,537.14,1839657960.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001248,103001248,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,29160.0,1839657960.0,21299.0,29160.0,1840262760.0,10.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1111.4550622,1111.45506229065,1111.46,1840262760.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001248,103001248,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,29160.0,1839657960.0,21299.0,29160.0,1840262760.0,11.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1098.6084892,1098.60848928761,1098.61,1840262760.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001248,103001248,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,29160.0,1839657960.0,21299.0,29160.0,1840262760.0,12.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.1558337749,1.15583377492251,1.16,1840262760.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001248,103001248,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,29160.0,1839657960.0,21299.0,29160.0,1840262760.0,13.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),89.972148576,89.9721485760341,89.97,1840262760.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001248,103001248,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,29160.0,1839657960.0,21299.0,29160.0,1840262760.0,14.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),335.85,335.85,335.85,1840262760.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001248,103001248,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,29160.0,1839657960.0,21299.0,29160.0,1840262760.0,15.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1432288595,0.143228859522644,0.14,1840262760.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001248,103001248,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,29160.0,1839657960.0,21299.0,29160.0,1840262760.0,16.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.8394379657,4.83943796571502,4.84,1840262760.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001248,103001248,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,29160.0,1839657960.0,21299.0,29160.0,1840262760.0,17.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1840262760.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001248,103001248,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,29160.0,1839657960.0,21299.0,29160.0,1840262760.0,18.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),628.17052984,628.170529849189,628.17,1840262760.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001279,103001279,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,29400.0,1839658200.0,21299.0,29400.0,1840263000.0,1.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1224.2519041,1224.25190419179,1224.25,1839658200.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001279,103001279,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,29400.0,1839658200.0,21299.0,29400.0,1840263000.0,2.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1211.5689079,1211.56890790625,1211.57,1839658200.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001279,103001279,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,29400.0,1839658200.0,21299.0,29400.0,1840263000.0,3.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.0359792982,1.03597929822456,1.04,1839658200.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001279,103001279,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,29400.0,1839658200.0,21299.0,29400.0,1840263000.0,4.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),81.682535806,81.682535806237,81.68,1839658200.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001279,103001279,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,29400.0,1839658200.0,21299.0,29400.0,1840263000.0,5.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),203.22,203.22,203.22,1839658200.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001279,103001279,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,29400.0,1839658200.0,21299.0,29400.0,1840263000.0,6.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1884412757,0.188441275719961,0.19,1839658200.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001279,103001279,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,29400.0,1839658200.0,21299.0,29400.0,1840263000.0,7.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),3.6783192955,3.67831929555613,3.68,1839658200.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001279,103001279,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,29400.0,1839658200.0,21299.0,29400.0,1840263000.0,8.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),4.0,4,4.00,1839658200.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001279,103001279,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,29400.0,1839658200.0,21299.0,29400.0,1840263000.0,9.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),433.46414151,433.464141516554,433.46,1839658200.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001279,103001279,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,29400.0,1839658200.0,21299.0,29400.0,1840263000.0,10.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1460.9122979,1460.9122979457,1460.91,1840263000.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001279,103001279,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,29400.0,1839658200.0,21299.0,29400.0,1840263000.0,11.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1444.4921365,1444.49213652802,1444.49,1840263000.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001279,103001279,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,29400.0,1839658200.0,21299.0,29400.0,1840263000.0,12.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.1239662668,1.1239662668852,1.12,1840263000.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001279,103001279,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,29400.0,1839658200.0,21299.0,29400.0,1840263000.0,13.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),68.450378671,68.4503786713394,68.45,1840263000.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001279,103001279,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,29400.0,1839658200.0,21299.0,29400.0,1840263000.0,14.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),474.03,474.03,474.03,1840263000.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001279,103001279,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,29400.0,1839658200.0,21299.0,29400.0,1840263000.0,15.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1309365934,0.130936593454198,0.13,1840263000.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001279,103001279,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,29400.0,1839658200.0,21299.0,29400.0,1840263000.0,16.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),5.2937621353,5.29376213535304,5.29,1840263000.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001279,103001279,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,29400.0,1839658200.0,21299.0,29400.0,1840263000.0,17.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1840263000.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001279,103001279,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,29400.0,1839658200.0,21299.0,29400.0,1840263000.0,18.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),522.77500785,522.775007853582,522.78,1840263000.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001284,103001284,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21292.0,28800.0,1839657600.0,21299.0,28800.0,1840262400.0,1.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),2091.2371719,2091.23717199094,2091.24,1839657600.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001284,103001284,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21292.0,28800.0,1839657600.0,21299.0,28800.0,1840262400.0,2.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),2016.2762165,2016.27621658663,2016.28,1839657600.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001284,103001284,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21292.0,28800.0,1839657600.0,21299.0,28800.0,1840262400.0,3.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),3.5845267293,3.58452672935947,3.58,1839657600.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001284,103001284,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21292.0,28800.0,1839657600.0,21299.0,28800.0,1840262400.0,4.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),47.818583821,47.818583821746,47.82,1839657600.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001284,103001284,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21292.0,28800.0,1839657600.0,21299.0,28800.0,1840262400.0,5.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),390.6,390.6,390.60,1839657600.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001284,103001284,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21292.0,28800.0,1839657600.0,21299.0,28800.0,1840262400.0,6.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.0991182671,0.099118267102185,0.10,1839657600.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001284,103001284,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21292.0,28800.0,1839657600.0,21299.0,28800.0,1840262400.0,7.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),6.9931325559,6.99313255593292,6.99,1839657600.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001284,103001284,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21292.0,28800.0,1839657600.0,21299.0,28800.0,1840262400.0,8.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.5,1.5,1.50,1839657600.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001284,103001284,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21292.0,28800.0,1839657600.0,21299.0,28800.0,1840262400.0,9.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),482.43966747,482.43966747772,482.44,1839657600.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001284,103001284,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21292.0,28800.0,1839657600.0,21299.0,28800.0,1840262400.0,10.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1833.4112756,1833.41127562524,1833.41,1840262400.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001284,103001284,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21292.0,28800.0,1839657600.0,21299.0,28800.0,1840262400.0,11.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1756.4743516,1756.47435162032,1756.47,1840262400.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001284,103001284,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21292.0,28800.0,1839657600.0,21299.0,28800.0,1840262400.0,12.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),4.1963810863,4.1963810863268,4.20,1840262400.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001284,103001284,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21292.0,28800.0,1839657600.0,21299.0,28800.0,1840262400.0,13.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),54.543135699,54.5431356998158,54.54,1840262400.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001284,103001284,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21292.0,28800.0,1839657600.0,21299.0,28800.0,1840262400.0,14.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),229.18,229.18,229.18,1840262400.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001284,103001284,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21292.0,28800.0,1839657600.0,21299.0,28800.0,1840262400.0,15.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1217880766,0.121788076676951,0.12,1840262400.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001284,103001284,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21292.0,28800.0,1839657600.0,21299.0,28800.0,1840262400.0,16.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),5.6914206995,5.69142069956942,5.69,1840262400.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001284,103001284,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21292.0,28800.0,1839657600.0,21299.0,28800.0,1840262400.0,17.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),4.0,4,4.00,1840262400.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001284,103001284,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21292.0,28800.0,1839657600.0,21299.0,28800.0,1840262400.0,18.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),447.85283738,447.852837388132,447.85,1840262400.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001288,103001288,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21292.0,29760.0,1839658560.0,21306.0,29760.0,1840868160.0,1.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),968.15956827,968.159568272994,968.16,1839658560.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001288,103001288,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21292.0,29760.0,1839658560.0,21306.0,29760.0,1840868160.0,2.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),912.88591629,912.885916292019,912.89,1839658560.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001288,103001288,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21292.0,29760.0,1839658560.0,21306.0,29760.0,1840868160.0,3.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),5.7091469001,5.70914690019254,5.71,1839658560.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001288,103001288,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21292.0,29760.0,1839658560.0,21306.0,29760.0,1840868160.0,4.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),103.28875866,103.288758668553,103.29,1839658560.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001288,103001288,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21292.0,29760.0,1839658560.0,21306.0,29760.0,1840868160.0,5.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),264.6,264.6,264.60,1839658560.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001288,103001288,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21292.0,29760.0,1839658560.0,21306.0,29760.0,1840868160.0,6.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.0958865537,0.0958865537204639,0.10,1839658560.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001288,103001288,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21292.0,29760.0,1839658560.0,21306.0,29760.0,1840868160.0,7.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),7.228825666,7.22882566601218,7.23,1839658560.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001288,103001288,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21292.0,29760.0,1839658560.0,21306.0,29760.0,1840868160.0,8.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1839658560.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001288,103001288,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21292.0,29760.0,1839658560.0,21306.0,29760.0,1840868160.0,9.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),1077.1975283,1077.19752833822,1077.20,1839658560.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001288,103001288,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21292.0,29760.0,1839658560.0,21306.0,29760.0,1840868160.0,10.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1529.9327843,1529.93278432458,1529.93,1840263360.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001288,103001288,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21292.0,29760.0,1839658560.0,21306.0,29760.0,1840868160.0,11.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1485.8437588,1485.84375883041,1485.84,1840263360.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001288,103001288,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21292.0,29760.0,1839658560.0,21306.0,29760.0,1840868160.0,12.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),2.8817622542,2.88176225425749,2.88,1840263360.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001288,103001288,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21292.0,29760.0,1839658560.0,21306.0,29760.0,1840868160.0,13.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),65.36234861,65.3623486107246,65.36,1840263360.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001288,103001288,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21292.0,29760.0,1839658560.0,21306.0,29760.0,1840868160.0,14.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),441.23,441.23,441.23,1840263360.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001288,103001288,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21292.0,29760.0,1839658560.0,21306.0,29760.0,1840868160.0,15.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1118192099,0.111819209990277,0.11,1840263360.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001288,103001288,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21292.0,29760.0,1839658560.0,21306.0,29760.0,1840868160.0,16.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),6.1988202261,6.1988202261509,6.20,1840263360.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001288,103001288,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21292.0,29760.0,1839658560.0,21306.0,29760.0,1840868160.0,17.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1840263360.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001288,103001288,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21292.0,29760.0,1839658560.0,21306.0,29760.0,1840868160.0,18.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),584.53595421,584.535954210443,584.54,1840263360.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001288,103001288,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21292.0,29760.0,1839658560.0,21306.0,29760.0,1840868160.0,19.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),2174.5959874,2174.59598743937,2174.60,1840868160.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001288,103001288,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21292.0,29760.0,1839658560.0,21306.0,29760.0,1840868160.0,20.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),2158.3444961,2158.34449615399,2158.34,1840868160.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001288,103001288,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21292.0,29760.0,1839658560.0,21306.0,29760.0,1840868160.0,21.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),0.747333821,0.74733382105218,0.75,1840868160.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001288,103001288,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21292.0,29760.0,1839658560.0,21306.0,29760.0,1840868160.0,22.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),45.985553444,45.9855534442293,45.99,1840868160.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001288,103001288,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21292.0,29760.0,1839658560.0,21306.0,29760.0,1840868160.0,23.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),474.83,474.83,474.83,1840868160.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001288,103001288,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21292.0,29760.0,1839658560.0,21306.0,29760.0,1840868160.0,24.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1679845838,0.167984583818242,0.17,1840868160.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001288,103001288,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21292.0,29760.0,1839658560.0,21306.0,29760.0,1840868160.0,25.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.1262547122,4.12625471221768,4.13,1840868160.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001288,103001288,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21292.0,29760.0,1839658560.0,21306.0,29760.0,1840868160.0,26.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1840868160.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001288,103001288,001,Part A,1.0,Y,1.0,Y,1.0,6: CBA,6.0,6: CBA,6.0,21292.0,29760.0,1839658560.0,21306.0,29760.0,1840868160.0,27.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),273.7486524,273.748652400064,273.75,1840868160.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001290,103001290,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21292.0,30120.0,1839658920.0,21306.0,30120.0,1840868520.0,1.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1027.0014188,1027.00141881452,1027.00,1839658920.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001290,103001290,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21292.0,30120.0,1839658920.0,21306.0,30120.0,1840868520.0,2.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1014.7581156,1014.75811567731,1014.76,1839658920.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001290,103001290,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21292.0,30120.0,1839658920.0,21306.0,30120.0,1840868520.0,3.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.1921408201,1.19214082014981,1.19,1839658920.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001290,103001290,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21292.0,30120.0,1839658920.0,21306.0,30120.0,1840868520.0,4.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),97.370848927,97.3708489277757,97.37,1839658920.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001290,103001290,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21292.0,30120.0,1839658920.0,21306.0,30120.0,1840868520.0,5.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),270.63,270.63,270.63,1839658920.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001290,103001290,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21292.0,30120.0,1839658920.0,21306.0,30120.0,1840868520.0,6.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1617210631,0.161721063164977,0.16,1839658920.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001290,103001290,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21292.0,30120.0,1839658920.0,21306.0,30120.0,1840868520.0,7.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.286066187,4.2860661870176,4.29,1839658920.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001290,103001290,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21292.0,30120.0,1839658920.0,21306.0,30120.0,1840868520.0,8.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),2.0,2,2.00,1839658920.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001290,103001290,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21292.0,30120.0,1839658920.0,21306.0,30120.0,1840868520.0,9.0,TREATMENT,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,TBM Ubrogepant 2 x 50 mg (Test 2),2.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),602.0913233,602.091323307989,602.09,1839658920.0,B: TBM Ubrogepant 2 x 50 mg (Test 2),B
3110-103-002,3110-103-002.103001290,103001290,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21292.0,30120.0,1839658920.0,21306.0,30120.0,1840868520.0,10.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1109.5540025,1109.55400255958,1109.55,1840263720.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001290,103001290,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21292.0,30120.0,1839658920.0,21306.0,30120.0,1840868520.0,11.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1095.9116716,1095.91167168365,1095.91,1840263720.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001290,103001290,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21292.0,30120.0,1839658920.0,21306.0,30120.0,1840868520.0,12.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.2295328433,1.22953284332769,1.23,1840263720.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001290,103001290,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21292.0,30120.0,1839658920.0,21306.0,30120.0,1840868520.0,13.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),90.126302793,90.1263027931176,90.13,1840263720.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001290,103001290,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21292.0,30120.0,1839658920.0,21306.0,30120.0,1840868520.0,14.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),234.64,234.64,234.64,1840263720.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001290,103001290,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21292.0,30120.0,1839658920.0,21306.0,30120.0,1840868520.0,15.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1744569913,0.174456991378188,0.17,1840263720.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001290,103001290,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21292.0,30120.0,1839658920.0,21306.0,30120.0,1840868520.0,16.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),3.9731694045,3.97316940458602,3.97,1840263720.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001290,103001290,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21292.0,30120.0,1839658920.0,21306.0,30120.0,1840868520.0,17.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),4.0,4,4.00,1840263720.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001290,103001290,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21292.0,30120.0,1839658920.0,21306.0,30120.0,1840868520.0,18.0,TREATMENT,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,TBM Ubrogepant 1 x 100 mg (Test 1),1.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),516.61043837,516.610438372982,516.61,1840263720.0,A: TBM Ubrogepant 1 x 100 mg (Test 1),A
3110-103-002,3110-103-002.103001290,103001290,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21292.0,30120.0,1839658920.0,21306.0,30120.0,1840868520.0,19.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),794.11663571,794.116635717581,794.12,1840868520.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001290,103001290,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21292.0,30120.0,1839658920.0,21306.0,30120.0,1840868520.0,20.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),774.30159546,774.301595467193,774.30,1840868520.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001290,103001290,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21292.0,30120.0,1839658920.0,21306.0,30120.0,1840868520.0,21.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),2.4952304685,2.49523046856747,2.50,1840868520.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001290,103001290,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21292.0,30120.0,1839658920.0,21306.0,30120.0,1840868520.0,22.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),125.92608629,125.926086297938,125.93,1840868520.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001290,103001290,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21292.0,30120.0,1839658920.0,21306.0,30120.0,1840868520.0,23.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),170.87,170.87,170.87,1840868520.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001290,103001290,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21292.0,30120.0,1839658920.0,21306.0,30120.0,1840868520.0,24.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1296994589,0.129699458972821,0.13,1840868520.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001290,103001290,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21292.0,30120.0,1839658920.0,21306.0,30120.0,1840868520.0,25.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),5.34425653,5.34425653005383,5.34,1840868520.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001290,103001290,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21292.0,30120.0,1839658920.0,21306.0,30120.0,1840868520.0,26.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),2.0,2,2.00,1840868520.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001290,103001290,001,Part A,1.0,Y,1.0,Y,1.0,3: BAC,3.0,3: BAC,3.0,21292.0,30120.0,1839658920.0,21306.0,30120.0,1840868520.0,27.0,TREATMENT,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,CT Ubrogepant 2 x 50 mg (Reference 1),3.0,Period 3 Day 15,25.0,3.0,Period 3,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),970.9067971,970.906797107969,970.91,1840868520.0,C: CT Ubrogepant 2 x 50 mg (Reference 1),C
3110-103-002,3110-103-002.103001303,103001303,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,29520.0,1839658320.0,21299.0,29520.0,1840263120.0,1.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),853.79912607,853.799126078072,853.80,1839658320.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001303,103001303,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,29520.0,1839658320.0,21299.0,29520.0,1840263120.0,2.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),844.56916942,844.569169422771,844.57,1839658320.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001303,103001303,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,29520.0,1839658320.0,21299.0,29520.0,1840263120.0,3.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.0810454559,1.08104545593751,1.08,1839658320.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001303,103001303,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,29520.0,1839658320.0,21299.0,29520.0,1840263120.0,4.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),117.12356799,117.12356799819,117.12,1839658320.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001303,103001303,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,29520.0,1839658320.0,21299.0,29520.0,1840263120.0,5.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),171.82,171.82,171.82,1839658320.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001303,103001303,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,29520.0,1839658320.0,21299.0,29520.0,1840263120.0,6.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1430125892,0.143012589256513,0.14,1839658320.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001303,103001303,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,29520.0,1839658320.0,21299.0,29520.0,1840263120.0,7.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.8467563881,4.84675638811553,4.85,1839658320.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001303,103001303,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,29520.0,1839658320.0,21299.0,29520.0,1840263120.0,8.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),4.0,4,4.00,1839658320.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001303,103001303,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,29520.0,1839658320.0,21299.0,29520.0,1840263120.0,9.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),818.97383025,818.973830255688,818.97,1839658320.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001303,103001303,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,29520.0,1839658320.0,21299.0,29520.0,1840263120.0,10.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),906.78153076,906.781530761034,906.78,1840263120.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001303,103001303,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,29520.0,1839658320.0,21299.0,29520.0,1840263120.0,11.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),898.66564954,898.665649540857,898.67,1840263120.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001303,103001303,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,29520.0,1839658320.0,21299.0,29520.0,1840263120.0,12.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),0.8950205694,0.895020569438048,0.90,1840263120.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001303,103001303,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,29520.0,1839658320.0,21299.0,29520.0,1840263120.0,13.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),110.28014643,110.280146438441,110.28,1840263120.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001303,103001303,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,29520.0,1839658320.0,21299.0,29520.0,1840263120.0,14.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),272.93,272.93,272.93,1840263120.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001303,103001303,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,29520.0,1839658320.0,21299.0,29520.0,1840263120.0,15.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1552511632,0.155251163221509,0.16,1840263120.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001303,103001303,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,29520.0,1839658320.0,21299.0,29520.0,1840263120.0,16.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.4646826869,4.46468268692441,4.46,1840263120.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001303,103001303,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,29520.0,1839658320.0,21299.0,29520.0,1840263120.0,17.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1840263120.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001303,103001303,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21292.0,29520.0,1839658320.0,21299.0,29520.0,1840263120.0,18.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),710.33378526,710.333785268296,710.33,1840263120.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001305,103001305,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29400.0,1840435800.0,21315.0,29400.0,1841645400.0,1.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1278.9346101,1278.93461018299,1278.93,1840435800.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001305,103001305,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29400.0,1840435800.0,21315.0,29400.0,1841645400.0,2.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1239.338909,1239.33890906544,1239.34,1840435800.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001305,103001305,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29400.0,1840435800.0,21315.0,29400.0,1841645400.0,3.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),3.0959910539,3.0959910539823,3.10,1840435800.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001305,103001305,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29400.0,1840435800.0,21315.0,29400.0,1841645400.0,4.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),78.190080402,78.190080402697,78.19,1840435800.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001305,103001305,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29400.0,1840435800.0,21315.0,29400.0,1841645400.0,5.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),254.67,254.67,254.67,1840435800.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001305,103001305,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29400.0,1840435800.0,21315.0,29400.0,1841645400.0,6.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1285493085,0.128549308544611,0.13,1840435800.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001305,103001305,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29400.0,1840435800.0,21315.0,29400.0,1841645400.0,7.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),5.3920724149,5.39207241491616,5.39,1840435800.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001305,103001305,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29400.0,1840435800.0,21315.0,29400.0,1841645400.0,8.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),3.0,3,3.00,1840435800.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001305,103001305,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29400.0,1840435800.0,21315.0,29400.0,1841645400.0,9.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),608.24971591,608.24971591008,608.25,1840435800.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001305,103001305,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29400.0,1840435800.0,21315.0,29400.0,1841645400.0,10.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1204.5856369,1204.5856369733,1204.59,1841645400.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001305,103001305,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29400.0,1840435800.0,21315.0,29400.0,1841645400.0,11.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1173.3098292,1173.30982924409,1173.31,1841645400.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001305,103001305,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29400.0,1840435800.0,21315.0,29400.0,1841645400.0,12.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),2.5963955379,2.5963955379544,2.60,1841645400.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001305,103001305,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29400.0,1840435800.0,21315.0,29400.0,1841645400.0,13.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),83.01609859,83.0160985907689,83.02,1841645400.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001305,103001305,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29400.0,1840435800.0,21315.0,29400.0,1841645400.0,14.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),164.9,164.9,164.90,1841645400.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001305,103001305,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29400.0,1840435800.0,21315.0,29400.0,1841645400.0,15.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1413232885,0.141323288538807,0.14,1841645400.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001305,103001305,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29400.0,1840435800.0,21315.0,29400.0,1841645400.0,16.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.9046918432,4.90469184326694,4.90,1841645400.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001305,103001305,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29400.0,1840435800.0,21315.0,29400.0,1841645400.0,17.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),3.0,3,3.00,1841645400.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001305,103001305,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29400.0,1840435800.0,21315.0,29400.0,1841645400.0,18.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),587.41980496,587.419804967057,587.42,1841645400.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001306,103001306,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,28800.0,1840435200.0,21308.0,28800.0,1841040000.0,1.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1310.3933604,1310.3933604971,1310.39,1840435200.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001306,103001306,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,28800.0,1840435200.0,21308.0,28800.0,1841040000.0,2.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1281.2301051,1281.23010518794,1281.23,1840435200.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001306,103001306,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,28800.0,1840435200.0,21308.0,28800.0,1841040000.0,3.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),2.2255344225,2.22553442258738,2.23,1840435200.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001306,103001306,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,28800.0,1840435200.0,21308.0,28800.0,1841040000.0,4.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),76.312962973,76.312962973244,76.31,1840435200.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001306,103001306,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,28800.0,1840435200.0,21308.0,28800.0,1841040000.0,5.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),238.3,238.3,238.30,1840435200.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001306,103001306,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,28800.0,1840435200.0,21308.0,28800.0,1841040000.0,6.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1515605837,0.151560583794339,0.15,1840435200.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001306,103001306,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,28800.0,1840435200.0,21308.0,28800.0,1841040000.0,7.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.5734000437,4.57340004377733,4.57,1840435200.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001306,103001306,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,28800.0,1840435200.0,21308.0,28800.0,1841040000.0,8.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),2.0,2,2.00,1840435200.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001306,103001306,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,28800.0,1840435200.0,21308.0,28800.0,1841040000.0,9.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),503.51457524,503.514575246012,503.51,1840435200.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001306,103001306,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,28800.0,1840435200.0,21308.0,28800.0,1841040000.0,10.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1632.394079,1632.39407903809,1632.39,1841040000.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001306,103001306,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,28800.0,1840435200.0,21308.0,28800.0,1841040000.0,11.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1621.4274289,1621.42742890385,1621.43,1841040000.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001306,103001306,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,28800.0,1840435200.0,21308.0,28800.0,1841040000.0,12.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),0.6718138882,0.671813888267694,0.67,1841040000.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001306,103001306,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,28800.0,1840435200.0,21308.0,28800.0,1841040000.0,13.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),61.25971742,61.2597174200279,61.26,1841040000.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001306,103001306,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,28800.0,1840435200.0,21308.0,28800.0,1841040000.0,14.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),415.56,415.56,415.56,1841040000.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001306,103001306,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,28800.0,1840435200.0,21308.0,28800.0,1841040000.0,15.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1805473846,0.18054738464014,0.18,1841040000.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001306,103001306,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,28800.0,1840435200.0,21308.0,28800.0,1841040000.0,16.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),3.8391427377,3.83914273774444,3.84,1841040000.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001306,103001306,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,28800.0,1840435200.0,21308.0,28800.0,1841040000.0,17.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),2.0,2,2.00,1841040000.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001306,103001306,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,28800.0,1840435200.0,21308.0,28800.0,1841040000.0,18.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),339.29994356,339.299943569542,339.30,1841040000.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001325,103001325,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,28920.0,1840435320.0,21308.0,28920.0,1841040120.0,1.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),3310.2325685,3310.23256851817,3310.23,1840435320.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001325,103001325,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,28920.0,1840435320.0,21308.0,28920.0,1841040120.0,2.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),3240.3602508,3240.3602508766,3240.36,1840435320.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001325,103001325,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,28920.0,1840435320.0,21308.0,28920.0,1841040120.0,3.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),2.1107978426,2.11079784260731,2.11,1840435320.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001325,103001325,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,28920.0,1840435320.0,21308.0,28920.0,1841040120.0,4.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),30.20935778,30.2093577807934,30.21,1840435320.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001325,103001325,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,28920.0,1840435320.0,21308.0,28920.0,1841040120.0,5.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),669.73,669.73,669.73,1840435320.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001325,103001325,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,28920.0,1840435320.0,21308.0,28920.0,1841040120.0,6.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1279476665,0.127947666568909,0.13,1840435320.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001325,103001325,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,28920.0,1840435320.0,21308.0,28920.0,1841040120.0,7.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),5.4174272899,5.41742728998215,5.42,1840435320.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001325,103001325,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,28920.0,1840435320.0,21308.0,28920.0,1841040120.0,8.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1840435320.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001325,103001325,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,28920.0,1840435320.0,21308.0,28920.0,1841040120.0,9.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),236.10714123,236.107141231243,236.11,1840435320.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001325,103001325,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,28920.0,1840435320.0,21308.0,28920.0,1841040120.0,10.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),2408.5471984,2408.54719847875,2408.55,1841040120.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001325,103001325,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,28920.0,1840435320.0,21308.0,28920.0,1841040120.0,11.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),2340.1080402,2340.10804022085,2340.11,1841040120.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001325,103001325,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,28920.0,1840435320.0,21308.0,28920.0,1841040120.0,12.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),2.8415120243,2.84151202439078,2.84,1841040120.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001325,103001325,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,28920.0,1840435320.0,21308.0,28920.0,1841040120.0,13.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),41.51880439,41.5188043909459,41.52,1841040120.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001325,103001325,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,28920.0,1840435320.0,21308.0,28920.0,1841040120.0,14.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),385.49,385.49,385.49,1841040120.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001325,103001325,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,28920.0,1840435320.0,21308.0,28920.0,1841040120.0,15.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1203989091,0.120398909188056,0.12,1841040120.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001325,103001325,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,28920.0,1840435320.0,21308.0,28920.0,1841040120.0,16.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),5.757088542,5.75708854203397,5.76,1841040120.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001325,103001325,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,28920.0,1840435320.0,21308.0,28920.0,1841040120.0,17.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),3.0,3,3.00,1841040120.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001325,103001325,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,28920.0,1840435320.0,21308.0,28920.0,1841040120.0,18.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),344.84369228,344.843692280434,344.84,1841040120.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001327,103001327,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29040.0,1840435440.0,21308.0,29040.0,1841040240.0,1.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1249.0690612,1249.06906125041,1249.07,1840435440.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001327,103001327,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29040.0,1840435440.0,21308.0,29040.0,1841040240.0,2.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1232.1764004,1232.17640044162,1232.18,1840435440.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001327,103001327,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29040.0,1840435440.0,21308.0,29040.0,1841040240.0,3.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.3524200809,1.3524200809103,1.35,1840435440.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001327,103001327,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29040.0,1840435440.0,21308.0,29040.0,1841040240.0,4.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),80.059624485,80.0596244853687,80.06,1840435440.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001327,103001327,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29040.0,1840435440.0,21308.0,29040.0,1841040240.0,5.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),265.16,265.16,265.16,1840435440.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001327,103001327,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29040.0,1840435440.0,21308.0,29040.0,1841040240.0,6.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1562808861,0.156280886112775,0.16,1840435440.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001327,103001327,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29040.0,1840435440.0,21308.0,29040.0,1841040240.0,7.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.4352652317,4.43526523173,4.44,1840435440.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001327,103001327,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29040.0,1840435440.0,21308.0,29040.0,1841040240.0,8.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.5,1.5,1.50,1840435440.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001327,103001327,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29040.0,1840435440.0,21308.0,29040.0,1841040240.0,9.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),512.28033367,512.280333678147,512.28,1840435440.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001327,103001327,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29040.0,1840435440.0,21308.0,29040.0,1841040240.0,10.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1316.2156627,1316.21566277841,1316.22,1841040240.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001327,103001327,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29040.0,1840435440.0,21308.0,29040.0,1841040240.0,11.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1299.6140101,1299.61401011245,1299.61,1841040240.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001327,103001327,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29040.0,1840435440.0,21308.0,29040.0,1841040240.0,12.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.2613170573,1.26131705733703,1.26,1841040240.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001327,103001327,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29040.0,1840435440.0,21308.0,29040.0,1841040240.0,13.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),75.975391288,75.9753912887718,75.98,1841040240.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001327,103001327,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29040.0,1840435440.0,21308.0,29040.0,1841040240.0,14.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),387.96,387.96,387.96,1841040240.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001327,103001327,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29040.0,1840435440.0,21308.0,29040.0,1841040240.0,15.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1343239763,0.134323976345537,0.13,1841040240.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001327,103001327,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29040.0,1840435440.0,21308.0,29040.0,1841040240.0,16.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),5.160264008,5.16026400809402,5.16,1841040240.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001327,103001327,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29040.0,1840435440.0,21308.0,29040.0,1841040240.0,17.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0488888888,1.04888888888889,1.05,1841040240.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001327,103001327,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29040.0,1840435440.0,21308.0,29040.0,1841040240.0,18.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),565.61303019,565.613030195978,565.61,1841040240.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001328,103001328,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29520.0,1840435920.0,21308.0,29520.0,1841040720.0,1.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1372.7018542,1372.7018542944,1372.70,1840435920.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001328,103001328,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29520.0,1840435920.0,21308.0,29520.0,1841040720.0,2.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1346.2074438,1346.20744388313,1346.21,1840435920.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001328,103001328,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29520.0,1840435920.0,21308.0,29520.0,1841040720.0,3.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.9300921265,1.93009212658822,1.93,1840435920.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001328,103001328,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29520.0,1840435920.0,21308.0,29520.0,1841040720.0,4.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),72.849031045,72.8490310457126,72.85,1840435920.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001328,103001328,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29520.0,1840435920.0,21308.0,29520.0,1841040720.0,5.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),289.16,289.16,289.16,1840435920.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001328,103001328,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29520.0,1840435920.0,21308.0,29520.0,1841040720.0,6.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1366325932,0.136632593207683,0.14,1840435920.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001328,103001328,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29520.0,1840435920.0,21308.0,29520.0,1841040720.0,7.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),5.0730734467,5.07307344673138,5.07,1840435920.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001328,103001328,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29520.0,1840435920.0,21308.0,29520.0,1841040720.0,8.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),2.0,2,2.00,1840435920.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001328,103001328,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29520.0,1840435920.0,21308.0,29520.0,1841040720.0,9.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),533.1746206,533.174620604481,533.17,1840435920.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001328,103001328,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29520.0,1840435920.0,21308.0,29520.0,1841040720.0,10.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1302.1297563,1302.1297563758,1302.13,1841040720.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001328,103001328,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29520.0,1840435920.0,21308.0,29520.0,1841040720.0,11.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1274.9632793,1274.96327932725,1274.96,1841040720.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001328,103001328,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29520.0,1840435920.0,21308.0,29520.0,1841040720.0,12.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),2.0863110542,2.08631105429608,2.09,1841040720.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001328,103001328,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29520.0,1840435920.0,21308.0,29520.0,1841040720.0,13.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),76.797261955,76.7972619551592,76.80,1841040720.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001328,103001328,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29520.0,1840435920.0,21308.0,29520.0,1841040720.0,14.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),220.98,220.98,220.98,1841040720.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001328,103001328,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29520.0,1840435920.0,21308.0,29520.0,1841040720.0,15.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1476083922,0.14760839224144,0.15,1841040720.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001328,103001328,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29520.0,1840435920.0,21308.0,29520.0,1841040720.0,16.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.6958521127,4.69585211270493,4.70,1841040720.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001328,103001328,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29520.0,1840435920.0,21308.0,29520.0,1841040720.0,17.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),3.0,3,3.00,1841040720.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001328,103001328,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29520.0,1840435920.0,21308.0,29520.0,1841040720.0,18.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),520.27707089,520.277070896778,520.28,1841040720.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001329,103001329,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29640.0,1840436040.0,21308.0,29640.0,1841040840.0,1.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1313.6862183,1313.68621833499,1313.69,1840436040.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001329,103001329,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29640.0,1840436040.0,21308.0,29640.0,1841040840.0,2.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1301.0824965,1301.0824965167,1301.08,1840436040.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001329,103001329,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29640.0,1840436040.0,21308.0,29640.0,1841040840.0,3.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),0.9594164605,0.959416460520166,0.96,1840436040.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001329,103001329,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29640.0,1840436040.0,21308.0,29640.0,1841040840.0,4.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),76.121678528,76.121678528944,76.12,1840436040.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001329,103001329,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29640.0,1840436040.0,21308.0,29640.0,1841040840.0,5.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),371.54,371.54,371.54,1840436040.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001329,103001329,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29640.0,1840436040.0,21308.0,29640.0,1841040840.0,6.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.152335955,0.152335955020339,0.15,1840436040.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001329,103001329,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29640.0,1840436040.0,21308.0,29640.0,1841040840.0,7.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.5501220015,4.55012200151567,4.55,1840436040.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001329,103001329,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29640.0,1840436040.0,21308.0,29640.0,1841040840.0,8.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1840436040.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001329,103001329,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29640.0,1840436040.0,21308.0,29640.0,1841040840.0,9.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),499.69607318,499.696073187585,499.70,1840436040.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001329,103001329,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29640.0,1840436040.0,21308.0,29640.0,1841040840.0,10.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1439.4324866,1439.43248666005,1439.43,1841040840.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001329,103001329,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29640.0,1840436040.0,21308.0,29640.0,1841040840.0,11.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1409.1720868,1409.17208680341,1409.17,1841040840.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001329,103001329,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29640.0,1840436040.0,21308.0,29640.0,1841040840.0,12.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),2.1022451651,2.1022451651662,2.10,1841040840.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001329,103001329,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29640.0,1840436040.0,21308.0,29640.0,1841040840.0,13.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),69.47182374,69.47182374078,69.47,1841040840.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001329,103001329,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29640.0,1840436040.0,21308.0,29640.0,1841040840.0,14.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),286.23,286.23,286.23,1841040840.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001329,103001329,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29640.0,1840436040.0,21308.0,29640.0,1841040840.0,15.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1490396697,0.149039669712427,0.15,1841040840.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001329,103001329,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29640.0,1840436040.0,21308.0,29640.0,1841040840.0,16.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.6507562845,4.65075628453402,4.65,1841040840.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001329,103001329,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29640.0,1840436040.0,21308.0,29640.0,1841040840.0,17.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),4.0,4,4.00,1841040840.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001329,103001329,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29640.0,1840436040.0,21308.0,29640.0,1841040840.0,18.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),466.12974837,466.129748373881,466.13,1841040840.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001340,103001340,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29760.0,1840436160.0,21308.0,29760.0,1841040960.0,1.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1276.6958554,1276.69585548423,1276.70,1840436160.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001340,103001340,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29760.0,1840436160.0,21308.0,29760.0,1841040960.0,2.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1254.9328916,1254.93289165087,1254.93,1840436160.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001340,103001340,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29760.0,1840436160.0,21308.0,29760.0,1841040960.0,3.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.7046318228,1.70463182283156,1.70,1840436160.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001340,103001340,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29760.0,1840436160.0,21308.0,29760.0,1841040960.0,4.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),78.327190904,78.327190904894,78.33,1840436160.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001340,103001340,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29760.0,1840436160.0,21308.0,29760.0,1841040960.0,5.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),307.37,307.37,307.37,1840436160.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001340,103001340,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29760.0,1840436160.0,21308.0,29760.0,1841040960.0,6.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1406058486,0.140605848699246,0.14,1840436160.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001340,103001340,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29760.0,1840436160.0,21308.0,29760.0,1841040960.0,7.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.9297179809,4.92971798095382,4.93,1840436160.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001340,103001340,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29760.0,1840436160.0,21308.0,29760.0,1841040960.0,8.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1840436160.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001340,103001340,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29760.0,1840436160.0,21308.0,29760.0,1841040960.0,9.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),557.06922314,557.069223147571,557.07,1840436160.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001340,103001340,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29760.0,1840436160.0,21308.0,29760.0,1841040960.0,10.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1485.9060548,1485.90605480319,1485.91,1841040960.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001340,103001340,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29760.0,1840436160.0,21308.0,29760.0,1841040960.0,11.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1462.269061,1462.26906107352,1462.27,1841040960.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001340,103001340,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29760.0,1840436160.0,21308.0,29760.0,1841040960.0,12.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.5907461749,1.59074617491879,1.59,1841040960.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001340,103001340,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29760.0,1840436160.0,21308.0,29760.0,1841040960.0,13.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),67.299005665,67.299005665096,67.30,1841040960.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001340,103001340,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29760.0,1840436160.0,21308.0,29760.0,1841040960.0,14.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),217.48,217.48,217.48,1841040960.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001340,103001340,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29760.0,1840436160.0,21308.0,29760.0,1841040960.0,15.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.167957061,0.16795706109686,0.17,1841040960.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001340,103001340,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29760.0,1840436160.0,21308.0,29760.0,1841040960.0,16.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.1269308716,4.1269308716959,4.13,1841040960.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001340,103001340,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29760.0,1840436160.0,21308.0,29760.0,1841040960.0,17.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),3.0,3,3.00,1841040960.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001340,103001340,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29760.0,1840436160.0,21308.0,29760.0,1841040960.0,18.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),400.69173171,400.691731717579,400.69,1841040960.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001349,103001349,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29160.0,1840435560.0,21308.0,29160.0,1841040360.0,1.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),867.57246622,867.572466221919,867.57,1840435560.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001349,103001349,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29160.0,1840435560.0,21308.0,29160.0,1841040360.0,2.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),855.04907737,855.049077376454,855.05,1840435560.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001349,103001349,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29160.0,1840435560.0,21308.0,29160.0,1841040360.0,3.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.4434977287,1.44349772878361,1.44,1840435560.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001349,103001349,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29160.0,1840435560.0,21308.0,29160.0,1841040360.0,4.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),115.26414667,115.264146677542,115.26,1840435560.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001349,103001349,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29160.0,1840435560.0,21308.0,29160.0,1841040360.0,5.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),280.03,280.03,280.03,1840435560.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001349,103001349,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29160.0,1840435560.0,21308.0,29160.0,1841040360.0,6.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.2946486806,0.294648680603424,0.29,1840435560.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001349,103001349,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29160.0,1840435560.0,21308.0,29160.0,1841040360.0,7.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),2.3524530269,2.35245302690791,2.35,1840435560.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001349,103001349,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29160.0,1840435560.0,21308.0,29160.0,1841040360.0,8.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1840435560.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001349,103001349,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29160.0,1840435560.0,21308.0,29160.0,1841040360.0,9.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),391.19179641,391.191796418322,391.19,1840435560.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001349,103001349,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29160.0,1840435560.0,21308.0,29160.0,1841040360.0,10.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),940.83686819,940.836868199123,940.84,1841040360.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001349,103001349,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29160.0,1840435560.0,21308.0,29160.0,1841040360.0,11.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),931.38285225,931.382852255457,931.38,1841040360.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001349,103001349,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29160.0,1840435560.0,21308.0,29160.0,1841040360.0,12.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.0048517722,1.00485177220589,1.00,1841040360.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001349,103001349,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29160.0,1840435560.0,21308.0,29160.0,1841040360.0,13.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),106.28835176,106.288351764331,106.29,1841040360.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001349,103001349,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29160.0,1840435560.0,21308.0,29160.0,1841040360.0,14.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),229.95,229.95,229.95,1841040360.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001349,103001349,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29160.0,1840435560.0,21308.0,29160.0,1841040360.0,15.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1618359868,0.161835986856485,0.16,1841040360.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001349,103001349,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29160.0,1840435560.0,21308.0,29160.0,1841040360.0,16.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.2830225466,4.28302254661459,4.28,1841040360.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001349,103001349,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29160.0,1840435560.0,21308.0,29160.0,1841040360.0,17.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),3.0,3,3.00,1841040360.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001349,103001349,001,Part B,2.0,Y,1.0,Y,1.0,2: ED,8.0,2: ED,8.0,21301.0,29160.0,1840435560.0,21308.0,29160.0,1841040360.0,18.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),656.76586418,656.765864186852,656.77,1841040360.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001354,103001354,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29880.0,1840436280.0,21308.0,29880.0,1841041080.0,1.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1163.5533345,1163.55333453414,1163.55,1840436280.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001354,103001354,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29880.0,1840436280.0,21308.0,29880.0,1841041080.0,2.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1141.8833116,1141.88331163503,1141.88,1840436280.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001354,103001354,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29880.0,1840436280.0,21308.0,29880.0,1841041080.0,3.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),1.862400481,1.86240048100482,1.86,1840436280.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001354,103001354,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29880.0,1840436280.0,21308.0,29880.0,1841041080.0,4.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),85.943632347,85.9436323475775,85.94,1840436280.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001354,103001354,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29880.0,1840436280.0,21308.0,29880.0,1841041080.0,5.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),271.14,271.14,271.14,1840436280.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001354,103001354,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29880.0,1840436280.0,21308.0,29880.0,1841041080.0,6.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1536685039,0.153668503974518,0.15,1840436280.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001354,103001354,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29880.0,1840436280.0,21308.0,29880.0,1841041080.0,7.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.5106652478,4.51066524780438,4.51,1840436280.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001354,103001354,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29880.0,1840436280.0,21308.0,29880.0,1841041080.0,8.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),3.0,3,3.00,1840436280.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001354,103001354,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29880.0,1840436280.0,21308.0,29880.0,1841041080.0,9.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),559.27942372,559.279423725172,559.28,1840436280.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001354,103001354,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29880.0,1840436280.0,21308.0,29880.0,1841041080.0,10.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),937.67607553,937.676075539378,937.68,1841041080.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001354,103001354,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29880.0,1840436280.0,21308.0,29880.0,1841041080.0,11.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),894.20643766,894.206437665222,894.21,1841041080.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001354,103001354,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29880.0,1840436280.0,21308.0,29880.0,1841041080.0,12.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),4.6358906884,4.63589068849291,4.64,1841041080.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001354,103001354,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29880.0,1840436280.0,21308.0,29880.0,1841041080.0,13.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),106.64663694,106.646636944936,106.65,1841041080.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001354,103001354,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29880.0,1840436280.0,21308.0,29880.0,1841041080.0,14.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),134.22,134.22,134.22,1841041080.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001354,103001354,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29880.0,1840436280.0,21308.0,29880.0,1841041080.0,15.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1138725842,0.113872584223734,0.11,1841041080.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001354,103001354,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29880.0,1840436280.0,21308.0,29880.0,1841041080.0,16.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),6.0870418045,6.08704180453189,6.09,1841041080.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001354,103001354,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29880.0,1840436280.0,21308.0,29880.0,1841041080.0,17.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1841041080.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001354,103001354,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29880.0,1840436280.0,21308.0,29880.0,1841041080.0,18.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),936.54357343,936.543573432911,936.54,1841041080.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001358,103001358,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29280.0,1840435680.0,21308.0,29280.0,1841040480.0,1.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1727.0962444,1727.09624445955,1727.10,1840435680.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001358,103001358,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29280.0,1840435680.0,21308.0,29280.0,1841040480.0,2.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1684.6628935,1684.66289354314,1684.66,1840435680.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001358,103001358,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29280.0,1840435680.0,21308.0,29280.0,1841040480.0,3.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),2.4569187184,2.45691871848652,2.46,1840435680.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001358,103001358,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29280.0,1840435680.0,21308.0,29280.0,1841040480.0,4.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),57.900652798,57.9006527984736,57.90,1840435680.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001358,103001358,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29280.0,1840435680.0,21308.0,29280.0,1841040480.0,5.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),261.45,261.45,261.45,1840435680.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001358,103001358,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29280.0,1840435680.0,21308.0,29280.0,1841040480.0,6.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.153652725,0.153652725019164,0.15,1840435680.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001358,103001358,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29280.0,1840435680.0,21308.0,29280.0,1841040480.0,7.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),4.5111284584,4.51112845849947,4.51,1840435680.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001358,103001358,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29280.0,1840435680.0,21308.0,29280.0,1841040480.0,8.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),4.0,4,4.00,1840435680.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001358,103001358,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29280.0,1840435680.0,21308.0,29280.0,1841040480.0,9.0,TREATMENT,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Fed TBM Ubrogepant 1 x 100 mg (Test 3),4.0,Period 1 Day 1,1.0,1.0,Period 1,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),376.8280243,376.82802430775,376.83,1840435680.0,D: Fed TBM Ubrogepant 1 x 100 mg (Test 3),D
3110-103-002,3110-103-002.103001358,103001358,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29280.0,1840435680.0,21308.0,29280.0,1841040480.0,10.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),2.0,AUC Infinity Obs (h*ng/mL),AUCIFO,AUC^{sub 0-inf} (h*ng/mL),1842.2905228,1842.29052282309,1842.29,1841040480.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001358,103001358,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29280.0,1840435680.0,21308.0,29280.0,1841040480.0,11.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),1.0,AUC to Last Nonzero Conc (h*ng/mL),AUCLST,AUC^{sub 0-t} (h*ng/mL),1791.7746624,1791.77466245419,1791.77,1841040480.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001358,103001358,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29280.0,1840435680.0,21308.0,29280.0,1841040480.0,12.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),3.0,AUC %Extrapolation Obs (%),AUCPEO,AUC^{sub ext} (%),2.7420137998,2.74201379983756,2.74,1841040480.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001358,103001358,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29280.0,1840435680.0,21308.0,29280.0,1841040480.0,13.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),8.0,Total CL Obs by F (L/h),CLFO,CL/F (L/h),54.280255345,54.2802553458082,54.28,1841040480.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001358,103001358,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29280.0,1840435680.0,21308.0,29280.0,1841040480.0,14.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),4.0,Max Conc (ng/mL),CMAX,C^{sub max} (ng/mL),414.5,414.5,414.50,1841040480.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001358,103001358,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29280.0,1840435680.0,21308.0,29280.0,1841040480.0,15.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),6.0,Lambda z (/h),LAMZ,^{unicode 03BB}^{sub z} (/h),0.1165970441,0.116597044116171,0.12,1841040480.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001358,103001358,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29280.0,1840435680.0,21308.0,29280.0,1841040480.0,16.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),7.0,Half-Life Lambda z (h),LAMZHL,t^{sub 1/2} (h),5.9448092,5.94480920004568,5.94,1841040480.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001358,103001358,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29280.0,1840435680.0,21308.0,29280.0,1841040480.0,17.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),5.0,Time of CMAX (h),TMAX,T^{sub max} (h),1.0,1,1.00,1841040480.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
3110-103-002,3110-103-002.103001358,103001358,001,Part B,2.0,Y,1.0,Y,1.0,1: DE,7.0,1: DE,7.0,21301.0,29280.0,1840435680.0,21308.0,29280.0,1841040480.0,18.0,TREATMENT,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),5.0,Period 2 Day 8,8.0,2.0,Period 2,UBRO,1.0,Ubrogepant (ng/mL),9.0,Vz Obs by F (L),VZFO,V^{sub z}/F (L),465.53714768,465.537147680401,465.54,1841040480.0,E: Fasted TBM Ubrogepant 1 x 100 mg (Reference 2),E
